

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

The effect of PIFR-based Optimized Inhalation Therapy in Patients Recovering From AECOPD: protocol of a prospective, multi-center, superiority, randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-034804
Article Type:	Protocol
Date Submitted by the Author:	06-Oct-2019
Complete List of Authors:	Hua, Jianlan; Zhongshan Hospital Fudan University, Department of Pulmonary and Critical Care Medicine Zhang, Jing; Zhongshan Hospital Fudan University, Department of Pulmonary and Critical Care Medicine Zhang, wei; Fudan University, Department of Biostatistics Zeng, Ying-ying; Fifth People's Hospital of Shanghai Fudan University Zuo, Yi-hui; Zhongshan Hospital Fudan University, Department of Pulmonary and Critical Care Medicine
Keywords:	RESPIRATORY MEDICINE (see Thoracic Medicine), Chronic airways disease < THORACIC MEDICINE, MEDICAL EDUCATION & TRAINING

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **The effect of PIFR-based Optimized Inhalation Therapy in**
5
6 **Patients Recovering From AECOPD: protocol of a**
7
8 **prospective, multi-center, superiority, randomized**
9
10 **controlled trial**
11
12
13

14 Jian-lan Hua¹, Wei Zhang², Yi-hui Zuo¹, Ying-ying Zeng³, Jing Zhang^{1*}

15
16
17 ¹Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Shanghai Medical
18
19 College, Fudan University, Shanghai, China.

20
21
22 ²Department of Biostatistics, School of Public Health, Fudan University, Shanghai, China

23
24
25 ³National standardized training base for resident doctors, the Fifth People's Hospital of Shanghai,
26
27 Fudan University

28
29
30 * Correspondence: Jing Zhang

31
32 Department of Pulmonary and Critical Care Medicine, Zhongshan hospital, Shanghai Medical
33
34 College, Fudan University, 180 Feng lin road, shanghai 200032, People's Republic of China

35
36
37 Email: jingatl@hotmai.com
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract:

Introduction: Chronic Obstructive Pulmonary Disease (COPD) is a global respiratory disease. Acute exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) is a major cause of disease progression and death, and causes huge medical expenditures. Effective inhalation therapy is important during the AE recovery period. However, the invalid inhalation using DPI due to the unrecovered inspiratory flow rate after AECOPD results in increased risk of treatment failure and early recurrence. We envisage that choosing the right inhaler based on peak inhalation flow rate (PIFR) and training inhaler techniques will contribute to reducing early relapse rates. Therefore, a prospective multicenter randomized trial is designed to verify this hypothesis.

Methods and analysis: The study is aimed at determining whether the optimized inhalation therapy based on PIFR can reduce the rate of treatment failure in patients recovering from AECOPD. In the study, 416 patients with AECOPD whose exacerbated symptoms are relieved by 5-7 days of standard therapy will be recruited and be randomized into PIFR group, which receives inhaler depending on their PIFR and is trained to use the inhaler appropriately, and control group, which receives inhaler depending on the judgment of a respiratory physician, at a 1:1 ratio. The primary outcome of the study is 30-day treatment failure rate. Other endpoints include PIFR, the error rate of inhalation device use, satisfaction with inhalation devices, 30-day mortality, 90-day mortality, symptoms and life quality of patients and COPD-related treatment costs.

Ethics and dissemination: This trial has been registered in the Ethics Committee of Zhongshan Hospital of Fudan University (B2019-142).

Trial registration: This trial has been registered in Clinical Trails (NCT04000958).

Strengths and limitations of this study:

The trial is a prospective, multi-center, single-blind, superiority, randomized study, maximizing the impact of confounders.

We will be able to verify the clinical significance of including PIFR in the discharge protocol as well as guide COPD inhaler choices and inhaler technique training through the study.

Keywords: chronic obstructive pulmonary disease, acute exacerbation of chronic obstructive pulmonary disease, peak inhalation flow rate

Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a global respiratory disease that severely threatens human health. COPD has a significant socioeconomic burden, and is currently the fourth leading cause of death in the world but is projected to be the 3rd leading cause of death by 2020¹. In China, COPD ranked among the top three leading causes of death and the direct medical cost of COPD ranged from 72 to 3,565 USD per capita per year, accounting for 33.33% to 118.09% of local average annual income². The overall prevalence of spirometry-defined COPD was 8.6% among the general Chinese population aged 20 years or older³. Acute exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) is a major cause of disease progression and death, and causes huge medical expenditures⁴.

Inhalation therapy is the core pharmaceutical therapy for COPD including inhaled corticosteroid (ICS), both short- and long-acting beta2-agonists and, more recently, muscarinic antagonists⁵. Existing common devices include pressure metered dose inhaler (pMDI), dry powder inhalers (DPIs), soft mist inhalers (SMIs), and nebulizers⁶. Common inhaler errors include insufficient inspiratory effort, no breath-hold (or holds breath for less than 3s), etc (Table 2)^{7 8}. Inhaler errors are associated with poor disease outcomes (exacerbations) and greater health-economic burden⁹. MDIs require complex coordination techniques with a slow inhalation by the patient to achieve a clinically effective dose. DPIs decrease the complexity of administration, but effective medication delivery is dependent on the force of the patient's inspiratory effort to overcome internal resistance¹⁰. Several *in vitro* studies have demonstrated the inhalation flow rate dependency of DPI. Specifically, the results showed that both the amount of medication delivered to the patient and the effective aerodynamic particle size of the medication were adversely affected when the testing peak inhalation flow rate (PIFR) was less than 60 liters/min¹¹, which may result in ineffective inhalation of medications using a DPI. Several studies suggest that patients with insufficient PIFR in stable phase of COPD may have an adverse effect on prognosis using inappropriate inhaler^{12 13}. Other risk factors for early AECOPD recurrence include age grades, GOLD

1
2
3
4 grades, AE frequency in the previous year, pleural effusion, use of accessory respiratory
5 muscles, noninvasive mechanical ventilation, controlled oxygen therapy and length of
6 hospital stay, while inhaled long-acting β -2-agonists (LABA) and inhaled
7 corticosteroids (ICS) are protection factors¹⁴. An investigation suggests that one of five
8 stable outpatients more than 60 years of age with severe COPD did not reach the
9 recommended PIFR for DPI devices¹⁵. Some small sample studies has shown that a
10 significant proportion of patients are not suitable for DPI during AECOPD because of
11 their insufficient PIFR^{13 16}. However, there is no study about the PIFR status and the
12 impact of inhaler choices on prognosis for patients recovering from AECOPD.
13
14
15
16
17
18
19
20

21 Thirty-day readmission rates after hospitalization for AECOPD are approximately
22 15.8%-20%^{17 18}. Readmissions are costly and adversely affect quality of life. But little
23 is known about PIFRs of the patients recovering from AECOPD as well as the clinical
24 impact of the inhaler (DPI or pMDI) selected for the patients. Generally, discharge
25 protocols for patients recovering from COPD do not include an assessment of PIFR or
26 patients' ability to use their inhaler device when they recuperate after discharge.
27 Clinicians typically select the inhaler they use during the stable phase of COPD for
28 patients who will be discharged. We hypothesize PIFR of patients recovering from
29 AECOPD have not returned to the level at the stable phase of COPD, which may result
30 in poor COPD management and treatment failure (including recurrence resulting in an
31 emergency visit, admission, or need for intensified medication) for the patients due to
32 the ineffective inhalation of medications.
33
34
35
36
37
38
39
40
41
42
43
44

45 The aim of this study is to determine whether the optimized inhalation therapy based
46 PIFR can reduce the rate of treatment failure in patients recovering from AECOPD.
47 Errors in inhaler use and quality of life are also to be evaluated.
48
49
50
51
52
53

54 **Methods and analysis**

55 **Trial design**

56
57 This is a prospective, multi-center, single-blind, superiority, randomized study of
58
59
60

1
2
3
4 patients hospitalized for a COPD exacerbation. This study is designed to determine
5 whether PIFR based inhaler choice and training can reduce the rate of treatment failure
6 in patients recovering from AECOPD. The primary study outcome is 30-day treatment
7 failure rate. Treatment failure means AECOPD recurrence resulting in an emergency
8 visit, admission, or need for intensified medication. Other endpoints include symptoms
9 and life quality of patients the error rate of inhalation device use, satisfaction with
10 inhalation devices, PIFR, 30-day mortality, 90-day mortality, and COPD-related
11 treatment costs.
12
13
14
15
16
17
18

19 This trial has been registered in the Ethics Committee of Zhongshan Hospital of
20 Fudan University (B2019-142) and Clinical Trails (NCT04000958).
21
22
23
24

25 Inclusion criteria

26
27 All patients meeting AECOPD diagnostic criteria who hospitalized for COPD related
28 reasons will be followed. The definition of COPD follows the GOLD definition and the
29 definition of AECOPD follows Expert Consensus on Acute Exacerbation of Chronic
30 Obstructive Pulmonary Disease in the People's republic of China⁴. AECOPD is defined
31 as sudden worsening of respiratory symptoms that require additional treatment (typical
32 manifestations include dyspnea, aggravated cough, increased sputum volume, and/or
33 sputum purulence) and is beyond normal day-to-day variations, leading to a change in
34 medications^{4 19}. The subjects will be enrolled and randomized into the study group if
35 all of the following criteria are met: (1) 40–80 years old; (2) patients with AECOPD
36 whose acute respiratory symptoms have been controlled and met discharge criteria after
37 5-7 day-standard AECOPD treatment including atomized or inhaled bronchodilator
38 plus oral or intravenous glucocorticoid (prednisone equivalent dose 40-50mg) or
39 Pulmicort 2mg atomization twice daily plus broad-spectrum antibiotics; (3) patients
40 with moderate and above COPD with a recorded spirometry measured in the stable
41 disease status, ie, post-bronchodilator forced expiratory volume in one second
42 (FEV1)/forced vital capacity (FVC) <70% and FEV1% predicted value <80%; (4)
43 patients have signed an informed consent form.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Discharge criteria is as follows: (1) physician are confident that the patient can
5 manage successfully at home; (2) long-acting bronchodilators, either beta 2-agonists
6 and/or anticholinergics with or without inhaled corticosteroids can be used, and inhaled
7 short-acting β 2-agonist therapy is required no more frequently than every 4 hours; (3)
8 the patient, if previously ambulatory, is able to walk across the room; (4) the patient is
9 able to eat and sleep without frequent awakening due to dyspnea; (5) the patient has
10 been clinically stable for 12–24 hours; (6) arterial blood gases have been stable for 12–
11 24 hours⁴.
12
13
14
15
16
17
18
19
20
21

22 Exclusion criteria

23
24 Exclusion criteria include: (1) patients who is already using home nebulization
25 therapy because of the severity of the disease; (2) patients with bronchial asthma,
26 pulmonary interstitial fibrosis, bronchiectasis, pulmonary embolism and other lung
27 diseases; or hypertension, heart disease, chronic liver and kidney disease, diabetes,
28 chronic gastrointestinal diseases, malignant tumors, critically ill; (3) patient's mental
29 state cannot match the observation or suffer from cognitive impairment; (4) patient's
30 peak inspiratory flow rates (PIFR) is less than 20L/min.
31
32
33
34
35
36
37
38
39
40

41 Sample size

42 The sample size was calculated using PASS 15.0 (Power Analysis and Sample Size
43 Software) to ensure the study power. Several studies have found that 30-47% patients
44 hospitalized for AECOPD had a PIFR < 60 liters/minute prior to discharge^{5 10}. For the
45 control group, 30-day treatment failure rates after hospitalization for AECOPD are
46 approximately 20% according to the literature and our retrospective cohort study^{17, 18}.
47 For PIFR group, 30-day treatment failure rates are 10% based on our preliminary
48 research. The participants will be divided into PIFR group and control group in a 1:1
49 ratio. To test the superiority hypothesis with 80% power with 2-side alpha at 0.05 level,
50 197 subjects will be enrolled for each group. Considering 5% dropout rate, the
51 minimum number of the participants in the study was determined to be 208 per group.
52
53
54
55
56
57
58
59
60

Study outline


The flow chart of the study design is shown in Figure 1. The study will recruit 416 patients with AECOPD whose exacerbated symptoms are relieved by 5-7 days of standard therapy. After enrollment, the participants are divided into PIFR group and control group at a 1:1 ratio according to a random envelope method. All the patients will be given inhaled corticosteroid (ICS)/long-acting β agonist (LABA) (budesonide/formoterol - Symbicort turbuhaler® (AstraZeneca AB) 160/4.5 μg bid or Beclometasone/Formoterol Foster® (Chiesi Farmaceutici S.p.A.) pressure pMDI 100/6 μg 2 puff bid). For symptomatic patients before acute exacerbation, Spiriva handihaler® 18 μg qd or Spiriva respimat® (Boehringer IngelheimPharma GmbH & Co.KG) 2.5 μg qd will be prescribed in combination with ICS/LABA.

For PIFR group, PIFR is measured by InCheck DIAL® (Clement Clarke International Ltd, Harlow, UK and Alliance Tech Medical). The InCheck DIAL® is designed to simulate the “internal resistance” of common inhaler devices, and measure inspiratory flow. These measurements enable the healthcare professional to encourage patients to modify their inspiratory technique (by inhaling with more, or less effort), in order to achieve a flow rate consistent with clinical efficacy. The colored ‘flow’ icons show the clinically effective flow ranges for each different inhaler device. The InCheck DIAL® is accurate to $\pm 10\%$ or 10 L/min, whichever is greater, and is a low-range inspiratory flow meter (15 to 120 L/min) that has a selectable resistance from high to low, shown by the colored ‘flow’ icons calibrated to enable the measurement of airflow as if the patient was using certain different inhalers. Moreover, the InCheck DIAL® is an inhalation airflow training meter that can help educate and assess patients who use inhaler devices.

If PIFR is less than 60L/min , the patient will be given pMDI with spacer. If PIFR value is over 60 L/min, the patient will be given dry powder inhaler (DPI). Furthermore, InCheck DIAL® will be used for an inhalation device training. The control group will be given DPI or pMDI with spacer according to the judgment of a respiratory physician.

Both groups will be taught to use the device after the prescription, and then be reminded to use medication via a WeChat public account.

Figure 1. The flow chart of the study



Study step

The participants will be followed up for 3 months and 3 visits will be performed at baseline (symptoms of AECOPD are relieved by 5-7 days of standard therapy), 1 and 3 months after enrollment.

Demographics, clinical characteristics, evaluation of respiratory symptoms and quality of life in the stable phase, PIFR, routine laboratory tests for AE patients (e.g. blood routine, C-reactive protein, liver and kidney function, blood electrolytes, B-type natriuretic peptide, D-dimer), chest X-ray or CT and echocardiography or electrocardiogram in the stable phase will be collected at baseline. Demographics includes age, gender, age, height, weight, ethnicity, occupation (number of years of work), marital status, location, etc. Clinical characteristics includes past disease history, history of drug sensitivity, history of vaccination, family disease history, current medical history, comorbidities, medications, etc. Respiratory symptoms will be assessed with the modified Medical Research Council (mMRC) dyspnea scale and the COPD Assessment Test (CAT) score for the patients. Quality of life will be assessed with St. George's Respiratory Questionnaire (SGRQ) scale. All baseline data will be collected by attending physician on the day of enrollment.

CAT score, mMRC score, SGRQ score, PIFR, spirometry, the error rate of inhalation device use, satisfaction with inhalation devices, condition of AE and COPD medicine treatment will be collected at both 1- and 3-month visit. The data to be collected for each visit is shown in Table 1.

Table 1. Data collected at each visit

	V0	V1	V2	V3
	Hospitalization \pm 1 day	At the time of discharge (meet discharge standards)	1 month after discharge	3 month after discharge
Basic Information	√			

Information of COPD at stable phase	√			
Blood routine	√	√		
Liver and kidney function	√	√		
Electrolyte	√	√		
C-reactive protein	√	√		
procalcitonin	√	√		
brain natriuretic peptide	√	√		
D-dimer , Fibrinogen	√	√		
cardiac troponin T	√	√		
CAT score	√	√	√	√
mMRC	√	√	√	√
SGRQ		√	√	√
Drug for COPD	Stable phase	AE phase	Stable phase	Stable phase
PIFR		PIFR√	PIFR√	PIFR√
Prognosis			√	√
Pulmonary function		√	√	√
Echocardiography at stable phase				
CT at stable phase				
CT at AE phase				
Error of inhaler use			√	√
Satisfaction with the inhaler			√	√
Daily cost of COPD related treatment			√	√

Endpoints

The primary endpoint is 30-day treatment failure rate of AECOPD. Treatment failure means AECOPD recurrence resulting in an emergency visit, admission, or need for intensified medication.

Secondary endpoints include PIFR, the error rate of inhalation device use, satisfaction with inhalation devices, 30-day mortality, 90-day mortality, symptoms and

life quality of patients and COPD-related treatment costs.

Patients' satisfaction with inhalation devices will be assessed by the following items. If the patient meets any of the following, the result will be unsatisfactory: (1)the patient has forgotten to use the inhaler; (2)the patient has forgotten to use the inhaler in the last two weeks; (3)the patient has reduced the frequency of using inhaler without medical advice; (4)the patient has forgotten to bring an inhaler when traveling or leaving home; (5)the patient has quitted the inhaler without medical advice when feeling his condition improved; (6)he patient has felt it difficult to comply with the COPD treatment plan; (7)the patient has felt it difficult to use the inhaler.

The symptoms of patients are evaluated by the COPD assessment test (CAT) and the modified Medical Research Council (mMRC) dyspnea scale. The patients' quality of life are evaluated by St.George's Respiratory Questionnaire(SGRQ).

PIFR is measured by InCheck DIAL® (Clement Clarke International Ltd, Harlow, UK and Alliance Tech Medical).

The error rate of inhalation device use is described in Table 2^{7 8}.

Table 2. The error rate of inhalation device use

Turbuhaler (7 critical errors)	Diskus/Accuhaler (3 critical errors)	pMDI (7 critical errors)
Cover is not removed/ Cover is not covered properly.	-	Cover is not removed/ Cover is not covered properly.
Patient reduces dose due to shaking or tilting during preparation.	-	NA
Patient forces insufficiently when inhaling.	Patient forces insufficiently when inhaling.	-
Patient does not tilt head to make the chin slightly upturned.	-	Patient does not tilt head to make the chin slightly upturned.
Patient does not exhale to empty the lung before inhaling.	Patient does not exhale to empty the lung before inhaling.	Patient does not exhale to empty the lung before inhaling.
-	-	Patient exhales into the

		device before inhaling.
Patient does not seal the mouthpiece with the lips.	-	Patient does not seal the mouthpiece with the lips.
NA	NA	Releasing drug is out of sync with inhaling.
Patient does not hold breath(or hold breath less than 3s).	Patient does not hold breath(or hold breath less than 3s).	Patient does not hold breath(or hold breath less than 3s).

Randomization

Enrollment and randomization are performed at Zhongshan Hospital of Fudan University. After enrollment, patients will be assigned into two groups via a random envelope method in a 1:1 ratio to the PIFR group and control group by random number table method generated by SPSS.

Blinding

The study adopts blind evaluation. The investigator will enroll participants and assign them into two groups. All data at baseline, 1- and 3-month visit will be collected by attending physician, who will not be informed of which group the patient has been assigned. In addition, patients will not know the group they belong to. Blind evaluation maximizes the objectivity and reliability of the study.

Statistical analysis

1. Statistical analysis datasets

- Modified intent-to-treat set (MITTS)

Subjects that have undergone randomization and interventions, and carry out primary endpoints evaluation.

- Safety set (SS)

Subjects that are randomized, undergo the intervention, and with safety evaluation

1
2
3
4 data.

5 6 2. Statistical analysis methods

7
8 Statistical analyses were performed using SPSS 22.0. Continuous variables are
9 described as mean (SD) or median (p25,p75) and count variables are described as
10 frequency and percentage. All tests were both sided and statistical analysis, 0.05 was
11 set as the P value for significance. For discrete variables including 30-day
12 treatment failure rate, the error rate of inhalation device use, satisfaction with inhalation
13 devices, 30-day mortality and 90-day mortality, a chi-squared (χ^2) test, Fisher's exact
14 test or CMH χ^2 test will be used. For continuous variable including PIFR, CAT score,
15 mMRC score, SGRQ score and COPD-related treatment costs, Student's t-tests or
16 Mann-Whitney test will be used.
17
18
19
20
21
22
23
24
25
26
27

28 Patient and public Involvement

29
30 Patients or the public were not involved in the design, or conduct, or reporting, or
31 dissemination of our research. The results will be available to the public if necessary.
32
33
34
35
36
37

38 Discussion

39
40 Drug delivery by DPI depends on the inbuilt resistance of the inhaler and the PIFR
41 generated by the patient. PIFR generally depends on an individual's effort as well as
42 the respiratory muscle force, which may be decreased in patients with COPD due to
43 airway stenosis, lung hyperinflation, hypoxemia, and muscle wasting. DPI are breath-
44 actuated that require the individual to create turbulent forces to disaggregate the powder
45 into respirable particles which can reach the lower respiratory tract. Patients with a
46 sufficient PIFR (PIFR > 60 L/min) are able to release the powder and deaggregate the
47 drug resulting in lung deposition.
48
49
50
51
52
53
54

55
56 Sharma and colleagues have found that 31.7% of patients at discharge following
57 hospitalization for an exacerbation of COPD had PIFR less than 60 L/min³. Patients
58 with a PIFR less than 60 L/min have been considered not be able to inhale medications
59
60

1
2
3
4 using a DPI effectively into the lower respiratory tract according to the literature, while
5 a PIFR less than 30 liters/minute is insufficient^{20 21}. However, most clinicians in china
6 prescribe DPI to the patients recovering from AECOPD routinely due to the lack of the
7 availability of long-acting bronchodilators with pMDI without measuring their PIFR.
8 Inappropriate inhaler selection may result in treatment failure of AECOPD. Before our
9 study, it remains unclear whether treatment failure rate is related to PIFR-based inhaler
10 description. A suitable inspiratory flow rate helps to improve the treatment efficacy. In
11 addition to inhaler selection, PIFR group also receive inhaler training to help patients
12 master the correct inhalation method.
13
14
15
16
17
18
19
20

21 Our research has proposed to measure PIFR of patients recovering from AECOPD
22 by InCheck DIAL® and guide COPD inhaler choices and inhaler technique training.
23 The aim of this study is to determine whether the optimized inhalation therapy based
24 on PIFR measured against the simulated resistance can reduce the rate of treatment
25 failure in patients recovering from AECOPD. Therefore, we plan to verify the clinical
26 significance of including PIFR in the discharge protocol through comparing the
27 difference in 30-day treatment failure rates and other endpoints between PIFR group
28 and the control group.
29
30
31
32
33
34
35
36
37
38
39
40

41 **Conclusion**

42
43 The study investigates the effect of optimized inhalation therapy based on PIFR
44 measured against the simulated resistance in patients recovering from AECOPD on
45 reducing 30-day treatment failure rates. Other outcomes including symptoms and life
46 quality of patients, the error rate of inhalation device use, satisfaction with inhalation
47 devices, 30-day mortality, 90-day mortality, PIFR and COPD-related treatment costs
48 will also be evaluated. We expect to reduce treatment failure rate of AECOPD and
49 promote COPD management through guiding COPD treatment choices based on PIFR.
50
51
52
53
54
55
56
57
58
59
60

References

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet (London, England)* 2012;380(9859):2095-128. doi: 10.1016/s0140-6736(12)61728-0 [published Online First: 2012/12/19]
2. Zhu B, Wang Y, Ming J, et al. Disease burden of COPD in China: a systematic review. *Int J Chron Obstruct Pulmon Dis* 2018;13:1353-64. doi: 10.2147/copd.S161555 [published Online First: 2018/05/08]
3. Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. *Lancet (London, England)* 2018;391(10131):1706-17. doi: 10.1016/s0140-6736(18)30841-9 [published Online First: 2018/04/14]
4. Cai BQ, Cai SX, Chen RC, et al. Expert consensus on acute exacerbation of chronic obstructive pulmonary disease in the People's Republic of China. *Int J Chron Obstruct Pulmon Dis* 2014;9:381-95. doi: 10.2147/copd.S58454 [published Online First: 2014/05/09]
5. Mahler DA. Peak Inspiratory Flow Rate as a Criterion for Dry Powder Inhaler Use in Chronic Obstructive Pulmonary Disease. *Ann Am Thorac Soc* 2017;14(7):1103-07. doi: 10.1513/AnnalsATS.201702-156PS [published Online First: 2017/05/10]
6. Lopez-Campos JL, Soler-Cataluna JJ, Miravittles M. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2019 Report: Future Challenges. *Archivos de bronconeumologia* 2019 doi: 10.1016/j.arbres.2019.06.001 [published Online First: 2019/07/20]
7. Cho-Reyes S, Celli BR, Dembek C, et al. Inhalation Technique Errors with Metered-Dose Inhalers Among Patients with Obstructive Lung Diseases: A Systematic Review and Meta-Analysis of U.S. Studies. *Chronic Obstr Pulm Dis* 2019;6(3):267-80. doi: 10.15326/jcopdf.6.3.2018.0168 [published Online First: 2019/07/26]
8. Price DB, Roman-Rodriguez M, McQueen RB, et al. Inhaler Errors in the CRITIKAL Study: Type, Frequency, and Association with Asthma Outcomes. *The journal of allergy and clinical immunology In practice* 2017;5(4):1071-81.e9. doi: 10.1016/j.jaip.2017.01.004 [published Online First: 2017/03/14]
9. Usmani OS, Lavorini F, Marshall J, et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. *Respir Res* 2018;19(1):10. doi: 10.1186/s12931-017-0710-y [published Online First: 2018/01/18]
10. Sharma G, Mahler DA, Mayorga VM, et al. Prevalence of Low Peak Inspiratory Flow Rate at Discharge in Patients Hospitalized for COPD Exacerbation. *Chronic Obstr Pulm Dis* 2017;4(3):217-24. doi: 10.15326/jcopdf.4.3.2017.0183 [published Online First: 2017/08/30]
11. Ross DL, Schultz RK. Effect of inhalation flow rate on the dosing characteristics of dry powder inhaler (DPI) and metered dose inhaler (MDI) products. *Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine* 1996;9(2):215-26. doi: 10.1089/jam.1996.9.215 [published Online First: 1997/02/01]
12. Al-Showair RA, Tarsin WY, Assi KH, et al. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? *Respiratory medicine* 2007;101(11):2395-401.

- doi: 10.1016/j.rmed.2007.06.008 [published Online First: 2007/07/17]
13. Mahler DA, Waterman LA, Ward J, et al. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate. *Journal of aerosol medicine and pulmonary drug delivery* 2014;27(2):103-9. doi: 10.1089/jamp.2013.1038 [published Online First: 2013/06/12]
14. Liu D, Peng SH, Zhang J, et al. Prediction of short term re-exacerbation in patients with acute exacerbation of chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis* 2015;10:1265-73. doi: 10.2147/COPD.S83378 [published Online First: 2015/07/15]
15. Mahler DA, Waterman LA, Gifford AH. Prevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus(R) dry powder inhaler. *Journal of aerosol medicine and pulmonary drug delivery* 2013;26(3):174-9. doi: 10.1089/jamp.2012.0987 [published Online First: 2012/10/03]
16. Broeders ME, Molema J, Hop WC, et al. The course of inhalation profiles during an exacerbation of obstructive lung disease. *Respiratory medicine* 2004;98(12):1173-9. [published Online First: 2004/12/14]
17. Hu WP, Lhamo T, Liu D, et al. Development of a Nomogram to Predict the Risk of 30-Day Re-Exacerbation for Patients Hospitalized for Acute Exacerbation of Chronic Obstructive Pulmonary Disease. *Copd* 2019;16(2):160-67. doi: 10.1080/15412555.2019.1606187 [published Online First: 2019/05/17]
18. Loh CH, Peters SP, Lovings TM, et al. Suboptimal Inspiratory Flow Rates Are Associated with Chronic Obstructive Pulmonary Disease and All-Cause Readmissions. *Ann Am Thorac Soc* 2017;14(8):1305-11. doi: 10.1513/AnnalsATS.201611-903OC [published Online First: 2017/04/14]
19. Kim V, Aaron SD. What is a COPD exacerbation? Current definitions, pitfalls, challenges and opportunities for improvement. *Eur Respir J* 2018;52(5) doi: 10.1183/13993003.01261-2018 [published Online First: 2018/09/22]
20. Broeders ME, Molema J, Vermue NA, et al. In Check Dial: accuracy for Diskus and Turbuhaler. *International journal of pharmaceutics* 2003;252(1-2):275-80. [published Online First: 2003/01/29]
21. Atkins PJ. Dry powder inhalers: an overview. *Respiratory care* 2005;50(10):1304-12; discussion 12. [published Online First: 2005/09/28]

Contributors: JLH and JZ designed the protocol, drafted and critically revised the manuscript. WZ planned the Statistical analysis methods. All authors revised and approved the manuscript.

Ethics and dissemination: This trial has been registered in the Ethics Committee of Zhongshan Hospital of Fudan University (B2019-142) and Clinical Trails (NCT04000958).

Funding statement: This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

1
2
3 **Competing interests statement:** None declared.
4
5

6 **Word Count: 3988**
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only




Figure 1

209x297mm (300 x 300 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description
Administrative information		
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry
	2b	All items from the World Health Organization Trial Registration Data Set
Protocol version	3	Date and version identifier
Funding	4	Sources and types of financial, material, and other support
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors
	5b	Name and contact information for the trial sponsor
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)
Introduction		
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention
	6b	Explanation for choice of comparators
Objectives	7	Specific objectives or hypotheses
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)

Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size

Methods: Assignment of interventions (for controlled trials)

Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions
---------------------	-----	--

1			
2	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central
3	concealment		telephone; sequentially numbered, opaque, sealed envelopes),
4	mechanism		describing any steps to conceal the sequence until interventions are
5			assigned
6			
7	Implementation	16c	Who will generate the allocation sequence, who will enrol participants,
8			and who will assign participants to interventions
9			
10	Blinding	17a	Who will be blinded after assignment to interventions (eg, trial
11	(masking)		participants, care providers, outcome assessors, data analysts), and
12			how
13		17b	If blinded, circumstances under which unblinding is permissible, and
14			procedure for revealing a participant's allocated intervention during
15			the trial
16			
17			
18			
19			

Methods: Data collection, management, and analysis

20			
21	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other
22	methods		trial data, including any related processes to promote data quality (eg,
23			duplicate measurements, training of assessors) and a description of
24			study instruments (eg, questionnaires, laboratory tests) along with
25			their reliability and validity, if known. Reference to where data
26			collection forms can be found, if not in the protocol
27		18b	Plans to promote participant retention and complete follow-up,
28			including list of any outcome data to be collected for participants who
29			discontinue or deviate from intervention protocols
30			
31	Data	19	Plans for data entry, coding, security, and storage, including any
32	management		related processes to promote data quality (eg, double data entry;
33			range checks for data values). Reference to where details of data
34			management procedures can be found, if not in the protocol
35			
36	Statistical	20a	Statistical methods for analysing primary and secondary outcomes.
37	methods		Reference to where other details of the statistical analysis plan can be
38			found, if not in the protocol
39		20b	Methods for any additional analyses (eg, subgroup and adjusted
40			analyses)
41		20c	Definition of analysis population relating to protocol non-adherence
42			(eg, as randomised analysis), and any statistical methods to handle
43			missing data (eg, multiple imputation)
44			
45			
46			
47			
48			
49			
50			
51			

Methods: Monitoring

52			
53	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role
54			and reporting structure; statement of whether it is independent from
55			the sponsor and competing interests; and reference to where further
56			details about its charter can be found, if not in the protocol.
57			Alternatively, an explanation of why a DMC is not needed
58			
59			
60			

1			
2		21b	Description of any interim analyses and stopping guidelines, including
3			who will have access to these interim results and make the final
4			decision to terminate the trial
5			
6	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and
7			spontaneously reported adverse events and other unintended effects
8			of trial interventions or trial conduct
9			
10	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and
11			whether the process will be independent from investigators and the
12			sponsor
13			
14			

Ethics and dissemination

15			
16			
17	Research ethics	24	Plans for seeking research ethics committee/institutional review board
18	approval		(REC/IRB) approval
19			
20	Protocol	25	Plans for communicating important protocol modifications (eg,
21	amendments		changes to eligibility criteria, outcomes, analyses) to relevant parties
22			(eg, investigators, REC/IRBs, trial participants, trial registries, journals,
23			regulators)
24			
25			
26	Consent or assent	26a	Who will obtain informed consent or assent from potential trial
27			participants or authorised surrogates, and how (see Item 32)
28			
29		26b	Additional consent provisions for collection and use of participant data
30			and biological specimens in ancillary studies, if applicable
31			
32	Confidentiality	27	How personal information about potential and enrolled participants will
33			be collected, shared, and maintained in order to protect confidentiality
34			before, during, and after the trial
35			
36			
37	Declaration of	28	Financial and other competing interests for principal investigators for
38	interests		the overall trial and each study site
39			
40	Access to data	29	Statement of who will have access to the final trial dataset, and
41			disclosure of contractual agreements that limit such access for
42			investigators
43			
44			
45	Ancillary and	30	Provisions, if any, for ancillary and post-trial care, and for
46	post-trial care		compensation to those who suffer harm from trial participation
47			
48	Dissemination	31a	Plans for investigators and sponsor to communicate trial results to
49	policy		participants, healthcare professionals, the public, and other relevant
50			groups (eg, via publication, reporting in results databases, or other
51			data sharing arrangements), including any publication restrictions
52			
53		31b	Authorship eligibility guidelines and any intended use of professional
54			writers
55			
56		31c	Plans, if any, for granting public access to the full protocol, participant-
57			level dataset, and statistical code
58			
59			
60			

Appendices

Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.

For peer review only

BMJ Open

The effect of PIFR-based Optimized Inhalation Therapy in Patients Recovering From Acute exacerbation of Chronic Obstructive Pulmonary Disease: protocol of a prospective, multi-center, superiority, randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-034804.R1
Article Type:	Protocol
Date Submitted by the Author:	19-Dec-2019
Complete List of Authors:	Hua, Jianlan; Zhongshan Hospital Fudan University, Department of Pulmonary and Critical Care Medicine Zhang, wei; Fudan University, Department of Biostatistics Cao, Hui-fang; Shanghai Jing'an District Central Hospital Du, Chun-ling; Shanghai Qingpu District Central Hospital Ma, Jia-yun; North Branch of Shanghai Ninth People's Hospital Zuo, Yi-hui; Zhongshan Hospital Fudan University, Department of Pulmonary and Critical Care Medicine Zhang, Jing; Zhongshan Hospital Fudan University, Department of Pulmonary and Critical Care Medicine
Primary Subject Heading:	Respiratory medicine
Secondary Subject Heading:	Medical education and training, Pharmacology and therapeutics, Research methods
Keywords:	RESPIRATORY MEDICINE (see Thoracic Medicine), Chronic airways disease < THORACIC MEDICINE, MEDICAL EDUCATION & TRAINING

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **The effect of PIFR-based Optimized Inhalation Therapy in**
5
6 **Patients Recovering From Acute exacerbation of Chronic**
7
8 **Obstructive Pulmonary Disease: protocol of a prospective,**
9
10 **multi-center, superiority, randomized controlled trial**
11
12
13

14 Jian-lan Hua¹, Wei Zhang², Hui-fang Cao³, Chun-ling Du ⁴, Jia-yun Ma ⁵ , Yi-hui Zuo¹, Jing
15
16 Zhang^{1*}
17

18
19 ¹Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Shanghai Medical
20
21 College, Fudan University, Shanghai, China
22
23

24 ²Department of Biostatistics, School of Public Health, Fudan University, Shanghai, China
25
26

27 ³ Department of Pulmonary, Shanghai Jing 'an District Central Hospital, Shanghai, China
28
29

30 ⁴ Department of Pulmonary, Shanghai Qingpu District Central Hospital, Shanghai, China
31
32

33 ⁵ Department of Pulmonary, North Branch of Shanghai Ninth People's Hospital, Shanghai JiaoTong
34
35 University school of medicine, Shanghai, China
36

37 * Correspondence: Jing Zhang
38
39

40 Department of Pulmonary and Critical Care Medicine, Zhongshan hospital, Shanghai Medical
41
42 College, Fudan University, 180 Feng lin road, shanghai 200032, People's Republic of China
43
44

45 Email: jingatlas@hotmail.com
46
47

48
49
50 Date: 2019/12/10
51

52 version identifier: 1.2
53
54
55
56
57
58
59
60

Abstract:

Introduction: Chronic Obstructive Pulmonary Disease (COPD) is a global respiratory disease. Acute exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) is a major cause of disease progression and death, and causes huge medical expenditures. Effective inhalation therapy is important during the AE recovery period. However, the invalid inhalation using DPI due to the unrecovered inspiratory flow rate after AECOPD results in increased risk of treatment failure and early recurrence. We envisage that choosing the right inhaler based on peak inhalation flow rate (PIFR) and training inhaler techniques will contribute to reducing early relapse rates. Therefore, a prospective multicenter randomized trial is designed to verify this hypothesis.

Methods and analysis: The study is aimed at determining whether the optimized inhalation therapy based on PIFR can reduce the rate of treatment failure in patients recovering from AECOPD. In the study, 416 patients with AECOPD whose exacerbated symptoms are relieved by 5-7 days of standard therapy will be recruited and be randomized into PIFR group, which receives inhaler depending on their PIFR and is trained to use the inhaler appropriately, and control group, which receives inhaler depending on the judgment of a respiratory physician, at a 1:1 ratio. The primary outcome of the study is 30-day treatment failure rate. Other endpoints include PIFR, the error rate of inhalation device use, satisfaction with inhalation devices, 30-day mortality, 90-day mortality, symptoms and life quality of patients and COPD-related treatment costs.

Ethics and dissemination: This trial has been registered in the Ethics Committee of Zhongshan Hospital of Fudan University (B2019-142). Participants will be screened and recruited from hospitalized patients by physicians. No public recruitment documents will be used for participants enrollment.

Trial registration: This trial has been registered in Clinical Trials (NCT04000958).

Strengths and limitations of this study:

1. To our knowledge, this is the first multicenter, randomized trial designed to study the efficacy of PIFR-based inhaler prescription in preventing short-term re-exacerbation in patients recovering from severe acute exacerbation of COPD.
2. InCheck DIAL® is used to measure PIFR and objectively evaluate the capacity of using dry powder inhalers.

3. The inhaler technique will be trained as well to achieve optimal inhalation therapy.
4. Inhalers studied in this trial include turbuhaler, handihaler, respimat and pMDI.
5. The limitation of the study is the single-blind study design, which would yield bias, although blind evaluation is adopted to minimize the bias.

Keywords: chronic obstructive pulmonary disease, acute exacerbation of chronic obstructive pulmonary disease, peak inhalation flow rate

Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a global respiratory disease that severely threatens human health. COPD has a significant socioeconomic burden, and is currently the fourth leading cause of death in the world but is projected to be the 3rd leading cause of death by 2020¹. In China, COPD ranked among the top three leading causes of death and the direct medical cost of COPD ranged from 72 to 3,565 USD per capita per year, accounting for 33.33% to 118.09% of local average annual income². The overall prevalence of spirometry-defined COPD was 8.6% among the general Chinese population aged 20 years or older³. Acute exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) is a major cause of disease progression and death, and causes huge medical expenditures⁴.

Inhalation therapy is the core pharmaceutical therapy for COPD including inhaled corticosteroid (ICS), both short- and long-acting beta2-agonists and, more recently, muscarinic antagonists⁵. Existing common devices include pressure metered dose inhaler (pMDI), dry powder inhalers (DPIs), soft mist inhalers (SMIs), and nebulizers⁶. Common inhaler errors include insufficient inspiratory effort, no breath-hold (or holds breath for less than 3s), etc^{7 8}. Inhaler errors are associated with poor disease outcomes (exacerbations) and greater health-economic burden⁹. MDIs require complex coordination techniques with a slow inhalation by the patient to achieve a clinically effective dose. DPIs decrease the complexity of administration, but effective medication delivery is dependent on the force of the patient's inspiratory effort to

1
2
3
4 overcome internal resistance¹⁰. Several *in vitro* studies have demonstrated the
5 inhalation flow rate dependency of DPI. Specifically, the results showed that both the
6 amount of medication delivered to the patient and the effective aerodynamic particle
7 size of the medication were adversely affected when the testing peak inhalation flow
8 rate (PIFR) was less than 60 liters/min (measured at no resistance)¹¹, which may result
9 in ineffective inhalation of medications using a DPI. Several studies suggest that
10 patients with insufficient PIFR in stable phase of COPD may have an adverse effect on
11 prognosis using inappropriate inhaler^{12 13}. Moreover, it should be noted that expiratory
12 flow rate (such as FEV₁) is not correlated linearly with inspiratory flow parameters, and
13 it do not predict PIFR. Other risk factors for early AECOPD recurrence include age
14 grades, GOLD grades, AE frequency in the previous year, pleural effusion, use of
15 accessory respiratory muscles, noninvasive mechanical ventilation, controlled oxygen
16 therapy and length of hospital stay, while inhaled long-acting β -2-agonists (LABA) and
17 inhaled corticosteroids (ICS) are protection factors¹⁴. An investigation suggests that one
18 of five stable outpatients more than 60 years of age with severe COPD did not reach the
19 recommended PIFR for DPI devices¹⁵. Some small sample studies has shown that a
20 significant proportion of patients are not suitable for DPI during AECOPD because of
21 their insufficient PIFR^{13 16}. However, there is no study about the PIFR status and the
22 impact of inhaler choices on prognosis for patients recovering from AECOPD.

23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41 Thirty-day readmission rates after hospitalization for AECOPD are approximately
42 15.8%-20%^{17 18}. Readmissions are costly and adversely affect quality of life. But little
43 is known about PIFRs of the patients recovering from AECOPD as well as the clinical
44 impact of the inhaler (DPI or pMDI) selected for the patients. Generally, discharge
45 protocols for patients recovering from AECOPD do not include an assessment of PIFR
46 or patients' ability to use their inhaler device when they recuperate after discharge.
47 Clinicians typically select the inhaler they use during the stable phase of COPD for
48 patients who will be discharged. Furthermore, although some evidence has suggested
49 that incorrect use of inhalers is associated with poor prognosis, studies on the effect of
50 training patients on the use of inhalers to reduce relapses are still scarce. We
51 hypothesize PIFR of patients recovering from AECOPD have not returned to the level
52
53
54
55
56
57
58
59
60

1
2
3
4 at the stable phase of COPD as well as untrained patients have higher rate of inhaler
5 errors. It may result in suboptimal COPD management and treatment failure (including
6 recurrence resulting in an emergency visit, admission, or need for intensified
7 medication) for the patients due to the ineffective inhalation of medications.
8
9

10
11 The aim of this study is to determine whether the optimized inhalation therapy based
12 PIFR can reduce the rate of treatment failure in patients recovering from AECOPD.
13 Errors in inhaler use and quality of life are also to be evaluated.
14
15
16
17

18 19 20 21 **Methods and analysis**

22 23 24 **Trial design**

25
26 This is a prospective, multi-center, single-blind, superiority, randomized study of
27 patients hospitalized for a COPD exacerbation. This study is designed to determine
28 whether PIFR based inhaler choice and training can reduce the rate of treatment failure
29 in patients recovering from AECOPD. The primary study outcome is 30-day treatment
30 failure rate. Treatment failure means AECOPD recurrence resulting in an emergency
31 visit, admission, or need for intensified medication. Other endpoints include symptoms
32 and life quality of patients the error rate of inhalation device use, satisfaction with
33 inhalation devices, PIFR, 30-day mortality, 90-day mortality, and COPD-related
34 treatment costs. The enrollment, conduct and data analysis of the trail are performed at
35 Zhongshan Hospital of Fudan University, Shanghai Jing 'an District Central Hospital,
36 Shanghai Qingpu District Central Hospital and North Branch of Shanghai Ninth
37 People's Hospital in China. The study is expected to last for 2 years. Recruitment of
38 participants has started since November 2019.
39
40
41
42
43
44
45
46
47
48
49
50

51 This trial has been registered in the Ethics Committee of Zhongshan Hospital of
52 Fudan University (B2019-142) and Clinical Trails (NCT04000958).
53
54
55

56 57 58 **Inclusion criteria**

59 All patients meeting AECOPD diagnostic criteria who hospitalized for COPD related
60

1
2
3
4 reasons will be followed. The definition of COPD follows the GOLD definition and the
5
6 definition of AECOPD follows Expert Consensus on Acute Exacerbation of Chronic
7
8 Obstructive Pulmonary Disease in the People's republic of China⁴. AECOPD is defined
9
10 as sudden worsening of respiratory symptoms that require additional treatment (typical
11
12 manifestations include dyspnea, aggravated cough, increased sputum volume, and/or
13
14 sputum purulence) and is beyond normal day-to-day variations, leading to a change in
15
16 medications^{4 19}. The subjects will be enrolled and randomized into the study group if
17
18 all of the following criteria are met: (1) 40–80 years old; (2) patients with AECOPD
19
20 whose acute respiratory symptoms have been controlled and met discharge criteria after
21
22 5-7 day-standard AECOPD treatment including atomized or inhaled bronchodilator
23
24 plus oral or intravenous glucocorticoid (prednisone equivalent dose 40-50mg) or
25
26 Pulmicort 2mg atomization twice daily plus broad-spectrum antibiotics; (3) patients
27
28 with moderate and above COPD with a recorded spirometry measured in the stable
29
30 disease status, ie, post-bronchodilator forced expiratory volume in one second
31
32 (FEV1)/forced vital capacity (FVC) <70% and FEV1% predicted value <80%; (4)
33
34 patients have signed an informed consent form.

35
36 Discharge criteria is as follows: (1) physician are confident that the patient can
37
38 manage successfully at home; (2) long-acting bronchodilators, either beta 2-agonists
39
40 and/or anticholinergics with or without inhaled corticosteroids can be used, and inhaled
41
42 short-acting β 2-agonist therapy is required no more frequently than every 4 hours; (3)
43
44 the patient, if previously ambulatory, is able to walk across the room; (4) the patient is
45
46 able to eat and sleep without frequent awakening due to dyspnea; (5) the patient has
47
48 been clinically stable for 12–24 hours; (6) arterial blood gases have been stable for 12–
49
50 24 hours⁴.

51 52 53 Exclusion criteria

54
55 Exclusion criteria include:(1) patients who is already using home nebulization
56
57 therapy because of the severity of the disease; (2) patients with bronchial asthma,
58
59 pulmonary interstitial fibrosis, bronchiectasis, pulmonary embolism and other lung
60

1
2
3
4 diseases; or hypertension, heart disease, chronic liver and kidney disease, diabetes,
5 chronic gastrointestinal diseases, malignant tumors, critically ill; (3) patient's mental
6 state cannot match the observation or suffer from cognitive impairment; (4) patient's
7 peak inspiratory flow rates (PIFR) is less than 20L/min.
8
9
10

11 12 13 14 Sample size

15
16 The sample size was calculated using PASS 15.0 (Power Analysis and Sample Size
17 Software) to ensure the study power. Several studies have found that 30-47% patients
18 hospitalized for AECOPD had a PIFR < 60 liters/minute prior to discharge^{5 10}. For the
19 control group, 30-day treatment failure rates after hospitalization for AECOPD are
20 approximately 20% according to the literature and our retrospective cohort study^{17, 18}.
21 For PIFR group, 30-day treatment failure rates are 10% based on our preliminary
22 research. The participants will be divided into PIFR group and control group in a 1:1
23 ratio. To test the superiority hypothesis with 80% power with 2-side alpha at 0.05 level,
24 197 subjects will be enrolled for each group. Considering 5% dropout rate, the
25 minimum number of the participants in the study was determined to be 208 per group.
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 Study outline

41 The flow chart of the study design is shown in Figure 1. The study will recruit 416
42 patients with AECOPD whose exacerbated symptoms are relieved by 5-7 days of
43 standard therapy. After enrollment, the participants are divided into PIFR group and
44 control group at a 1:1 ratio according to a random envelope method. All the patients
45 will be given inhaled corticosteroid (ICS)/long-acting β agonist (LABA) (budesonide/
46 formoterol - Symbicort turbuhaler® (AstraZeneca AB) 160/4.5 μg bid or
47 Beclometasone/ Formoterol Foster® (Chiesi Farmaceutici S.p.A.) pressure pMDI 100/6
48 μg 2 puff bid). For symptomatic patients (mMRC \geq 2, CAT \geq 10) before acute
49 exacerbation, Spiriva handihaler® 18 μg qd or Spiriva respimat® (Boehringer
50 IngelheimPharma GmbH & Co.KG) 2.5 μg qd will be prescribed in combination with
51
52
53
54
55
56
57
58
59
60

1
2
3
4 ICS/LABA.

5 For PIFR group, PIFR is measured by InCheck DIAL® (Clement Clarke
6 International Ltd, Harlow, UK and Alliance Tech Medical). The InCheck DIAL® is
7 designed to simulate the “internal resistance” of common inhaler devices, and measure
8 inspiratory flow. These measurements enable the healthcare professional to encourage
9 patients to modify their inspiratory technique (by inhaling with more, or less effort), in
10 order to achieve a flow rate consistent with clinical efficacy. The colored ‘flow’ icons
11 show the clinically effective flow ranges for each different inhaler device. The InCheck
12 DIAL® is accurate to $\pm 10\%$ or 10 L/min, whichever is greater, and is a low-range
13 inspiratory flow meter (15 to 120 L/min) that has a selectable resistance from high to
14 low, shown by the colored ‘flow’ icons calibrated to enable the measurement of airflow
15 as if the patient was using certain different inhalers. In this study, we set the resistance
16 of the InCheck DIAL® to zero when measuring PIFR. Before measuring. We will first
17 train patients to use the InCheck DIAL® correctly. After patients are able to reach their
18 maximum value of PIFR steadily, we will measure the PIFR 3 times and take the
19 average as a result.
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 Moreover, the InCheck DIAL® is an inhalation airflow training meter that can help
35 educate and assess patients who use inhaler devices. When training the patient, we will
36 set the corresponding resistance for the InCheck DIAL® according to the inhaler that
37 the patient is prescribed. We will also explain to the patient the proper operation of the
38 inhaler and demonstrate some common mistakes.
39
40
41
42
43

44 If PIFR is less than 60L/min (measured without a resistance), the patient will be given
45 pMDI with spacer. If PIFR value is over 60 L/min (measured without a resistance), the
46 patient will be given dry powder inhaler (DPI). Furthermore, InCheck DIAL® will be
47 used for an inhalation device training. The control group will be given DPI or pMDI
48 with spacer according to the judgment of a respiratory physician.
49
50
51
52
53

54 Both groups will be taught to use the device after the prescription, and then be
55 reminded to use medication via a WeChat public account.
56
57
58
59
60

Study step

The participants will be followed up for 3 months and 3 visits will be performed at baseline (symptoms of AECOPD are relieved by 5-7 days of standard therapy), 1 and 3 months after enrollment.

Demographics, clinical characteristics, evaluation of respiratory symptoms and quality of life in the stable phase, PIFR, routine laboratory tests for AE patients (e.g. blood routine, C-reactive protein, liver and kidney function, blood electrolytes, B-type natriuretic peptide, D-dimer), chest X-ray or CT and echocardiography or electrocardiogram in the stable phase will be collected at baseline. Demographics includes age, gender, age, height, weight, ethnicity, occupation (number of years of work), marital status, location, etc. Clinical characteristics includes past disease history, history of drug sensitivity, history of vaccination, family disease history, current medical history, comorbidities, medications, etc. Respiratory symptoms will be assessed with the modified Medical Research Council (mMRC) dyspnea scale and the COPD Assessment Test (CAT) score for the patients. Quality of life will be assessed with St. George's Respiratory Questionnaire (SGRQ) scale. All baseline data will be collected by attending physician on the day of enrollment.

CAT score, mMRC score, SGRQ score, PIFR, spirometry, the error rate of inhalation device use, satisfaction with inhalation devices, condition of AE and COPD medicine treatment will be collected at both 1- and 3-month visit. The data to be collected for each visit is shown in Table 1.

Table 1. Data collected at each visit

	V0	V1	V2	V3
	Hospitalization \pm 1 day	At the time of discharge (meet discharge standards)	1 month after discharge	3 month after discharge
Basic Information	√			

Information of COPD at stable phase	√			
Blood routine	√	√		
Liver and kidney function	√	√		
Electrolyte	√	√		
C-reactive protein	√	√		
procalcitonin	√	√		
brain natriuretic peptide	√	√		
D-dimer , Fibrinogen	√	√		
cardiac troponin T	√	√		
CAT score	√	√	√	√
mMRC	√	√	√	√
SGRQ		√	√	√
Drug for COPD	Stable phase	AE phase	Stable phase	Stable phase
PIFR		PIFR√	PIFR√	PIFR√
Prognosis			√	√
Pulmonary function		√	√	√
Echocardiography at stable phase				
CT at stable phase				
CT at AE phase				
Error of inhaler use			√	√
Satisfaction with the inhaler			√	√
Daily cost of COPD related treatment			√	√

Endpoints

The primary endpoint is 30-day treatment failure rate of AECOPD. Treatment failure means AECOPD recurrence resulting in an emergency visit, admission, or need for intensified medication.

Secondary endpoints include PIFR, the error rate of inhalation device use, satisfaction with inhalation devices, 30-day mortality, 90-day mortality, symptoms and

life quality of patients and COPD-related treatment costs.

Patient's satisfaction with inhalation devices will be assessed by FSI-10 questionnaire. The FSI-10 questionnaire is completed by patients themselves, which has been widely applied to assess patients' opinions about ease of use, portability, and usability of inhalers²⁰. The symptoms of patients are evaluated by the COPD assessment test (CAT) and the modified Medical Research Council (mMRC) dyspnea scale. The patients' quality of life are evaluated by St. George's Respiratory Questionnaire (SGRQ).

PIFR is measured by InCheck DIAL® (Clement Clarke International Ltd, Harlow, UK and Alliance Tech Medical).

The error rate of inhalation device use is described in Table 2^{7,8}.

Table 2. The error rate of inhalation device use

Turbuhaler	Handihaler/Accuhaler	pMDI	Respimat
Cover is not removed/ Cover is not covered properly.	Cover is not removed/ Cover is not covered properly.	Cover is not removed/ Cover is not covered properly.	Cover is not removed/ Cover is not covered properly.
Patient reduces dose due to shaking or tilting during preparation.	-	Patient dose not shake device before inhaling	The device is not installed correctly before use.
Device is not held upright.	-	Device is not held upright.	-
Patient does not twist grip at the base or twist around and then back until click is heard.	-	-	Patient dose not turn the device toward the arrow in the label until it clicks.
Patient forces insufficiently when inhaling.	Patient forces insufficiently when inhaling.	Patient dose not inhale deeply and slowly.	Patient dose not inhale deeply and slowly.
Patient does not tilt head to make the chin slightly upturned.	Patient does not hold the head in a vertical position.	Patient does not tilt head to make the chin slightly upturned.	Patient dose not point the inhaler toward the back of throat.

Patient does not exhale to empty the lung before inhaling.	Patient does not exhale to empty the lung before inhaling.	Patient does not exhale to empty the lung before inhaling.	Patient does not exhale to empty the lung before inhaling.
-	Patient does not turn the head away from device and exhale.	Patient exhales into the device before inhaling.	Patient covers the air entries while inhaling.
Patient does not seal the mouthpiece with the lips.	Patient does not put the mouthpiece in mouth, and close the lips.	Patient does not seal the mouthpiece with the lips.	Patient does not seal the mouthpiece with the lips.
NA	NA	Releasing drug is out of sync with inhaling.	Releasing drug is out of sync with inhaling.
Patient does not hold breath(or hold breath less than 3s).	Patient does not hold breath(or hold breath less than 3s).	Patient does not hold breath(or hold breath less than 3s).	Patient does not hold breath(or hold breath less than 10s).
Patient does not put the cover back and wait for 30-60 seconds for the second dose.	Patient dose not dispose of the capsule and put the cover back on the device.	Patient does not exhale and wait for 30-60 seconds before the second puff.	Patient dose not inhales twice to complete the total daily dosage.

Randomization

Enrollment and randomization are performed at Zhongshan Hospital of Fudan University. After enrollment, patients will be assigned into two groups via a random envelope method in a 1:1 ratio to the PIFR group and control group by random number table method generated by SPSS.

Blinding

The study adopts blind evaluation. The investigator will enroll participants and assign them into two groups. All data at baseline, 1- and 3-month visit will be collected by attending physician, who will not be informed of which group the patient has been assigned. In addition, patients will not know the group they belong to. Blind evaluation

1
2
3
4 maximizes the objectivity and reliability of the study.
5
6
7

8 Statistical analysis 9

10 1. Statistical analysis datasets

- 11 • Modified intent-to-treat set (MITTS)

12
13
14 Subjects that have undergone randomization and interventions, and carry out
15
16 primary endpoints evaluation.

- 17 • Safety set (SS)

18
19
20 Subjects that are randomized, undergo the intervention, and with safety evaluation
21
22 data.

23 2. Statistical analysis methods

24
25 Statistical analyses were performed using SPSS 22.0. Continuous variables are
26
27 described as mean (SD) or median (p25,p75) and count variables are described as
28
29 frequency and percentage. All tests were both sided and statistical analysis, 0.05 was
30
31 set as the P value for significance. For discrete variables including 30-day
32
33 treatment failure rate, the error rate of inhalation device use, satisfaction with inhalation
34
35 devices, 30-day mortality and 90-day mortality, a chi-squared (χ^2) test, Fisher's exact
36
37 test or CMH χ^2 test will be used. For continuous variable including PIFR, CAT score,
38
39 mMRC score, SGRQ score and COPD-related treatment costs, Student's t-tests or
40
41 Mann-Whitney test will be used. Subgroup analysis by exacerbation history and GOLD
42
43 grades will be performed to rule out the influence of confounding factors to the certain
44
45 extent.
46
47
48
49
50

51 Patient and public Involvement 52

53
54 Patients or the public were not involved in the design, or conduct, or reporting, or
55
56 dissemination of our research. The results will be available to the public if necessary.
57
58
59
60

Ethics and dissemination

This trial has been registered in the Ethics Committee of Zhongshan Hospital of Fudan University (B2019-142). In this study, diagnosis and treatment were performed in accordance with the routine management of COPD. Neither Additional drug intervention nor invasive examination and charges are needed. Therefore, the study is relatively safe with minimal additional risks. Participants will be screened and recruited from hospitalized patients by physicians. No additional public recruitment documents will be used for participants enrollment. All participants will sign informed consent. All information of participants will be kept private and will not be provided to any company or institution.

Discussion

Drug delivery by DPI depends on the inbuilt resistance of the inhaler and the PIFR generated by the patient. PIFR generally depends on an individual's effort as well as the respiratory muscle force, which may be decreased in patients with COPD due to airway stenosis, lung hyperinflation, hypoxemia, and muscle wasting. DPI are breath-actuated that require the individual to create turbulent forces to disaggregate the powder into respirable particles which can reach the lower respiratory tract. Patients with a sufficient PIFR (PIFR > 60 L/min) are able to release the powder and deaggregate the drug resulting in lung deposition.

Sharma and colleagues have found that 31.7% of patients at discharge following hospitalization for an exacerbation of COPD had PIFR less than 60 L/min³. Patients with a PIFR less than 60 L/min have been considered not be able to inhale medications using a DPI effectively into the lower respiratory tract according to the literature, while a PIFR less than 30 liters/minute is insufficient^{21 22}. However, most clinicians in china prescribe DPI to the patients recovering from AECOPD routinely due to the lack of the availability of long-acting bronchodilators with pMDI without measuring their PIFR. Inappropriate inhaler selection may result in treatment failure of AECOPD. Before our

1
2
3
4 study, it remains unclear whether treatment failure rate is related to PIFR-based inhaler
5 description. A suitable inspiratory flow rate helps to improve the treatment efficacy. In
6 addition to inhaler selection, PIFR group also receive inhaler training to help patients
7 master the correct inhalation method.
8
9

10
11 Our research has proposed to measure PIFR of patients recovering from AECOPD
12 by InCheck DIAL® and guide COPD inhaler choices and inhaler technique training.
13 The aim of this study is to determine whether the optimized inhalation therapy based
14 on PIFR measured against the simulated resistance can reduce the rate of treatment
15 failure in patients recovering from AECOPD. Therefore, we plan to verify the clinical
16 significance of including PIFR in the discharge protocol through comparing the
17 difference in 30-day treatment failure rates and other endpoints between PIFR group
18 and the control group.
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33 References

- 34 1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for
35 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study
36 2010. *Lancet (London, England)* 2012;380(9859):2095-128. doi: 10.1016/s0140-
37 6736(12)61728-0 [published Online First: 2012/12/19]
- 38 2. Zhu B, Wang Y, Ming J, et al. Disease burden of COPD in China: a systematic review. *Int J Chron*
39 *Obstruct Pulmon Dis* 2018;13:1353-64. doi: 10.2147/copd.S161555 [published Online First:
40 2018/05/08]
- 41 3. Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in
42 China (the China Pulmonary Health [CPH] study): a national cross-sectional study. *Lancet*
43 *(London, England)* 2018;391(10131):1706-17. doi: 10.1016/s0140-6736(18)30841-9
44 [published Online First: 2018/04/14]
- 45 4. Cai BQ, Cai SX, Chen RC, et al. Expert consensus on acute exacerbation of chronic obstructive
46 pulmonary disease in the People's Republic of China. *Int J Chron Obstruct Pulmon Dis*
47 2014;9:381-95. doi: 10.2147/copd.S58454 [published Online First: 2014/05/09]
- 48 5. Mahler DA. Peak Inspiratory Flow Rate as a Criterion for Dry Powder Inhaler Use in Chronic
49 Obstructive Pulmonary Disease. *Ann Am Thorac Soc* 2017;14(7):1103-07. doi:
50 10.1513/AnnalsATS.201702-156PS [published Online First: 2017/05/10]
- 51 6. Lopez-Campos JL, Soler-Cataluna JJ, Miravittles M. Global Strategy for the Diagnosis, Management,
52 and Prevention of Chronic Obstructive Lung Disease 2019 Report: Future Challenges. *Archivos*
53 *de bronconeumologia* 2019 doi: 10.1016/j.arbres.2019.06.001 [published Online First:
54
55
56
57
58
59
60

- 2019/07/20]
7. Cho-Reyes S, Celli BR, Dembek C, et al. Inhalation Technique Errors with Metered-Dose Inhalers Among Patients with Obstructive Lung Diseases: A Systematic Review and Meta-Analysis of U.S. Studies. *Chronic Obstr Pulm Dis* 2019;6(3):267-80. doi: 10.15326/jcopdf.6.3.2018.0168 [published Online First: 2019/07/26]
 8. Price DB, Roman-Rodriguez M, McQueen RB, et al. Inhaler Errors in the CRITIKAL Study: Type, Frequency, and Association with Asthma Outcomes. *The journal of allergy and clinical immunology In practice* 2017;5(4):1071-81.e9. doi: 10.1016/j.jaip.2017.01.004 [published Online First: 2017/03/14]
 9. Usmani OS, Lavorini F, Marshall J, et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. *Respir Res* 2018;19(1):10. doi: 10.1186/s12931-017-0710-y [published Online First: 2018/01/18]
 10. Sharma G, Mahler DA, Mayorga VM, et al. Prevalence of Low Peak Inspiratory Flow Rate at Discharge in Patients Hospitalized for COPD Exacerbation. *Chronic Obstr Pulm Dis* 2017;4(3):217-24. doi: 10.15326/jcopdf.4.3.2017.0183 [published Online First: 2017/08/30]
 11. Ross DL, Schultz RK. Effect of inhalation flow rate on the dosing characteristics of dry powder inhaler (DPI) and metered dose inhaler (MDI) products. *Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine* 1996;9(2):215-26. doi: 10.1089/jam.1996.9.215 [published Online First: 1997/02/01]
 12. Al-Showair RA, Tarsin WY, Assi KH, et al. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? *Respiratory medicine* 2007;101(11):2395-401. doi: 10.1016/j.rmed.2007.06.008 [published Online First: 2007/07/17]
 13. Mahler DA, Waterman LA, Ward J, et al. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate. *Journal of aerosol medicine and pulmonary drug delivery* 2014;27(2):103-9. doi: 10.1089/jamp.2013.1038 [published Online First: 2013/06/12]
 14. Liu D, Peng SH, Zhang J, et al. Prediction of short term re-exacerbation in patients with acute exacerbation of chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis* 2015;10:1265-73. doi: 10.2147/COPD.S83378 [published Online First: 2015/07/15]
 15. Mahler DA, Waterman LA, Gifford AH. Prevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus(R) dry powder inhaler. *Journal of aerosol medicine and pulmonary drug delivery* 2013;26(3):174-9. doi: 10.1089/jamp.2012.0987 [published Online First: 2012/10/03]
 16. Broeders ME, Molema J, Hop WC, et al. The course of inhalation profiles during an exacerbation of obstructive lung disease. *Respiratory medicine* 2004;98(12):1173-9. [published Online First: 2004/12/14]
 17. Hu WP, Lhamo T, Liu D, et al. Development of a Nomogram to Predict the Risk of 30-Day Re-Exacerbation for Patients Hospitalized for Acute Exacerbation of Chronic Obstructive Pulmonary Disease. *Copd* 2019;16(2):160-67. doi: 10.1080/15412555.2019.1606187 [published Online First: 2019/05/17]
 18. Loh CH, Peters SP, Lovings TM, et al. Suboptimal Inspiratory Flow Rates Are Associated with Chronic Obstructive Pulmonary Disease and All-Cause Readmissions. *Ann Am Thorac Soc* 2017;14(8):1305-11. doi: 10.1513/AnnalsATS.201611-903OC [published Online First: 2017/04/14]

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
19. Kim V, Aaron SD. What is a COPD exacerbation? Current definitions, pitfalls, challenges and opportunities for improvement. *Eur Respir J* 2018;52(5) doi: 10.1183/13993003.01261-2018 [published Online First: 2018/09/22]
 20. Perpina Tordera M, Viejo JL, Sanchis J, et al. [Assessment of patient satisfaction and preferences with inhalers in asthma with the FSI-10 Questionnaire]. *Archivos de bronconeumologia* 2008;44(7):346-52. [published Online First: 2008/08/30]
 21. Broeders ME, Molema J, Vermue NA, et al. In Check Dial: accuracy for Diskus and Turbuhaler. *International journal of pharmaceutics* 2003;252(1-2):275-80. [published Online First: 2003/01/29]
 22. Atkins PJ. Dry powder inhalers: an overview. *Respiratory care* 2005;50(10):1304-12; discussion 12. [published Online First: 2005/09/28]

21
22
23
24

Figure legends : Figure 1. The flowchart shows the process of patient's admission, recruitment, intervention and visits. V0, V1, V2, and V3 are all time points to collect data.

25
26
27
28
29
30
31
32

Contributors: JLH and JZ planned the study. WZ planned the Statistical analysis methods. All authors contributed to design and development of the trail (JLH, JZ, WZ, HFC, CLD, JYM and YHZ). JLH drafted the manuscript. JZ , HFC, CLD, JYM and YHZ contributed to revised the manuscript. All authors read and approved the final manuscript.

33
34
35
36

Ethics and dissemination: This trial has been registered in the Ethics Committee of Zhongshan Hospital of Fudan University (B2019-142) and Clinical Trails (NCT04000958).

37
38
39
40

Funding statement: This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.


41
42
43

Competing interests statement: None declared.

44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Word Count: 5024

Figure 1. The flow chart of the study





SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Reported on page No
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	2
	2b	All items from the World Health Organization Trial Registration Data Set	N/A
Protocol version	3	Date and version identifier	1
Funding	4	Sources and types of financial, material, and other support	N/A
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1
	5b	Name and contact information for the trial sponsor	N/A
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	N/A
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	N/A
Introduction			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	3-5
	6b	Explanation for choice of comparators	3-5

1			
2	Objectives	7	Specific objectives or hypotheses
3			4-5
4	Trial	8	Description of trial design including type of trial (eg, parallel
5	design		group, crossover, factorial, single group), allocation ratio, and
6			framework (eg, superiority, equivalence, noninferiority,
7			exploratory)
8			
9			
10	Methods: Participants, interventions, and outcomes		
11			
12	Study	9	Description of study settings (eg, community clinic, academic
13	setting		hospital) and list of countries where data will be collected.
14			Reference to where list of study sites can be obtained
15			
16	Eligibility	10	Inclusion and exclusion criteria for participants. If applicable,
17	criteria		eligibility criteria for study centres and individuals who will
18			perform the interventions (eg, surgeons, psychotherapists)
19			
20	Interventio	11	Interventions for each group with sufficient detail to allow
21	ns	a	replication, including how and when they will be administered
22			
23			
24		11	Criteria for discontinuing or modifying allocated interventions for
25		b	a given trial participant (eg, drug dose change in response to
26			harms, participant request, or improving/worsening disease)
27			
28		11	Strategies to improve adherence to intervention protocols, and
29		c	any procedures for monitoring adherence (eg, drug tablet
30			return, laboratory tests)
31			
32			
33		11	Relevant concomitant care and interventions that are permitted
34		d	or prohibited during the trial
35			
36	Outcomes	12	Primary, secondary, and other outcomes, including the specific
37			measurement variable (eg, systolic blood pressure), analysis
38			metric (eg, change from baseline, final value, time to event),
39			method of aggregation (eg, median, proportion), and time point
40			for each outcome. Explanation of the clinical relevance of
41			chosen efficacy and harm outcomes is strongly recommended
42			
43			
44	Participant	13	Time schedule of enrolment, interventions (including any run-
45	timeline		ins and washouts), assessments, and visits for participants. A
46			schematic diagram is highly recommended (see Figure)
47			
48			
49	Sample	14	Estimated number of participants needed to achieve study
50	size		objectives and how it was determined, including clinical and
51			statistical assumptions supporting any sample size calculations
52			
53	Recruitmen	15	Strategies for achieving adequate participant enrolment to
54	t		reach target sample size
55			
56			
57			
58			
59			
60			

Methods: Assignment of interventions (for controlled trials)

Allocation:

1				
2	Sequen	16	Method of generating the allocation sequence (eg, computer-	12
3	ce	a	generated random numbers), and list of any factors for	
4	generati		stratification. To reduce predictability of a random sequence,	
5	on		details of any planned restriction (eg, blocking) should be	
6			provided in a separate document that is unavailable to those	
7			who enrol participants or assign interventions	
8				
9				
10	Allocatio	16	Mechanism of implementing the allocation sequence (eg,	12
11	n	b	central telephone; sequentially numbered, opaque, sealed	
12	conceal		envelopes), describing any steps to conceal the sequence until	
13	ment		interventions are assigned	
14	mechani			
15	sm			
16				
17				
18	Impleme	16	Who will generate the allocation sequence, who will enrol	13
19	ntation	c	participants, and who will assign participants to interventions	
20				
21	Blinding	17	Who will be blinded after assignment to interventions (eg, trial	13
22	(masking)	a	participants, care providers, outcome assessors, data	
23			analysts), and how	
24				
25				
26		17	If blinded, circumstances under which unblinding is permissible,	13
27		b	and procedure for revealing a participant's allocated	
28			intervention during the trial	
29				
30				
31	Methods: Data collection, management, and analysis			
32	Data	18	Plans for assessment and collection of outcome, baseline, and	9-10
33	collection	a	other trial data, including any related processes to promote	
34	methods		data quality (eg, duplicate measurements, training of	
35			assessors) and a description of study instruments (eg,	
36			questionnaires, laboratory tests) along with their reliability and	
37			validity, if known. Reference to where data collection forms can	
38			be found, if not in the protocol	
39				
40				
41				
42		18	Plans to promote participant retention and complete follow-up,	9-10
43		b	including list of any outcome data to be collected for	
44			participants who discontinue or deviate from intervention	
45			protocols	
46				
47	Data	19	Plans for data entry, coding, security, and storage, including	N/A
48	manageme		any related processes to promote data quality (eg, double data	
49	nt		entry; range checks for data values). Reference to where	
50			details of data management procedures can be found, if not in	
51			the protocol	
52				
53				
54	Statistical	20	Statistical methods for analysing primary and secondary	13
55	methods	a	outcomes. Reference to where other details of the statistical	
56			analysis plan can be found, if not in the protocol	
57				
58				
59				
60				

1			
2	20	Methods for any additional analyses (eg, subgroup and	13
3	b	adjusted analyses)	
4			
5	20	Definition of analysis population relating to protocol non-	13
6	c	adherence (eg, as randomised analysis), and any statistical	
7		methods to handle missing data (eg, multiple imputation)	
8			

Methods: Monitoring

11	Data	21	Composition of data monitoring committee (DMC); summary of	N/A
12	monitoring	a	its role and reporting structure; statement of whether it is	
13			independent from the sponsor and competing interests; and	
14			reference to where further details about its charter can be	
15			found, if not in the protocol. Alternatively, an explanation of why	
16			a DMC is not needed	
17				
18				
19		21	Description of any interim analyses and stopping guidelines,	N/A
20		b	including who will have access to these interim results and	
21			make the final decision to terminate the trial	
22				
23				
24	Harms	22	Plans for collecting, assessing, reporting, and managing	N/A
25			solicited and spontaneously reported adverse events and other	
26			unintended effects of trial interventions or trial conduct	
27				
28				
29	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and	N/A
30			whether the process will be independent from investigators and	
31			the sponsor	
32				

Ethics and dissemination

35	Research	24	Plans for seeking research ethics committee/institutional review	14
36	ethics		board (REC/IRB) approval	
37	approval			
38				
39				
40	Protocol	25	Plans for communicating important protocol modifications (eg,	14
41	amendmen		changes to eligibility criteria, outcomes, analyses) to relevant	
42	ts		parties (eg, investigators, REC/IRBs, trial participants, trial	
43			registries, journals, regulators)	
44				
45	Consent or	26	Who will obtain informed consent or assent from potential trial	14
46	assent	a	participants or authorised surrogates, and how (see Item 32)	
47				
48		26	Additional consent provisions for collection and use of	N/A
49		b	participant data and biological specimens in ancillary studies, if	
50			applicable	
51				
52				
53	Confidentia	27	How personal information about potential and enrolled	14
54	lity		participants will be collected, shared, and maintained in order to	
55			protect confidentiality before, during, and after the trial	
56				
57				
58	Declaration	28	Financial and other competing interests for principal	N/A
59	of interests		investigators for the overall trial and each study site	
60				

1				
2	Access to	29	Statement of who will have access to the final trial dataset, and	14
3	data		disclosure of contractual agreements that limit such access for	
4			investigators	
5				
6	Ancillary	30	Provisions, if any, for ancillary and post-trial care, and for	N/A
7	and post-		compensation to those who suffer harm from trial participation	
8	trial care			
9				
10	Disseminati	31	Plans for investigators and sponsor to communicate trial results	14
11	on policy	a	to participants, healthcare professionals, the public, and other	
12			relevant groups (eg, via publication, reporting in results	
13			databases, or other data sharing arrangements), including any	
14			publication restrictions	
15				
16				
17				
18		31	Authorship eligibility guidelines and any intended use of	N/A
19		b	professional writers	
20				
21		31	Plans, if any, for granting public access to the full protocol,	N/A
22		c	participant-level dataset, and statistical code	
23				
24	Appendice			
25	s			
26				
27	Informed	32	Model consent form and other related documentation given to	N/A
28	consent		participants and authorised surrogates	
29	materials			
30				
31				
32	Biological	33	Plans for collection, laboratory evaluation, and storage of	N/A
33	specimens		biological specimens for genetic or molecular analysis in the	
34			current trial and for future use in ancillary studies, if applicable	
35				

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.

BMJ Open

The effect of PIFR-based Optimized Inhalation Therapy in Patients Recovering From Acute exacerbation of Chronic Obstructive Pulmonary Disease: protocol of a prospective, multi-center, superiority, randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-034804.R2
Article Type:	Protocol
Date Submitted by the Author:	28-Jan-2020
Complete List of Authors:	Hua, Jianlan; Zhongshan Hospital Fudan University, Department of Pulmonary and Critical Care Medicine Zhang, wei; Fudan University, Department of Biostatistics Cao, Hui-fang; Shanghai Jing'an District Central Hospital Du, Chun-ling; Shanghai Qingpu District Central Hospital Ma, Jia-yun; North Branch of Shanghai Ninth People's Hospital Zuo, Yi-hui; Zhongshan Hospital Fudan University, Department of Pulmonary and Critical Care Medicine Zhang, Jing; Zhongshan Hospital Fudan University, Department of Pulmonary and Critical Care Medicine
Primary Subject Heading:	Respiratory medicine
Secondary Subject Heading:	Medical education and training, Pharmacology and therapeutics, Research methods
Keywords:	RESPIRATORY MEDICINE (see Thoracic Medicine), Chronic airways disease < THORACIC MEDICINE, MEDICAL EDUCATION & TRAINING

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **The effect of PIFR-based Optimized Inhalation Therapy in**
5
6 **Patients Recovering From Acute exacerbation of Chronic**
7
8 **Obstructive Pulmonary Disease: protocol of a prospective,**
9
10 **multi-center, superiority, randomized controlled trial**
11
12
13

14 Jian-lan Hua¹, Wei Zhang², Hui-fang Cao³, Chun-ling Du⁴, Jia-yun Ma⁵, Yi-hui Zuo¹, Jing
15
16 Zhang^{1*}
17

18
19 ¹Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Shanghai Medical
20
21 College, Fudan University, Shanghai, China
22

23
24 ²Department of Biostatistics, School of Public Health, Fudan University, Shanghai, China
25

26
27 ³ Department of Pulmonary, Shanghai Jing 'an District Central Hospital, Shanghai, China
28

29
30 ⁴ Department of Pulmonary, Shanghai Qingpu District Central Hospital, Shanghai, China
31

32
33 ⁵ Department of Pulmonary, North Branch of Shanghai Ninth People's Hospital, Shanghai JiaoTong
34
35 University school of medicine, Shanghai, China
36

37
38 * Correspondence: Jing Zhang
39

40
41 Department of Pulmonary and Critical Care Medicine, Zhongshan hospital, Shanghai Medical
42
43 College, Fudan University, 180 Feng lin road, shanghai 200032, People's Republic of China
44

45
46 Email: jingatlas@hotmail.com
47

48
49
50 Date: 2019/1/21

51
52 version identifier: 1.3
53
54
55
56
57
58
59
60

Abstract:

Introduction: Chronic Obstructive Pulmonary Disease (COPD) is a global respiratory disease. Acute exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) is a major cause of disease progression and death, and causes huge medical expenditures. Effective inhalation therapy is important during the AE recovery period. However, the invalid inhalation using DPI due to the unrecovered inspiratory flow rate after AECOPD results in increased risk of treatment failure and early recurrence. We envisage that choosing the right inhaler based on peak inhalation flow rate (PIFR) and training inhaler techniques will contribute to reducing early relapse rates. Therefore, a prospective multicenter randomized trial is designed to verify this hypothesis.

Methods and analysis: The study is aimed at determining whether the optimized inhalation therapy based on PIFR can reduce the rate of treatment failure in patients recovering from AECOPD. In the study, 416 patients with AECOPD whose exacerbated symptoms are relieved by 5-7 days of standard therapy will be recruited and be randomized into PIFR group, which receives inhaler depending on their PIFR and is trained to use the inhaler appropriately, and control group, which receives inhaler depending on the judgment of a respiratory physician, at a 1:1 ratio. The primary outcome of the study is 30-day treatment failure rate. Other endpoints include PIFR, the error rate of inhalation device use, satisfaction with inhalation devices, 30-day mortality, 90-day mortality, symptoms and life quality of patients and COPD-related treatment costs.

Ethics and dissemination: This trial has been registered in the Ethics Committee of Zhongshan Hospital of Fudan University (B2019-142). Participants will be screened and recruited from hospitalized patients by physicians. No public recruitment documents will be used for participants enrollment. The results will be disseminated through peer-reviewed journals and conference presentations, and proliferation activities will include diverse social non-academic groups and patients.

Trial registration: This trial has been registered in Clinical Trials (NCT04000958).

Strengths and limitations of this study:

1. To our knowledge, this is the first multicenter, randomized trial designed to study the efficacy of PIFR-based inhaler prescription in preventing short-term re-exacerbation in patients recovering from severe acute exacerbation of COPD.

1
2
3
4 2. InCheck DIAL® is used to measure PIFR and objectively evaluate the capacity of using dry
5 powder inhalers.

6
7 3. The inhaler technique will be trained as well to achieve optimal inhalation therapy.

8
9 4. Inhalers studied in this trial include turbuhaler, handihaler, respimat and pMDI.

10
11 5. The limitation of the study is the single-blind study design, which would yield bias, although blind
12 evaluation is adopted to minimize the bias.
13
14

15
16
17 **Keywords:** chronic obstructive pulmonary disease, acute exacerbation of chronic obstructive
18 pulmonary disease, peak inhalation flow rate
19
20

21 22 23 **Introduction**

24
25 Chronic Obstructive Pulmonary Disease (COPD) is a global respiratory disease that
26 severely threatens human health. COPD has a significant socioeconomic burden, and is
27 currently the fourth leading cause of death in the world but is projected to be the 3rd
28 leading cause of death by 2020¹. In China, COPD ranked among the top three leading
29 causes of death and the direct medical cost of COPD ranged from 72 to 3,565 USD per
30 capita per year, accounting for 33.33% to 118.09% of local average annual income².
31 The overall prevalence of spirometry-defined COPD was 8.6% among the general
32 Chinese population aged 20 years or older³. Acute exacerbation of Chronic Obstructive
33 Pulmonary Disease (AECOPD) is a major cause of disease progression and death, and
34 causes huge medical expenditures⁴.
35
36
37
38
39
40
41
42
43
44

45 Inhalation therapy is the core pharmaceutical therapy for COPD including inhaled
46 corticosteroid (ICS), both short- and long-acting beta2-agonists and, more recently,
47 muscarinic antagonists⁵. Existing common devices include pressure metered dose
48 inhaler (pMDI), dry powder inhalers (DPIs), soft mist inhalers (SMIs), and nebulizers⁶.
49 Common inhaler errors include insufficient inspiratory effort, no breath-hold (or holds
50 breath for less than 3s), etc^{7 8}. Inhaler errors are associated with poor disease outcomes
51 (exacerbations) and greater health-economic burden⁹. MDIs require complex
52 coordination techniques with a slow inhalation by the patient to achieve a clinically
53
54
55
56
57
58
59
60

1
2
3
4 effective dose. DPIs decrease the complexity of administration, but effective
5 medication delivery is dependent on the force of the patient's inspiratory effort to
6 overcome internal resistance¹⁰. Several *in vitro* studies have demonstrated the
7 inhalation flow rate dependency of DPI. Specifically, the results showed that using a
8 DPI both the amount of medication delivered to the patient and the effective
9 aerodynamic particle size of the medication were adversely affected when the testing
10 peak inhalation flow rate (PIFR) was less than a certain threshold (60 liters/min
11 measured at no resistance)¹¹, which may result in ineffective inhalation of medications
12 using a DPI. Several studies suggest that patients with insufficient PIFR in stable phase
13 of COPD may have an adverse effect on prognosis using inappropriate inhaler^{12 13}.
14 Moreover, it should be noted that expiratory flow rate (such as FEV₁) is not correlated
15 linearly with inspiratory flow parameters, and it do not predict PIFR. Other risk factors
16 for early AECOPD recurrence include age grades, GOLD grades, AE frequency in the
17 previous year, pleural effusion, use of accessory respiratory muscles, noninvasive
18 mechanical ventilation, controlled oxygen therapy and length of hospital stay, while
19 inhaled long-acting β -2-agonists (LABA) and inhaled corticosteroids (ICS) are
20 protection factors¹⁴. An investigation suggests that one of five stable outpatients more
21 than 60 years of age with severe COPD did not reach the recommended PIFR for DPI
22 devices¹⁵. Some small sample studies has shown that a significant proportion of patients
23 are not suitable for DPI during AECOPD because of their insufficient PIFR^{13 16}.
24 However, there is no study about the PIFR status and the impact of inhaler choices on
25 prognosis for patients recovering from AECOPD.

26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Thirty-day readmission rates after hospitalization for AECOPD are approximately
15.8%-20%^{17 18}. Readmissions are costly and adversely affect quality of life. But little
is known about PIFRs of the patients recovering from AECOPD as well as the clinical
impact of the inhaler (DPI or pMDI) selected for the patients. Generally, discharge
protocols for patients recovering from AECOPD do not include an assessment of PIFR
or patients' ability to use their inhaler device when they recuperate after discharge.
Clinicians typically select the inhaler they use during the stable phase of COPD for
patients who will be discharged. Furthermore, although some evidence has suggested

1
2
3
4 that incorrect use of inhalers is associated with poor prognosis, studies on the effect of
5 training patients on the use of inhalers to reduce relapses are still scarce. We
6 hypothesize PIFR of patients recovering from AECOPD have not returned to the level
7 at the stable phase of COPD as well as untrained patients have higher rate of inhaler
8 errors. It may result in suboptimal COPD management and treatment failure (including
9 recurrence resulting in an emergency visit, admission, or need for intensified
10 medication) for the patients due to the ineffective inhalation of medications.
11
12
13
14
15
16

17 The aim of this study is to determine whether the optimized inhalation therapy based
18 PIFR can reduce the rate of treatment failure in patients recovering from AECOPD.
19 Errors in inhaler use and quality of life are also to be evaluated.
20
21
22
23
24
25
26

27 **Methods and analysis**

28 **Trial design**

29
30 This is a prospective, multi-center, single-blind, superiority, randomized study of
31 patients hospitalized for a COPD exacerbation. This study is designed to determine
32 whether PIFR based inhaler choice and training can reduce the rate of treatment failure
33 in patients recovering from AECOPD. The primary study outcome is 30-day treatment
34 failure rate. Treatment failure means AECOPD recurrence resulting in an emergency
35 visit, admission, or need for intensified medication. Other endpoints include symptoms
36 and life quality of patients the error rate of inhalation device use, satisfaction with
37 inhalation devices, PIFR, 30-day mortality, 90-day mortality, and COPD-related
38 treatment costs. The enrollment, conduct and data analysis of the trail are performed at
39 Zhongshan Hospital of Fudan University, Shanghai Jing 'an District Central Hospital,
40 Shanghai Qingpu District Central Hospital and North Branch of Shanghai Ninth
41 People's Hospital in China. The study is expected to last for 2 years. Recruitment of
42 participants has started since November 2019.
43
44
45
46
47
48
49
50
51
52
53
54
55
56

57 This trial has been registered in the Ethics Committee of Zhongshan Hospital of
58 Fudan University (B2019-142) and Clinical Trails (NCT04000958).
59
60

Inclusion criteria

All patients meeting AECOPD diagnostic criteria who hospitalized for COPD related reasons will be followed. The definition of COPD follows the GOLD definition and the definition of AECOPD follows Expert Consensus on Acute Exacerbation of Chronic Obstructive Pulmonary Disease in the People's republic of China⁴. AECOPD is defined as sudden worsening of respiratory symptoms that require additional treatment (typical manifestations include dyspnea, aggravated cough, increased sputum volume, and/or sputum purulence) and is beyond normal day-to-day variations, leading to a change in medications^{4 19}. The subjects will be enrolled and randomized into the study group if all of the following criteria are met: (1) 40–80 years old; (2) patients with AECOPD whose acute respiratory symptoms have been controlled and met discharge criteria after 5-7 day-standard AECOPD treatment including atomized or inhaled bronchodilator plus oral or intravenous glucocorticoid (prednisone equivalent dose 40-50mg) or Pulmicort 2mg atomization twice daily plus broad-spectrum antibiotics; (3) patients with moderate and above COPD with a recorded spirometry measured in the stable disease status, ie, post-bronchodilator forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) <70% and FEV1% predicted value <80%; (4) patients have signed an informed consent form.

Discharge criteria is as follows: (1) physician are confident that the patient can manage successfully at home; (2) long-acting bronchodilators, either beta 2-agonists and/or anticholinergics with or without inhaled corticosteroids can be used, and inhaled short-acting β 2-agonist therapy is required no more frequently than every 4 hours; (3) the patient, if previously ambulatory, is able to walk across the room; (4) the patient is able to eat and sleep without frequent awakening due to dyspnea; (5) the patient has been clinically stable for 12–24 hours; (6) arterial blood gases have been stable for 12–24 hours⁴.

Exclusion criteria

1
2
3
4 Exclusion criteria include:(1) patients who is already using home nebulization
5 therapy because of the severity of the disease; (2) patients with bronchial asthma,
6 pulmonary interstitial fibrosis, bronchiectasis, pulmonary embolism and other lung
7 diseases; or hypertension, heart disease, chronic liver and kidney disease, diabetes,
8 chronic gastrointestinal diseases, malignant tumors, critically ill; (3)patient's mental
9 state cannot match the observation or suffer from cognitive impairment; (4) patient's
10 peak inspiratory flow rates (PIFR) is less than 20L/min.
11
12
13
14
15
16
17
18
19

20 Sample size

21
22 The sample size was calculated using PASS 15.0 (Power Analysis and Sample Size
23 Software) to ensure the study power. Several studies have found that 30-47% patients
24 hospitalized for AECOPD had a PIFR < 60 liters/minute prior to discharge^{5 10}. For the
25 control group, 30-day treatment failure rates after hospitalization for AECOPD are
26 approximately 20% according to the literature and our retrospective cohort study^{17, 18}.
27 For PIFR group, 30-day treatment failure rates are 10% based on our preliminary
28 research. The participants will be divided into PIFR group and control group in a 1:1
29 ratio. To test the superiority hypothesis with 80% power with 2-side alpha at 0.05 level,
30 197 subjects will be enrolled for each group. Considering 5% dropout rate, the
31 minimum number of the participants in the study was determined to be 208 per group.
32
33
34
35
36
37
38
39
40
41
42
43
44

45 Study outline

46 The flow chart of the study design is shown in Figure 1. The study will recruit 416
47 patients with AECOPD whose exacerbated symptoms are relieved by 5-7 days of
48 standard therapy. After enrollment, the participants are divided into PIFR group and
49 control group at a 1:1 ratio according to a random envelope method. All the patients
50 will be given inhaled corticosteroid (ICS)/long-acting β agonist (LABA) (budesonide/
51 formoterol - Symbicort turbuhaler® (AstraZeneca AB) 160/4.5 μ g bid or
52 Beclometasone/ Formoterol Foster® (Chiesi Farmaceutici S.p.A.) pressure pMDI 100/6
53
54
55
56
57
58
59
60

1
2
3
4 μg 2 puff bid). For symptomatic patients ($\text{mMRC} \geq 2$, $\text{CAT} \geq 10$) before acute
5
6 exacerbation, Spiriva handihaler® 18 μg qd or Spiriva respimat® (Boehringer
7
8 IngelheimPharma GmbH & Co.KG) 2.5 μg qd will be prescribed in combination with
9
10 ICS/LABA.

11
12 For PIFR group, PIFR is measured by InCheck DIAL® (Clement Clarke
13
14 International Ltd, Harlow, UK and Alliance Tech Medical). The InCheck DIAL® is
15
16 designed to simulate the “internal resistance” of common inhaler devices, and measure
17
18 inspiratory flow. These measurements enable the healthcare professional to encourage
19
20 patients to modify their inspiratory technique (by inhaling with more, or less effort), in
21
22 order to achieve a flow rate consistent with clinical efficacy. The colored ‘flow’ icons
23
24 show the clinically effective flow ranges for each different inhaler device. The InCheck
25
26 DIAL® is accurate to $\pm 10\%$ or 10 L/min, whichever is greater, and is a low-range
27
28 inspiratory flow meter (15 to 120 L/min) that has a selectable resistance from high to
29
30 low, shown by the colored ‘flow’ icons calibrated to enable the measurement of airflow
31
32 as if the patient was using certain different inhalers. In this study, we set the resistance
33
34 of the InCheck DIAL® both to zero (correspond to pMDI) and Med High resistance
35
36 level of InCheck DIAL® (correspond to turbuhaler®) when measuring PIFR. Before
37
38 measuring, we will first train patients to use the InCheck DIAL® correctly. After
39
40 patients are able to reach their maximum value of PIFR steadily, we will measure the
41
42 PIFR 3 times and take the average as a result.

43
44 Moreover, the InCheck DIAL® is an inhalation airflow training meter that can help
45
46 educate and assess patients who use inhaler devices. When training the patient, we will
47
48 set the corresponding resistance for the InCheck DIAL® according to the inhaler that
49
50 the patient is prescribed. We will also explain to the patient the proper operation of the
51
52 inhaler and demonstrate some common mistakes.

53
54 If PIFR is less than 60L/min (measured without a resistance), the patient will be given
55
56 pMDI with spacer. If PIFR value is over 60 L/min (measured without a resistance), the
57
58 patient will be given dry powder inhaler (DPI). Furthermore, InCheck DIAL® will be
59
60 used for an inhalation device training.

1
2
3
4 The control group will be given DPI or pMDI with spacer according to the judgment
5 of a respiratory physician.
6

7 Both groups will be taught to use the device after the prescription, and then be
8 reminded to use medication via a WeChat public account.
9
10

11 12 13 14 15 16 Study step

17
18 The participants will be followed up for 3 months and 3 visits will be performed at
19 baseline(symptoms of AECOPD are relieved by 5-7 days of standard therapy), 1 and 3
20 months after enrollment.
21
22

23 Demographics, clinical characteristics, evaluation of respiratory symptoms and
24 quality of life in the stable phase, PIFR, routine laboratory tests for AE patients(e.g.
25 blood routine, C-reactive protein, liver and kidney function, blood electrolytes, B-type
26 natriuretic peptide, D-dimer), chest X-ray or CT and echocardiography or
27 electrocardiogram in the stable phase will be collected at baseline. Demographics
28 includes age, gender, age, height, weight, ethnicity, occupation(number of years of
29 work), marital status, location, etc. Clinical characteristics includes past disease history,
30 history of drug sensitivity, history of vaccination, family disease history, current
31 medical history, comorbidities, medications, etc. Respiratory symptoms will be
32 assessed with the modified Medical Research Council (mMRC) dyspnea scale and the
33 COPD Assessment Test (CAT) score for the patients. Quality of life will be assessed
34 with St.George's Respiratory Questionnaire(SGRQ) scale. All baseline data will be
35 collected by attending physician on the day of enrollment.
36
37
38
39
40
41
42
43
44
45
46
47
48

49 CAT score, mMRC score, SGRQ score, PIFR, spirometry, the error rate of inhalation
50 device use, satisfaction with inhalation devices, condition of AE and COPD medicine
51 treatment will be collected at both 1- and 3-month visit. The data to be collected for
52 each visit is shown in Table 1.
53
54
55
56
57
58
59
60

Table 1. Data collected at each visit

	V0	V1	V2	V3
	Hospitalization±1 day	At the time of discharge (meet discharge standards)	1 month after discharge	3 month after discharge
Basic Information	√			
Information of COPD at stable phase	√			
Blood routine	√	√		
Liver and kidney function	√	√		
Electrolyte	√	√		
C-reactive protein	√	√		
procalcitonin	√	√		
brain natriuretic peptide	√	√		
D-dimer , Fibrinogen	√	√		
cardiac troponin T	√	√		
CAT score	√	√	√	√
mMRC	√	√	√	√
SGRQ		√	√	√
Drug for COPD	Stable phase	AE phase	Stable phase	Stable phase
PIFR		PIFR√	PIFR√	PIFR√
Prognosis			√	√
Pulmonary function		√	√	√
Echocardiography at stable phase				
CT at stable phase				
CT at AE phase				
Error of inhaler use			√	√
Satisfaction with the inhaler			√	√
Daily cost of COPD related treatment			√	√

Endpoints

The primary endpoint is 30-day treatment failure rate of AECOPD. Treatment failure means AECOPD recurrence resulting in an emergency visit, admission, or need for intensified medication.

Secondary endpoints include PIFR, the error rate of inhalation device use, satisfaction with inhalation devices, 30-day mortality, 90-day mortality, symptoms and life quality of patients and COPD-related treatment costs.

Patient's satisfaction with inhalation devices will be assessed by FSI-10 questionnaire. The FSI-10 questionnaire is completed by patients themselves, which has been widely applied to assess patients' opinions about ease of use, portability, and usability of inhalers²⁰. The symptoms of patients are evaluated by the COPD assessment test (CAT) and the modified Medical Research Council (mMRC) dyspnea scale. The patients' quality of life are evaluated by St. George's Respiratory Questionnaire (SGRQ).

PIFR is measured by InCheck DIAL® (Clement Clarke International Ltd, Harlow, UK and Alliance Tech Medical).

The error rate of inhalation device use is described in Table 2^{7 8}.

Table 2. The error rate of inhalation device use

Turbuhaler	Handihaler/Accuhaler	pMDI	Respimat
Cover is not removed/ Cover is not covered properly.	Cover is not removed/ Cover is not covered properly.	Cover is not removed/ Cover is not covered properly.	Cover is not removed/ Cover is not covered properly.
Patient reduces dose due to shaking or tilting during preparation.	-		The device is not installed correctly before use.
Device is not held upright.	-	Device is not held upright.	-
Patient does not twist grip at the base or twist around and then back until click is	-	-	Patient dose not turn the device toward the arrow in the label until it clicks.

heard.			
Patient forces insufficiently when inhaling.	Patient forces insufficiently when inhaling.	Patient dose not inhale deeply and slowly.	Patient dose not inhale deeply and slowly.
Patient does not tilt head to make the chin slightly upturned.	Patient does not hold the head in a vertical position.	Patient does not tilt head to make the chin slightly upturned.	Patient dose not point the inhaler toward the back of throat.
Patient does not exhale to empty the lung before inhaling.	Patient does not exhale to empty the lung before inhaling.	Patient does not exhale to empty the lung before inhaling.	Patient does not exhale to empty the lung before inhaling.
-	Patient does not turn the head away from device and exhale.	Patient exhales into the device before inhaling.	Patient covers the air entries while inhaling.
Patient does not seal the mouthpiece with the lips.	Patient does not put the mouthpiece in mouth, and close the lips.	Patient does not seal the mouthpiece with the lips.	Patient does not seal the mouthpiece with the lips.
NA	NA	Releasing drug is out of sync with inhaling.	Releasing drug is out of sync with inhaling.
Patient does not hold breath(or hold breath less than 3s).	Patient does not hold breath(or hold breath less than 3s).	Patient does not hold breath(or hold breath less than 3s).	Patient does not hold breath(or hold breath less than 10s).
Patient does not put the cover back and wait for 30-60 seconds for the second dose.	Patient dose not dispose of the capsule and put the cover back on the device.	Patient does not exhale and wait for 30-60 seconds before the second puff.	Patient dose not inhales twice to complete the total daily dosage.

Randomization

Enrollment and randomization are performed at Zhongshan Hospital of Fudan University. After enrollment, patients will be assigned into two groups via a random envelope method in a 1:1 ratio to the PIFR group and control group by random number table method generated by SPSS.

Blinding

The study adopts blind evaluation. The investigator will enroll participants and assign them into two groups. All data at baseline, 1- and 3-month visit will be collected by attending physician, who will not be informed of which group the patient has been assigned. In addition, patients will not know the group they belong to. Blind evaluation maximizes the objectivity and reliability of the study.

Statistical analysis

1. Statistical analysis datasets

- Modified intent-to-treat set (MITTS)

Subjects that have undergone randomization and interventions, and carry out primary endpoints evaluation.

- Safety set (SS)

Subjects that are randomized, undergo the intervention, and with safety evaluation data.

2. Statistical analysis methods

Statistical analyses were performed using SPSS 22.0. Continuous variables are described as mean (SD) or median (p25,p75) and count variables are described as frequency and percentage. All tests were both sided and statistical analysis, 0.05 was set as the P value for significance. For discrete variables including 30-day treatment failure rate, the error rate of inhalation device use, satisfaction with inhalation devices, 30-day mortality and 90-day mortality, a chi-squared (χ^2) test, Fisher's exact test or CMH χ^2 test will be used. For continuous variable including PIFR, CAT score, mMRC score, SGRQ score and COPD-related treatment costs, Student's t-tests or Mann-Whitney test will be used. Subgroup analysis by exacerbation history and GOLD grades will be performed to rule out the influence of confounding factors to the certain extent.

Patient and public Involvement

Patients or the public were not involved in the design, or conduct, or reporting, or dissemination of our research. The results will be available to the public if necessary.

Ethics and dissemination

This trial has been registered in the Ethics Committee of Zhongshan Hospital of Fudan University (B2019-142). In this study, diagnosis and treatment were performed in accordance with the routine management of COPD. Neither Additional drug intervention nor invasive examination and charges are needed. Therefore, the study is relatively safe with minimal additional risks. Participants will be screened and recruited from hospitalized patients by physicians. No additional public recruitment documents will be used for participants enrollment. All participants will sign informed consent. All information of participants will be kept private and will not be provided to any company or institution. The results will be disseminated through peer-reviewed journals and conference presentations, and proliferation activities will include diverse social non-academic groups and patients.

Discussion

Drug delivery by DPI depends on the inbuilt resistance of the inhaler and the PIFR generated by the patient. PIFR generally depends on an individual's effort as well as the respiratory muscle force, which may be decreased in patients with COPD due to airway stenosis, lung hyperinflation, hypoxemia, and muscle wasting. DPI are breath-actuated that require the individual to create turbulent forces to disaggregate the powder into respirable particles which can reach the lower respiratory tract. Patients with a sufficient PIFR (PIFR > 60 L/min) are able to release the powder and deaggregate the drug resulting in lung deposition.

Sharma and colleagues have found that 31.7% of patients at discharge following

1
2
3
4 hospitalization for an exacerbation of COPD had PIFR less than 60 L/min³. Patients
5 with a PIFR less than 60 L/min have been considered not be able to inhale medications
6 using a DPI effectively into the lower respiratory tract according to the literature, while
7 a PIFR less than 30 liters/minute is insufficient^{21 22}. However, most clinicians in china
8 prescribe DPI to the patients recovering from AECOPD routinely due to the lack of the
9 availability of long-acting bronchodilators with pMDI without measuring their PIFR.
10 Inappropriate inhaler selection may result in treatment failure of AECOPD. Before our
11 study, it remains unclear whether treatment failure rate is related to PIFR-based inhaler
12 description. A suitable inspiratory flow rate helps to improve the treatment efficacy. In
13 addition to inhaler selection, PIFR group also receive inhaler training to help patients
14 master the correct inhalation method.
15
16
17
18
19
20
21
22
23
24

25 Our research has proposed to measure PIFR of patients recovering from AECOPD
26 by InCheck DIAL® and guide COPD inhaler choices and inhaler technique training.
27 The aim of this study is to determine whether the optimized inhalation therapy based
28 on PIFR measured against the simulated resistance can reduce the rate of treatment
29 failure in patients recovering from AECOPD. Therefore, we plan to verify the clinical
30 significance of including PIFR in the discharge protocol through comparing the
31 difference in 30-day treatment failure rates and other endpoints between PIFR group
32 and the control group.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 **References**

- 49 1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for
50 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study
51 2010. *Lancet (London, England)* 2012;380(9859):2095-128. doi: 10.1016/s0140-
52 6736(12)61728-0 [published Online First: 2012/12/19]
- 53 2. Zhu B, Wang Y, Ming J, et al. Disease burden of COPD in China: a systematic review. *Int J Chron*
54 *Obstruct Pulmon Dis* 2018;13:1353-64. doi: 10.2147/copd.S161555 [published Online First:
55 2018/05/08]
- 56 3. Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in
57 China (the China Pulmonary Health [CPH] study): a national cross-sectional study. *Lancet*
58 *(London, England)* 2018;391(10131):1706-17. doi: 10.1016/s0140-6736(18)30841-9
59
60

- [published Online First: 2018/04/14]
4. Cai BQ, Cai SX, Chen RC, et al. Expert consensus on acute exacerbation of chronic obstructive pulmonary disease in the People's Republic of China. *Int J Chron Obstruct Pulmon Dis* 2014;9:381-95. doi: 10.2147/copd.S58454 [published Online First: 2014/05/09]
 5. Mahler DA. Peak Inspiratory Flow Rate as a Criterion for Dry Powder Inhaler Use in Chronic Obstructive Pulmonary Disease. *Ann Am Thorac Soc* 2017;14(7):1103-07. doi: 10.1513/AnnalsATS.201702-156PS [published Online First: 2017/05/10]
 6. Lopez-Campos JL, Soler-Cataluna JJ, Miravittles M. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2019 Report: Future Challenges. *Archivos de bronconeumologia* 2019 doi: 10.1016/j.arbres.2019.06.001 [published Online First: 2019/07/20]
 7. Cho-Reyes S, Celli BR, Dembek C, et al. Inhalation Technique Errors with Metered-Dose Inhalers Among Patients with Obstructive Lung Diseases: A Systematic Review and Meta-Analysis of U.S. Studies. *Chronic Obstr Pulm Dis* 2019;6(3):267-80. doi: 10.15326/jcopdf.6.3.2018.0168 [published Online First: 2019/07/26]
 8. Price DB, Roman-Rodriguez M, McQueen RB, et al. Inhaler Errors in the CRITIKAL Study: Type, Frequency, and Association with Asthma Outcomes. *The journal of allergy and clinical immunology In practice* 2017;5(4):1071-81.e9. doi: 10.1016/j.jaip.2017.01.004 [published Online First: 2017/03/14]
 9. Usmani OS, Lavorini F, Marshall J, et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. *Respir Res* 2018;19(1):10. doi: 10.1186/s12931-017-0710-y [published Online First: 2018/01/18]
 10. Sharma G, Mahler DA, Mayorga VM, et al. Prevalence of Low Peak Inspiratory Flow Rate at Discharge in Patients Hospitalized for COPD Exacerbation. *Chronic Obstr Pulm Dis* 2017;4(3):217-24. doi: 10.15326/jcopdf.4.3.2017.0183 [published Online First: 2017/08/30]
 11. Ross DL, Schultz RK. Effect of inhalation flow rate on the dosing characteristics of dry powder inhaler (DPI) and metered dose inhaler (MDI) products. *Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine* 1996;9(2):215-26. doi: 10.1089/jam.1996.9.215 [published Online First: 1997/02/01]
 12. Al-Showair RA, Tarsin WY, Assi KH, et al. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? *Respiratory medicine* 2007;101(11):2395-401. doi: 10.1016/j.rmed.2007.06.008 [published Online First: 2007/07/17]
 13. Mahler DA, Waterman LA, Ward J, et al. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate. *Journal of aerosol medicine and pulmonary drug delivery* 2014;27(2):103-9. doi: 10.1089/jamp.2013.1038 [published Online First: 2013/06/12]
 14. Liu D, Peng SH, Zhang J, et al. Prediction of short term re-exacerbation in patients with acute exacerbation of chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis* 2015;10:1265-73. doi: 10.2147/COPD.S83378 [published Online First: 2015/07/15]
 15. Mahler DA, Waterman LA, Gifford AH. Prevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus(R) dry powder inhaler. *Journal of aerosol medicine and pulmonary drug delivery* 2013;26(3):174-9. doi: 10.1089/jamp.2012.0987 [published Online First: 2012/10/03]
 16. Broeders ME, Molema J, Hop WC, et al. The course of inhalation profiles during an exacerbation of

- 1
2
3 obstructive lung disease. *Respiratory medicine* 2004;98(12):1173-9. [published Online First:
4 2004/12/14]
5
6 17. Hu WP, Lhamo T, Liu D, et al. Development of a Nomogram to Predict the Risk of 30-Day Re-
7 Exacerbation for Patients Hospitalized for Acute Exacerbation of Chronic Obstructive
8 Pulmonary Disease. *Copd* 2019;16(2):160-67. doi: 10.1080/15412555.2019.1606187
9 [published Online First: 2019/05/17]
10
11 18. Loh CH, Peters SP, Lovings TM, et al. Suboptimal Inspiratory Flow Rates Are Associated with
12 Chronic Obstructive Pulmonary Disease and All-Cause Readmissions. *Ann Am Thorac Soc*
13 2017;14(8):1305-11. doi: 10.1513/AnnalsATS.201611-903OC [published Online First:
14 2017/04/14]
15
16 19. Kim V, Aaron SD. What is a COPD exacerbation? Current definitions, pitfalls, challenges and
17 opportunities for improvement. *Eur Respir J* 2018;52(5) doi: 10.1183/13993003.01261-2018
18 [published Online First: 2018/09/22]
19
20 20. Perpina Tordera M, Viejo JL, Sanchis J, et al. [Assessment of patient satisfaction and preferences
21 with inhalers in asthma with the FSI-10 Questionnaire]. *Archivos de bronconeumologia*
22 2008;44(7):346-52. [published Online First: 2008/08/30]
23
24 21. Broeders ME, Molema J, Vermue NA, et al. In Check Dial: accuracy for Diskus and Turbuhaler.
25 *International journal of pharmaceutics* 2003;252(1-2):275-80. [published Online First:
26 2003/01/29]
27
28 22. Atkins PJ. Dry powder inhalers: an overview. *Respiratory care* 2005;50(10):1304-12; discussion 12.
29 [published Online First: 2005/09/28]
30
31
32
33

34 **Figure legends** : Figure 1. The flowchart shows the process of patient's admission, recruitment,
35 intervention and visits. V0, V1, V2, and V3 are all time points to collect data.
36
37

38 **Contributors**: JLH and JZ planned the study. WZ planned the Statistical analysis methods. All
39 authors contributed to design and development of the trail (JLH, JZ, WZ, HFC, CLD, JYM and
40 YHZ). JLH drafted the manuscript. JZ , HFC, CLD, JYM and YHZ contributed to revised the
41 manuscript. All authors read and approved the final manuscript.
42
43
44
45


46 **Ethics and dissemination**: This trial has been registered in the Ethics Committee of Zhongshan
47 Hospital of Fudan University (B2019-142) and Clinical Trails (NCT04000958).
48
49

50 **Funding statement**: This research received no specific grant from any funding agency in the public,
51 commercial or not-for-profit sectors.
52
53

54 **Competing interests statement**: None declared.
55
56

57 **Word Count: 5085**
58
59
60

Figure 1. The flow chart of the study





SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Reported on page No
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	2
	2b	All items from the World Health Organization Trial Registration Data Set	N/A
Protocol version	3	Date and version identifier	1
Funding	4	Sources and types of financial, material, and other support	N/A
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1
	5b	Name and contact information for the trial sponsor	N/A
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	N/A
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	N/A
Introduction			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	3-5
	6b	Explanation for choice of comparators	3-5

1			
2	Objectives	7	Specific objectives or hypotheses
3			4-5
4	Trial	8	Description of trial design including type of trial (eg, parallel
5	design		group, crossover, factorial, single group), allocation ratio, and
6			framework (eg, superiority, equivalence, noninferiority,
7			exploratory)
8			
9			
10	Methods: Participants, interventions, and outcomes		
11			
12	Study	9	Description of study settings (eg, community clinic, academic
13	setting		hospital) and list of countries where data will be collected.
14			Reference to where list of study sites can be obtained
15			
16	Eligibility	10	Inclusion and exclusion criteria for participants. If applicable,
17	criteria		eligibility criteria for study centres and individuals who will
18			perform the interventions (eg, surgeons, psychotherapists)
19			
20	Interventio	11	Interventions for each group with sufficient detail to allow
21	ns	a	replication, including how and when they will be administered
22			
23			
24		11	Criteria for discontinuing or modifying allocated interventions for
25		b	a given trial participant (eg, drug dose change in response to
26			harms, participant request, or improving/worsening disease)
27			
28		11	Strategies to improve adherence to intervention protocols, and
29		c	any procedures for monitoring adherence (eg, drug tablet
30			return, laboratory tests)
31			
32			
33		11	Relevant concomitant care and interventions that are permitted
34		d	or prohibited during the trial
35			
36	Outcomes	12	Primary, secondary, and other outcomes, including the specific
37			measurement variable (eg, systolic blood pressure), analysis
38			metric (eg, change from baseline, final value, time to event),
39			method of aggregation (eg, median, proportion), and time point
40			for each outcome. Explanation of the clinical relevance of
41			chosen efficacy and harm outcomes is strongly recommended
42			
43			
44	Participant	13	Time schedule of enrolment, interventions (including any run-
45	timeline		ins and washouts), assessments, and visits for participants. A
46			schematic diagram is highly recommended (see Figure)
47			
48			
49	Sample	14	Estimated number of participants needed to achieve study
50	size		objectives and how it was determined, including clinical and
51			statistical assumptions supporting any sample size calculations
52			
53	Recruitmen	15	Strategies for achieving adequate participant enrolment to
54	t		reach target sample size
55			
56			
57			
58			
59			
60			

Methods: Assignment of interventions (for controlled trials)

Allocation:

1				
2	Sequen	16	Method of generating the allocation sequence (eg, computer-	12
3	ce	a	generated random numbers), and list of any factors for	
4	generati		stratification. To reduce predictability of a random sequence,	
5	on		details of any planned restriction (eg, blocking) should be	
6			provided in a separate document that is unavailable to those	
7			who enrol participants or assign interventions	
8				
9				
10	Allocatio	16	Mechanism of implementing the allocation sequence (eg,	12
11	n	b	central telephone; sequentially numbered, opaque, sealed	
12	conceal		envelopes), describing any steps to conceal the sequence until	
13	ment		interventions are assigned	
14	mechani			
15	sm			
16				
17				
18	Impleme	16	Who will generate the allocation sequence, who will enrol	13
19	ntation	c	participants, and who will assign participants to interventions	
20				
21	Blinding	17	Who will be blinded after assignment to interventions (eg, trial	13
22	(masking)	a	participants, care providers, outcome assessors, data	
23			analysts), and how	
24				
25				
26		17	If blinded, circumstances under which unblinding is permissible,	13
27		b	and procedure for revealing a participant's allocated	
28			intervention during the trial	
29				
30				
31	Methods: Data collection, management, and analysis			
32	Data	18	Plans for assessment and collection of outcome, baseline, and	9-10
33	collection	a	other trial data, including any related processes to promote	
34	methods		data quality (eg, duplicate measurements, training of	
35			assessors) and a description of study instruments (eg,	
36			questionnaires, laboratory tests) along with their reliability and	
37			validity, if known. Reference to where data collection forms can	
38			be found, if not in the protocol	
39				
40				
41				
42		18	Plans to promote participant retention and complete follow-up,	9-10
43		b	including list of any outcome data to be collected for	
44			participants who discontinue or deviate from intervention	
45			protocols	
46				
47	Data	19	Plans for data entry, coding, security, and storage, including	N/A
48	manageme		any related processes to promote data quality (eg, double data	
49	nt		entry; range checks for data values). Reference to where	
50			details of data management procedures can be found, if not in	
51			the protocol	
52				
53				
54	Statistical	20	Statistical methods for analysing primary and secondary	13
55	methods	a	outcomes. Reference to where other details of the statistical	
56			analysis plan can be found, if not in the protocol	
57				
58				
59				
60				

1			
2	20	Methods for any additional analyses (eg, subgroup and	13
3	b	adjusted analyses)	
4			
5	20	Definition of analysis population relating to protocol non-	13
6	c	adherence (eg, as randomised analysis), and any statistical	
7		methods to handle missing data (eg, multiple imputation)	
8			

Methods: Monitoring

11	Data	21	Composition of data monitoring committee (DMC); summary of	N/A
12	monitoring	a	its role and reporting structure; statement of whether it is	
13			independent from the sponsor and competing interests; and	
14			reference to where further details about its charter can be	
15			found, if not in the protocol. Alternatively, an explanation of why	
16			a DMC is not needed	
17				
18				
19		21	Description of any interim analyses and stopping guidelines,	N/A
20		b	including who will have access to these interim results and	
21			make the final decision to terminate the trial	
22				
23				
24	Harms	22	Plans for collecting, assessing, reporting, and managing	N/A
25			solicited and spontaneously reported adverse events and other	
26			unintended effects of trial interventions or trial conduct	
27				
28				
29	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and	N/A
30			whether the process will be independent from investigators and	
31			the sponsor	
32				

Ethics and dissemination

35	Research	24	Plans for seeking research ethics committee/institutional review	14
36	ethics		board (REC/IRB) approval	
37	approval			
38				
39				
40	Protocol	25	Plans for communicating important protocol modifications (eg,	14
41	amendmen		changes to eligibility criteria, outcomes, analyses) to relevant	
42	ts		parties (eg, investigators, REC/IRBs, trial participants, trial	
43			registries, journals, regulators)	
44				
45	Consent or	26	Who will obtain informed consent or assent from potential trial	14
46	assent	a	participants or authorised surrogates, and how (see Item 32)	
47				
48		26	Additional consent provisions for collection and use of	N/A
49		b	participant data and biological specimens in ancillary studies, if	
50			applicable	
51				
52				
53	Confidentia	27	How personal information about potential and enrolled	14
54	lity		participants will be collected, shared, and maintained in order to	
55			protect confidentiality before, during, and after the trial	
56				
57				
58	Declaration	28	Financial and other competing interests for principal	N/A
59	of interests		investigators for the overall trial and each study site	
60				

1				
2	Access to	29	Statement of who will have access to the final trial dataset, and	14
3	data		disclosure of contractual agreements that limit such access for	
4			investigators	
5				
6	Ancillary	30	Provisions, if any, for ancillary and post-trial care, and for	N/A
7	and post-		compensation to those who suffer harm from trial participation	
8	trial care			
9				
10	Disseminati	31	Plans for investigators and sponsor to communicate trial results	14
11	on policy	a	to participants, healthcare professionals, the public, and other	
12			relevant groups (eg, via publication, reporting in results	
13			databases, or other data sharing arrangements), including any	
14			publication restrictions	
15				
16				
17				
18		31	Authorship eligibility guidelines and any intended use of	N/A
19		b	professional writers	
20				
21		31	Plans, if any, for granting public access to the full protocol,	N/A
22		c	participant-level dataset, and statistical code	
23				
24	Appendice			
25	s			
26				
27	Informed	32	Model consent form and other related documentation given to	N/A
28	consent		participants and authorised surrogates	
29	materials			
30				
31				
32	Biological	33	Plans for collection, laboratory evaluation, and storage of	N/A
33	specimens		biological specimens for genetic or molecular analysis in the	
34			current trial and for future use in ancillary studies, if applicable	
35				

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.

BMJ Open

The effect of PIFR-based Optimized Inhalation Therapy in Patients Recovering From Acute exacerbation of Chronic Obstructive Pulmonary Disease: protocol of a prospective, multi-center, superiority, randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-034804.R3
Article Type:	Protocol
Date Submitted by the Author:	03-Mar-2020
Complete List of Authors:	Hua, Jianlan; Zhongshan Hospital Fudan University, Department of Pulmonary and Critical Care Medicine Zhang, wei; Fudan University, Department of Biostatistics Cao, Hui-fang; Shanghai Jing'an District Central Hospital Du, Chun-ling; Shanghai Qingpu District Central Hospital Ma, Jia-yun; North Branch of Shanghai Ninth People's Hospital Zuo, Yi-hui; Zhongshan Hospital Fudan University, Department of Pulmonary and Critical Care Medicine Zhang, Jing; Zhongshan Hospital Fudan University, Department of Pulmonary and Critical Care Medicine
Primary Subject Heading:	Respiratory medicine
Secondary Subject Heading:	Medical education and training, Pharmacology and therapeutics, Research methods
Keywords:	RESPIRATORY MEDICINE (see Thoracic Medicine), Chronic airways disease < THORACIC MEDICINE, MEDICAL EDUCATION & TRAINING

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **The effect of PIFR-based Optimized Inhalation Therapy in**
5
6 **Patients Recovering From Acute exacerbation of Chronic**
7
8 **Obstructive Pulmonary Disease: protocol of a prospective,**
9
10 **multi-center, superiority, randomized controlled trial**
11
12
13

14 Jian-lan Hua¹, Wei Zhang², Hui-fang Cao³, Chun-ling Du ⁴, Jia-yun Ma ⁵ , Yi-hui Zuo¹, Jing
15
16 Zhang^{1*}
17

18
19 ¹Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Shanghai Medical
20
21 College, Fudan University, Shanghai, China
22
23

24 ²Department of Biostatistics, School of Public Health, Fudan University, Shanghai, China
25
26

27 ³ Department of Pulmonary, Shanghai Jing 'an District Central Hospital, Shanghai, China
28
29

30 ⁴ Department of Pulmonary, Shanghai Qingpu District Central Hospital, Shanghai, China
31
32

33 ⁵ Department of Pulmonary, North Branch of Shanghai Ninth People's Hospital, Shanghai JiaoTong
34
35 University school of medicine, Shanghai, China
36

37 * Correspondence: Jing Zhang
38
39

40 Department of Pulmonary and Critical Care Medicine, Zhongshan hospital, Shanghai Medical
41
42 College, Fudan University, 180 Feng lin road, shanghai 200032, People's Republic of China
43
44

45 Email: jingatlas@hotmail.com
46
47

48
49
50 Date: 2019/2/21

51
52 version identifier: 1.4
53
54
55
56
57
58
59
60

Abstract:

Introduction: Chronic Obstructive Pulmonary Disease (COPD) is a global respiratory disease. Acute exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) is a major cause of disease progression and death, and causes huge medical expenditures. Effective inhalation therapy is important during the AE recovery period. However, the invalid inhalation using DPI due to the unrecovered inspiratory flow rate after AECOPD results in increased risk of treatment failure and early recurrence. We envisage that choosing the right inhaler based on peak inhalation flow rate (PIFR) and training inhaler techniques will contribute to reducing early relapse rates. Therefore, a prospective multicenter randomized trial is designed to verify this hypothesis.

Methods and analysis: The study is aimed at determining whether the optimized inhalation therapy based on PIFR can reduce the rate of treatment failure in patients recovering from AECOPD. In the study, 416 patients with AECOPD whose exacerbated symptoms are relieved by 5-7 days of standard therapy will be recruited and be randomized into PIFR group, which receives inhaler depending on their PIFR and is trained to use the inhaler appropriately, and control group, which receives inhaler depending on the judgment of a respiratory physician, at a 1:1 ratio. The primary outcome of the study is 30-day treatment failure rate. Other endpoints include PIFR, the error rate of inhalation device use, satisfaction with inhalation devices, 30-day mortality, 90-day mortality, symptoms and life quality of patients and COPD-related treatment costs.

Ethics and dissemination: This trial has been registered in the Ethics Committee of Zhongshan Hospital of Fudan University (B2019-142). Participants will be screened and recruited from hospitalized patients by physicians. No public recruitment documents will be used for participants enrollment. The results will be disseminated through peer-reviewed journals and conference presentations, and proliferation activities will include diverse social non-academic groups and patients.

Trial registration: This trial has been registered in ClinicalTrials.gov (NCT04000958).

Strengths and limitations of this study:

1. To our knowledge, this is the first multicenter, randomized trial designed to study the efficacy of PIFR-based inhaler prescription in preventing short-term re-exacerbation in patients recovering from severe acute exacerbation of COPD.

1
2
3
4 2. InCheck DIAL® is used to measure PIFR and objectively evaluate the capacity of using dry
5 powder inhalers.

6
7 3. The inhaler technique will be trained as well to achieve optimal inhalation therapy.

8
9 4. Inhalers studied in this trial include turbuhaler, handihaler, respimat and pMDI.

10
11 5. The limitation of the study is the single-blind study design, which would yield bias, although blind
12 evaluation is adopted to minimize the bias.
13
14

15
16
17 **Keywords:** chronic obstructive pulmonary disease, acute exacerbation of chronic obstructive
18 pulmonary disease, peak inhalation flow rate
19
20

21 22 23 **Introduction**

24
25 Chronic Obstructive Pulmonary Disease (COPD) is a global respiratory disease that
26 severely threatens human health. COPD has resulted in a significant socioeconomic
27 burden, and is currently the fourth leading cause of death in the world. Moreover, it is
28 projected to be the 3rd leading cause of death by 2020¹. In China, COPD ranked among
29 the top three leading causes of death and the direct medical cost of COPD ranged from
30 72 to 3,565 USD per capita per year, accounting for 33.33% to 118.09% of local
31 average annual income². The overall prevalence of spirometry-defined COPD was 8.6%
32 among the general Chinese population aged 20 years or older³. Acute exacerbation of
33 Chronic Obstructive Pulmonary Disease (AECOPD) is a major cause
34 of disease progression and death, and causes huge medical expenditures⁴.
35
36
37
38
39
40
41
42
43
44

45 Inhalation therapy is the core pharmaceutical therapy for COPD including inhaled
46 corticosteroid (ICS), both short-acting and long-acting beta2-agonists and, more
47 recently, muscarinic antagonists⁵. Existing common inhalers include pressure metered
48 dose inhaler (pMDI), dry powder inhalers (DPIs), soft mist inhalers (SMIs), and
49 nebulizers⁶. Common inhaler errors include insufficient inspiratory effort, no breath-
50 hold (or holds breath for less than 3s)^{7,8}. Inhaler errors are associated with poor disease
51 outcomes (exacerbations) and greater health-economic burden⁹. MDIs require complex
52 coordination techniques with a slow inhalation by the patient to achieve a clinically
53
54
55
56
57
58
59
60

1
2
3
4 effective dose. DPIs decrease the complexity of administration, but effective
5 medication delivery is dependent on the force of the patient's inspiratory effort to
6 overcome internal resistance¹⁰. Several *in vitro* studies have demonstrated the
7 inhalation flow rate dependency of DPI. Specifically, the results showed that using a
8 DPI both the amount of medication delivered to the patient and the effective
9 aerodynamic particle size of the medication were adversely affected when the testing
10 peak inhalation flow rate (PIFR) was less than a certain threshold (60 liters/min
11 measured at no resistance)¹¹, which may result in ineffective inhalation of medications
12 using a DPI. Several studies suggested that patients with insufficient PIFR in stable
13 phase of COPD may have an adverse effect on prognosis using inappropriate inhaler¹²
14 ¹³. Moreover, it should be noted that expiratory flow rate (such as FEV₁) is not
15 correlated linearly with inspiratory flow parameters, and it cannot predict PIFR. Other
16 risk factors for early AECOPD recurrence include age grades, GOLD grades, AE
17 frequency in the previous year, pleural effusion, use of accessory respiratory muscles,
18 noninvasive mechanical ventilation, controlled oxygen therapy and length of hospital
19 stay, while inhaled long-acting β -2-agonists (LABA) and inhaled corticosteroids (ICS)
20 are protection factors¹⁴. An investigation suggested that one of five stable outpatients
21 more than 60 years of age with severe COPD did not reach the recommended PIFR for
22 DPI devices¹⁵. Some small sample studies have shown that a significant proportion of
23 patients are not suitable for DPI during AECOPD because of their insufficient PIFR¹³
24 ¹⁶. However, there is no study about the PIFR status and the impact of inhaler choices
25 on prognosis for patients recovering from AECOPD.

26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Thirty-day readmission rates after hospitalization for AECOPD are approximately
15.8%-20%^{17 18}. Readmissions are costly and adversely affect quality of life. But little
is known about PIFRs of the patients recovering from AECOPD as well as the clinical
impact of the inhaler (DPI or pMDI) selected for the patients. Generally, discharge
protocols for patients recovering from AECOPD do not include an assessment of PIFR
or patients' ability to use their inhaler device when they recuperate after discharge.
Clinicians typically select the inhaler which they use during the stable phase of COPD
for patients about to be discharged. Furthermore, although some evidence has suggested

1
2
3
4 that incorrect use of inhalers is associated with poor prognosis, studies on the effect of
5 training patients on the use of inhalers to reduce relapses are still scarce. We
6 hypothesize that PIFR of patient recovering from AECOPD has not returned to the level
7 at the stable phase of COPD as well as untrained patients have higher rate of inhaler
8 errors. It may result in suboptimal COPD management and treatment failure (including
9 recurrence resulting in an emergency visit, admission, or need for intensified
10 medication) for the patients due to the ineffective inhalation of medications.
11
12
13
14
15
16

17 The aim of this study is to determine whether the optimized inhalation therapy based
18 PIFR can reduce the rate of treatment failure in patients recovering from AECOPD.
19 Errors in inhaler use and quality of life are also to be evaluated.
20
21
22
23
24
25
26

27 **Methods and analysis**

28 **Trial design**

29
30 This is a prospective, multi-center, single-blind, superiority, randomized study of
31 patients hospitalized for a COPD exacerbation. This study is designed to determine
32 whether PIFR based inhaler choice and training can reduce the rate of treatment failure
33 in patients recovering from AECOPD. The primary study outcome is 30-day treatment
34 failure rate. Treatment failure means AECOPD recurrence resulting in an emergency
35 visit, admission, or need for intensified medication. Other endpoints include symptoms
36 and life quality of patients the error rate of inhalation device use, satisfaction with
37 inhalation devices, PIFR, 30-day mortality, 90-day mortality, and COPD-related
38 treatment costs. The enrollment, conduct and data analysis of the trail are performed at
39 Zhongshan Hospital of Fudan University, Shanghai Jing 'an District Central Hospital,
40 Shanghai Qingpu District Central Hospital and North Branch of Shanghai Ninth
41 People's Hospital in China. The study is expected to last for 2 years. Recruitment of
42 participants has started since November 2019. A blank copy of the original consent
43 form is provided and shown as a supplementary document.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

This trial has been registered in the Ethics Committee of Zhongshan Hospital of

1
2
3
4 Fudan University (B2019-142) and ClinicalTrials.gov (NCT04000958).
5
6
7

8 Inclusion criteria 9

10 All patients meeting AECOPD diagnostic criteria who hospitalized for COPD related
11 reasons will be followed. The definition of COPD follows the GOLD definition and the
12 definition of AECOPD follows Expert Consensus on Acute Exacerbation of Chronic
13 Obstructive Pulmonary Disease in the People's republic of China⁴. AECOPD is defined
14 as sudden worsening of respiratory symptoms that require additional treatment (typical
15 manifestations include dyspnea, aggravated cough, increased sputum volume, and/or
16 sputum purulence) and is beyond normal day-to-day variations, leading to a change in
17 medications^{4 19}. The subjects will be enrolled and randomized into the study group if
18 all of the following criteria are met: (1) 40–80 years old; (2) patients with AECOPD
19 whose acute respiratory symptoms have been controlled and met discharge criteria after
20 5-7 day-standard AECOPD treatment including atomized or inhaled bronchodilator
21 plus oral or intravenous glucocorticoid (prednisone equivalent dose 40-50mg) or
22 Pulmicort 2mg atomization twice daily plus broad-spectrum antibiotics; (3) patients
23 with moderate and above COPD with a recorded spirometry measured in the stable
24 disease status, ie, post-bronchodilator forced expiratory volume in one second
25 (FEV1)/forced vital capacity (FVC) <70% and FEV1% predicted value <80%; (4)
26 patients have signed an informed consent form.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 Discharge criteria are as follows: (1) physician are confident that the patient can
44 manage successfully at home; (2) long-acting bronchodilators, either beta 2-agonists
45 and/or anticholinergics with or without inhaled corticosteroids can be used, and inhaled
46 short-acting β 2-agonist therapy is required no more frequently than every 4 hours; (3)
47 the patient, if previously ambulatory, is able to walk across the room; (4) the patient is
48 able to eat and sleep without frequent awakening due to dyspnea; (5) the patient has
49 been clinically stable for 12–24 hours; (6) arterial blood gases have been stable for 12–
50 24 hours⁴.
51
52
53
54
55
56
57
58
59
60

Exclusion criteria

Exclusion criteria include: (1) patients who are already using home nebulization therapy because of the severity of the disease; (2) patients with bronchial asthma, pulmonary interstitial fibrosis, bronchiectasis, pulmonary embolism and other lung diseases; or hypertension, heart disease, chronic liver and kidney disease, diabetes, chronic gastrointestinal diseases, malignant tumors, critically ill; (3) patient's mental state cannot match the observation or they suffer from cognitive impairment; (4) patient's peak inspiratory flow rates (PIFR) is less than 20L/min.

Sample size

The sample size was calculated using PASS 15.0 (Power Analysis and Sample Size Software) to ensure the study power. Several studies have found that 30-47% patients hospitalized for AECOPD had a PIFR < 60 liters/minute prior to discharge^{5 10}. For the control group, 30-day treatment failure rates after hospitalization for AECOPD are approximately 20% according to the literature and our retrospective cohort study^{17, 18}. For PIFR group, 30-day treatment failure rates are 10% based on our preliminary research. The participants will be divided into PIFR group and control group in a 1:1 ratio. To test the superiority hypothesis with 80% power with 2-side alpha at 0.05 level, 197 subjects will be enrolled for each group. Considering 5% dropout rate, the minimum number of the participants in the study has been determined to be 208 per group.

Study outline

The flow chart of the study design is shown in Figure 1. The study will recruit 416 patients with AECOPD whose exacerbated symptoms are relieved by 5-7 days of standard therapy. After enrollment, the participants are divided into PIFR group and control group at a 1:1 ratio according to a random envelope method. All the patients will be given inhaled corticosteroid (ICS)/long-acting β agonist (LABA) (budesonide/

1
2
3
4 formoterol - Symbicort turbuhaler® (AstraZeneca AB) 160/4.5 µg bid or
5
6 Beclometasone/ Formoterol Foster® (Chiesi Farmaceutici S.p.A.) pressure pMDI 100/6
7
8 µg 2 puff bid). For symptomatic patients (mMRC ≥ 2, CAT ≥ 10) before acute
9
10 exacerbation, Spiriva handihaler® 18µg qd or Spiriva respimat® (Boehringer
11
12 IngelheimPharma GmbH & Co.KG) 2.5µg qd will be prescribed in combination with
13
14 ICS/LABA.

15
16 For PIFR group, PIFR is measured by InCheck DIAL® (Clement Clarke
17
18 International Ltd, Harlow, UK and Alliance Tech Medical). The InCheck DIAL® is
19
20 designed to simulate the “internal resistance” of common inhaler devices, and measure
21
22 inspiratory flow. These measurements enable the healthcare professional to encourage
23
24 patients to modify their inspiratory technique (by inhaling with more, or less effort), in
25
26 order to achieve a flow rate consistent with clinical efficacy. The colored ‘flow’ icons
27
28 show the clinically effective flow ranges for each different inhaler device. The InCheck
29
30 DIAL® is accurate to +/- 10% or 10 L/min, whichever is greater, and is a low-range
31
32 inspiratory flow meter (15 to 120 L/min) that has a selectable resistance from high to
33
34 low, shown by the colored ‘flow’ icons calibrated to enable the measurement of airflow
35
36 as if the patient was using certain different inhalers. In this study, we will set the
37
38 resistance of the InCheck DIAL® both to zero (correspond to pMDI) and Med High
39
40 resistance level of InCheck DIAL® (correspond to turbuhaler®) when measuring PIFR.
41
42 Before measuring , we will first train patients to use the InCheck DIAL® correctly.
43
44 After patients are able to reach their maximum value of PIFR steadily, we will measure
45
46 the PIFR 3 times then take the average as a result.

47
48 Moreover, the InCheck DIAL® is an inhalation airflow training meter contributing
49
50 to assess and improve patients' ability to use inhalers. When training the patient, we
51
52 will set the corresponding resistance for the InCheck DIAL® according to the inhaler
53
54 that the patient is prescribed. We will also explain to the patient the proper operation of
55
56 the inhaler and demonstrate some common mistakes.

57
58 If PIFR is less than 60L/min (measured without a resistance), the patient will be given
59
60 pMDI with spacer. If PIFR value is over 60 L/min (measured without a resistance), the

1
2
3
4 patient will be given dry powder inhaler (DPI). Furthermore, InCheck DIAL® will be
5
6 used for an inhalation device training.

7
8 The control group will be given DPI or pMDI with spacer according to the judgment
9
10 of a respiratory physician.

11
12 Both groups will be taught to use the device after the prescription, and then be
13
14 reminded to use medication via a WeChat public account.

15 16 17 18 19 20 Study step

21
22 The participants will be followed up for 3 months. 3 visits will be performed at
23
24 baseline(symptoms of AECOPD are relieved by 5-7 days of standard therapy), 1 and 3
25
26 months after enrollment.

27
28 Demographics, clinical characteristics, evaluation of respiratory symptoms and
29
30 quality of life in the stable phase, PIFR, routine laboratory tests for AE patients(e.g.
31
32 blood routine, C-reactive protein, liver and kidney function, blood electrolytes, B-type
33
34 natriuretic peptide, D-dimer), chest X-ray or CT and echocardiography or
35
36 electrocardiogram in the stable phase will be collected at baseline. Demographics
37
38 includes age, gender, age, height, weight, ethnicity, occupation(number of years of
39
40 work), marital status, location, etc. Clinical characteristics includes past disease history,
41
42 history of drug sensitivity, history of vaccination, family disease history, current
43
44 medical history, comorbidities, medications, etc. Respiratory symptoms will be
45
46 assessed with the modified Medical Research Council (mMRC) dyspnea scale and the
47
48 COPD Assessment Test (CAT) score for the patients. Quality of life will be assessed
49
50 with St.George's Respiratory Questionnaire(SGRQ) scale. All baseline data will be
51
52 collected by attending physician on the day of enrollment.

53
54 CAT score, mMRC score, SGRQ score, PIFR, spirometry, the error rate of inhalation
55
56 device use, satisfaction with inhalation devices, condition of AE and COPD medicine
57
58 treatment will be collected at both 1-month and 3-month visit. The data to be collected
59
60 for each visit is shown in Table 1.

Table 1. Data collected at each visit

	V0	V1	V2	V3
	Hospitalization±1 day	At the time of discharge (meet standards)	1 month after discharge	3 month after discharge
Basic Information	√			
Information of COPD at stable phase	√			
Blood routine	√	√		
Liver and kidney function	√	√		
Electrolyte	√	√		
C-reactive protein	√	√		
procalcitonin	√	√		
brain natriuretic peptide	√	√		
D-dimer 、 Fibrinogen	√	√		
cardiac troponin T	√	√		
CAT score	√	√	√	√
mMRC	√	√	√	√
SGRQ		√	√	√
Drug for COPD	Stable phase	AE phase	Stable phase	Stable phase
PIFR		PIFR√	PIFR√	PIFR√
Prognosis			√	√
Pulmonary function		√	√	√
Echocardiography at stable phase				
CT at stable phase				
CT at AE phase				
Error of inhaler use			√	√
Satisfaction with the inhaler			√	√
Daily cost of COPD related treatment			√	√

Endpoints

The primary endpoint is 30-day treatment failure rate of AECOPD. Treatment failure means AECOPD recurrence resulting in an emergency visit, admission, or need for intensified medication.

Secondary endpoints include PIFR, the error rate of inhalation device use, satisfaction with inhalation devices, 30-day mortality, 90-day mortality, symptoms and life quality of patients and COPD-related treatment costs.

Patient's satisfaction with inhalation devices will be assessed by FSI-10 questionnaire. The FSI-10 questionnaire is supposed to be completed by patients themselves, which has been widely applied to assess patients' opinions about ease of use, portability, and usability of inhalers²⁰. The symptoms of patients are evaluated by the COPD assessment test (CAT) and the modified Medical Research Council (mMRC) dyspnea scale. The patients' quality of life are evaluated by St. George's Respiratory Questionnaire (SGRQ).

PIFR is measured by InCheck DIAL® (Clement Clarke International Ltd, Harlow, UK and Alliance Tech Medical).

The error rate of inhalation device use is described in Table 2^{7,8}.

Table 2. The error rate of inhalation device use

Turbuhaler	Handihaler/Accuhaler	pMDI	Respimat
Cover is not removed/ Cover is not covered properly.	Cover is not removed/ Cover is not covered properly.	Cover is not removed/ Cover is not covered properly.	Cover is not removed/ Cover is not covered properly.
Patient reduces dose due to shaking or tilting during preparation.	-		The device is not installed correctly before use.
Device is not held upright.	-	Device is not held upright.	-

Patient does not twist grip at the base or twist around and then back until click is heard.	-	-	Patient dose not turn the device toward the arrow in the label until it clicks.
Patient forces insufficiently when inhaling.	Patient forces insufficiently when inhaling.	Patient dose not inhale deeply and slowly.	Patient dose not inhale deeply and slowly.
Patient does not tilt head to make the chin slightly upturned.	Patient does not hold the head in a vertical position.	Patient does not tilt head to make the chin slightly upturned.	Patient dose not point the inhaler toward the back of throat.
Patient does not exhale to empty the lung before inhaling.	Patient does not exhale to empty the lung before inhaling.	Patient does not exhale to empty the lung before inhaling.	Patient does not exhale to empty the lung before inhaling.
-	Patient does not turn the head away from device and exhale.	Patient exhales into the device before inhaling.	Patient covers the air entries while inhaling.
Patient does not seal the mouthpiece with the lips.	Patient does not put the mouthpiece in mouth, and close the lips.	Patient does not seal the mouthpiece with the lips.	Patient does not seal the mouthpiece with the lips.
NA	NA	Releasing drug is out of sync with inhaling.	Releasing drug is out of sync with inhaling.
Patient does not hold breath(or hold breath less than 3s).	Patient does not hold breath(or hold breath less than 3s).	Patient does not hold breath(or hold breath less than 3s).	Patient does not hold breath(or hold breath less than 10s).
Patient does not put the cover back and wait for 30-60 seconds for the second dose.	Patient dose not dispose of the capsule and put the cover back on the device.	Patient does not exhale and wait for 30-60 seconds before the second puff.	Patient dose not inhales twice to complete the total daily dosage.

Randomization

Enrollment and randomization are performed at Zhongshan Hospital of Fudan

1
2
3
4 University. After enrollment, patients will be assigned into two groups in a 1:1 ratio to
5 the PIFR group and control group by random number table method generated by SPSS
6 22.0.
7
8
9

10 11 Blinding

12
13
14 The study adopts blind evaluation. The investigator will enroll participants and
15 assign them into two groups. All data at baseline, 1-month and 3-month visit will be
16 collected by attending physician, who will not be informed of which group the patient
17 has been assigned. In addition, patients will not know the group they belong to. Blind
18 evaluation maximizes the objectivity and reliability of the study.
19
20
21
22
23
24
25

26 27 Statistical analysis

28 29 1. Statistical analysis datasets

- 30 • Modified intent-to-treat set (MITTS)

31
32 Subjects that have undergone randomization and interventions, and carry out
33 primary endpoint evaluation.
34

- 35 • Safety set (SS)

36
37 Subjects that are randomized, undergo the intervention, and with safety evaluation
38 data.
39
40

41 42 2. Statistical analysis methods

43
44 Statistical analyses will be performed using SPSS 22.0. Continuous variables are
45 described as mean (SD) or median (p25,p75) and count variables are described as
46 frequency and percentage. All tests were both sided and statistical analysis, 0.05 was
47 set as the P value for significance. For discrete variables including 30-day treatment
48 failure rate, the error rate of inhalation device use, satisfaction with inhalation devices,
49 30-day mortality and 90-day mortality, a chi-squared (χ^2) test, Fisher's exact test or
50 CMH χ^2 test will be used. For continuous variables including PIFR, CAT score, mMRC
51 score, SGRQ score and COPD-related treatment costs, Student's t-tests or Mann-
52 Whitney test will be used. Subgroup analysis by exacerbation history and GOLD grades
53
54
55
56
57
58
59
60

1
2
3 will be performed to rule out the influence of confounding factors to the certain extent.
4
5
6
7
8
9

10 Patient and public Involvement

11 Patients or the public were not involved in the design, or conduct, or reporting, or
12 dissemination of our research. The results will be available to the public if necessary.
13
14
15
16
17
18
19

20 Ethics and dissemination

21 This trial has been registered in the Ethics Committee of Zhongshan Hospital of
22 Fudan University (B2019-142). In this study, diagnosis and treatment will be performed
23 in accordance with the routine management of COPD. Neither Additional drug
24 intervention nor invasive examination and charges will be needed. Therefore, the study
25 is relatively safe with minimal additional risks. Participants will be screened and
26 recruited from hospitalized patients by physicians. No additional public recruitment
27 documents will be used for participants enrollment. All participants will be supposed
28 to sign an informed consent. All information of participants will be kept private and
29 will not be provided to any company or institution. The results will be disseminated
30 through peer-reviewed journals and conference presentations, and proliferation
31 activities will include diverse social non-academic groups and patients.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 Discussion

49 Drug delivery by DPI depends on the inbuilt resistance of the inhaler and the PIFR
50 generated by the patient. PIFR generally depends on an individual's effort as well as
51 the respiratory muscle force, which may be decreased in patients with COPD due to
52 airway stenosis, lung hyperinflation, hypoxemia, and muscle wasting. DPIs are breath-
53 actuated that require the individuals to create turbulent forces to disaggregate the
54 powder into respirable particles which can reach the lower respiratory tract. Patients
55
56
57
58
59
60

1
2
3
4 with a sufficient PIFR (PIFR > 60 L/min) are able to release the powder and
5
6 disaggregate the drug resulting in lung deposition.

7
8 Sharma and colleagues have found that 31.7% of patients at discharge following
9
10 hospitalization for an exacerbation of COPD had PIFR less than 60 L/min³. Patients
11
12 with a PIFR less than 60 L/min have been considered not be able to inhale medications
13
14 using a DPI effectively into the lower respiratory tract according to the literature, while
15
16 a PIFR less than 30 liters/minute is insufficient^{21 22}. However, most clinicians in china
17
18 prescribe DPI to the patients recovering from AECOPD routinely due to the lack of the
19
20 availability of long-acting bronchodilators with pMDI without measuring their PIFR.
21
22 Inappropriate inhaler selection may result in treatment failure of AECOPD. Before our
23
24 study, it remains unclear whether treatment failure rate is related to PIFR-based inhaler
25
26 description. A suitable inspiratory flow rate helps to improve the treatment efficacy. In
27
28 addition to inhaler selection, PIFR group also receive inhaler training to help patients
29
30 master the correct inhalation method.

31
32 Our research has proposed to measure PIFR of patients recovering from AECOPD
33
34 by InCheck DIAL® and guide COPD inhaler choices and inhaler technique training.
35
36 The aim of this study is to determine whether the optimized inhalation therapy based
37
38 on PIFR measured against the simulated resistance can reduce the rate of treatment
39
40 failure in patients recovering from AECOPD. Therefore, we are planning to verify the
41
42 clinical significance of including PIFR in the discharge protocol through comparing the
43
44 difference in 30-day treatment failure rates and other endpoints between PIFR group
45
46 and the control group.

51 52 **References**

- 53
54 1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for
55
56 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study
57
58 2010. *Lancet (London, England)* 2012;380(9859):2095-128. doi: 10.1016/s0140-
59
60 6736(12)61728-0 [published Online First: 2012/12/19]
2. Zhu B, Wang Y, Ming J, et al. Disease burden of COPD in China: a systematic review. *Int J Chron*

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Obstruct Pulmon Dis* 2018;13:1353-64. doi: 10.2147/copd.S161555 [published Online First: 2018/05/08]
3. Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. *Lancet (London, England)* 2018;391(10131):1706-17. doi: 10.1016/s0140-6736(18)30841-9 [published Online First: 2018/04/14]
4. Cai BQ, Cai SX, Chen RC, et al. Expert consensus on acute exacerbation of chronic obstructive pulmonary disease in the People's Republic of China. *Int J Chron Obstruct Pulmon Dis* 2014;9:381-95. doi: 10.2147/copd.S58454 [published Online First: 2014/05/09]
5. Mahler DA. Peak Inspiratory Flow Rate as a Criterion for Dry Powder Inhaler Use in Chronic Obstructive Pulmonary Disease. *Ann Am Thorac Soc* 2017;14(7):1103-07. doi: 10.1513/AnnalsATS.201702-156PS [published Online First: 2017/05/10]
6. Lopez-Campos JL, Soler-Cataluna JJ, Miravittles M. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2019 Report: Future Challenges. *Archivos de bronconeumologia* 2019 doi: 10.1016/j.arbres.2019.06.001 [published Online First: 2019/07/20]
7. Cho-Reyes S, Celli BR, Dembek C, et al. Inhalation Technique Errors with Metered-Dose Inhalers Among Patients with Obstructive Lung Diseases: A Systematic Review and Meta-Analysis of U.S. Studies. *Chronic Obstr Pulm Dis* 2019;6(3):267-80. doi: 10.15326/jcopdf.6.3.2018.0168 [published Online First: 2019/07/26]
8. Price DB, Roman-Rodriguez M, McQueen RB, et al. Inhaler Errors in the CRITIKAL Study: Type, Frequency, and Association with Asthma Outcomes. *The journal of allergy and clinical immunology In practice* 2017;5(4):1071-81.e9. doi: 10.1016/j.jaip.2017.01.004 [published Online First: 2017/03/14]
9. Usmani OS, Lavorini F, Marshall J, et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. *Respir Res* 2018;19(1):10. doi: 10.1186/s12931-017-0710-y [published Online First: 2018/01/18]
10. Sharma G, Mahler DA, Mayorga VM, et al. Prevalence of Low Peak Inspiratory Flow Rate at Discharge in Patients Hospitalized for COPD Exacerbation. *Chronic Obstr Pulm Dis* 2017;4(3):217-24. doi: 10.15326/jcopdf.4.3.2017.0183 [published Online First: 2017/08/30]
11. Ross DL, Schultz RK. Effect of inhalation flow rate on the dosing characteristics of dry powder inhaler (DPI) and metered dose inhaler (MDI) products. *Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine* 1996;9(2):215-26. doi: 10.1089/jam.1996.9.215 [published Online First: 1997/02/01]
12. Al-Showair RA, Tarsin WY, Assi KH, et al. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? *Respiratory medicine* 2007;101(11):2395-401. doi: 10.1016/j.rmed.2007.06.008 [published Online First: 2007/07/17]
13. Mahler DA, Waterman LA, Ward J, et al. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate. *Journal of aerosol medicine and pulmonary drug delivery* 2014;27(2):103-9. doi: 10.1089/jamp.2013.1038 [published Online First: 2013/06/12]
14. Liu D, Peng SH, Zhang J, et al. Prediction of short term re-exacerbation in patients with acute exacerbation of chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis* 2015;10:1265-73. doi: 10.2147/COPD.S83378 [published Online First: 2015/07/15]

15. Mahler DA, Waterman LA, Gifford AH. Prevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus(R) dry powder inhaler. *Journal of aerosol medicine and pulmonary drug delivery* 2013;26(3):174-9. doi: 10.1089/jamp.2012.0987 [published Online First: 2012/10/03]
16. Broeders ME, Molema J, Hop WC, et al. The course of inhalation profiles during an exacerbation of obstructive lung disease. *Respiratory medicine* 2004;98(12):1173-9. [published Online First: 2004/12/14]
17. Hu WP, Lhamo T, Liu D, et al. Development of a Nomogram to Predict the Risk of 30-Day Re-Exacerbation for Patients Hospitalized for Acute Exacerbation of Chronic Obstructive Pulmonary Disease. *Copd* 2019;16(2):160-67. doi: 10.1080/15412555.2019.1606187 [published Online First: 2019/05/17]
18. Loh CH, Peters SP, Lovings TM, et al. Suboptimal Inspiratory Flow Rates Are Associated with Chronic Obstructive Pulmonary Disease and All-Cause Readmissions. *Ann Am Thorac Soc* 2017;14(8):1305-11. doi: 10.1513/AnnalsATS.201611-903OC [published Online First: 2017/04/14]
19. Kim V, Aaron SD. What is a COPD exacerbation? Current definitions, pitfalls, challenges and opportunities for improvement. *Eur Respir J* 2018;52(5) doi: 10.1183/13993003.01261-2018 [published Online First: 2018/09/22]
20. Perpina Tordera M, Viejo JL, Sanchis J, et al. [Assessment of patient satisfaction and preferences with inhalers in asthma with the FSI-10 Questionnaire]. *Archivos de bronconeumologia* 2008;44(7):346-52. [published Online First: 2008/08/30]
21. Broeders ME, Molema J, Vermue NA, et al. In Check Dial: accuracy for Diskus and Turbuhaler. *International journal of pharmaceutics* 2003;252(1-2):275-80. [published Online First: 2003/01/29]
22. Atkins PJ. Dry powder inhalers: an overview. *Respiratory care* 2005;50(10):1304-12; discussion 12. [published Online First: 2005/09/28]

Figure legends : Figure 1. The flowchart shows the process of patient's admission, recruitment, intervention and visits. V0, V1, V2, and V3 are all time points to collect data.

Contributors: JLH and JZ planned the study. WZ planned the Statistical analysis methods. All authors contributed to design and development of the trail (JLH, JZ, WZ, HFC, CLD, JYM and YHZ). JLH drafted the manuscript. JZ , HFC, CLD, JYM and YHZ contributed to revised the manuscript. All authors read and approved the final manuscript.

Ethics and dissemination: This trial has been registered in the Ethics Committee of Zhongshan Hospital of Fudan University (B2019-142) and Clinical Trails (NCT04000958).

Funding statement: This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Competing interests statement: None declared.

Word Count: 5111

For peer review only

Figure 1. The flow chart of the study



Informed consent

Participant Information Page

Project Title: Optimized Inhalation Therapy Based on Peak Inspiratory Flow Rates Measured Against the Simulated Resistance in Patients Recovering From Acute Exacerbation of Chronic Obstructive Pulmonary Disease: a Randomized Trial

Principal investigator: Jing Zhang

Sponsor: Zhongshan Hospital, Fudan University

Dear participant:

You are invited to participate in a clinical study of Optimized Inhalation Therapy Based on Peak Inspiratory Flow Rates Measured Against the Simulated Resistance in Patients Recovering From Acute Exacerbation of Chronic Obstructive Pulmonary Disease, supported by Zhongshan Hospital, Fudan University. Please read this informed consent carefully and make a careful decision on whether to participate in this study. Participation in this research is entirely your autonomous choice. As a subject, you need to give your written consent before joining the clinical study. When your research doctor or researcher discusses your informed consent with you, you can ask him / her to explain to you what you don't understand. We encourage you to discuss this thoroughly with your family and friends before making a decision to participate in this research. You have the right to refuse to participate in the study and to withdraw from the study at any time without penalty and without losing your rights. If you are participating in another study, please inform your research doctor or researcher. The background, purpose, research process and other important information of this research are as follows:

1. Background

Chronic obstructive pulmonary disease (COPD) is a common, multiple, highly disabling and highly lethal respiratory disease. Epidemiological surveys in different

1
2
3
4 periods in China have suggested that COPD has caused a heavy burden of disease. The
5 prevalence of people over 40 years of age is as high as 8.2-13.7%, and it is on the rise.
6 The number of disabled and deadly people caused by COPD exceeds 5 million and 1.28
7 million each year respectively. Expenditure for patients with advanced COPD accounts
8 for 40% of household income. Therefore, the prevention and treatment of COPD is an
9 important part of Chinese current health undertakings.
10
11
12
13
14

15 Inhalation therapy directly affects the lungs, which has the advantages of rapid onset,
16 excellent curative effect, and good safety. It has an irreplaceable clinical status and is
17 the first-line basic treatment method for COPD. There are three main types of inhalation
18 devices: aerosols, dry powder inhalers (DPI) and miniature nebulizers. Aerosols are
19 divided into pressure metered dose inhaler (pMDI), pMDI and spacers, new pMDI, soft
20 mist inhaler (SMI) and so on. Different inhalation devices have different requirements
21 on the hand and mouth coordination and inhalation ability of patients, and their use
22 methods also have their own characteristics. Research results at home and abroad show
23 that some patients with severe COPD are unable to effectively inhale DPI due to
24 suboptimal lung function. In addition, 28% -68% of patients are unable to benefit from
25 prescription drugs due to improper use of inhalers. Quite a few patients have poor
26 adherence to inhalation therapy, and they have stopped their medication or used
27 irregularly when their symptoms have improved slightly. Therefore, the key to
28 improving the standardization and efficacy of inhalation therapy is: (1) how to choose
29 the most suitable inhaler for patients; (2) how to improve the patients' capacity to use
30 inhalers; (3) how to improve patients' compliance.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47 In response to these problems, we have designed an optimized inhalation treatment
48 plan, which mainly includes 3 innovative measures and process improvements: (1)
49 selecting the most suitable inhalers for patients based on peak inspiratory flow rates
50 (PIFR), (2) the prescription was made after training and evaluation of the inhalation
51 device, (3) The WeChat public account will regularly push the inhaler using videos and
52 remind patients to take medication regularly to improve the accuracy and
53 standardization of patients' medication.
54
55
56
57
58
59
60

2. Study purpose

The aim of this study is to determine whether the optimized inhalation therapy based PIFR can reduce the rate of treatment failure in patients recovering from AECOPD and improve patients' prognosis. Errors in inhaler use and quality of life are also to be evaluated.

3. Study outline

(1) How many patients will participate in this study?

This study is a multi-center and approximately 250 people will participate in the study at our hospital.

(2) Study steps

If you agree to participate in this study, please sign this informed consent form. Before you are enrolled in the study, the doctor will ask, record your medical history, and collect information about your previous relevant examinations. We hope that you can truthfully and fully report your medical history and condition to your doctor in order to accurately evaluate your condition and determine whether you are suitable to participate in this study.

After determining that you will participate in this study, the doctor will assign you into the control or optimized group using a random envelope method. The control group will be treated and followed up according to the prescription drugs and devices of Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2019 Report. The optimized group will be given the appropriate inhaler based on their PIFR, and will be evaluated and trained their ability to use the inhalers before prescription. After the prescription, the WeChat public account will also be used to remind the medication regularly and provide patient education.

You will be needed to complete a total of 3 visits, including 2 on-site visits (i.e. baseline visits and 1-month visit), and 1 telephone visits (3-month visit).

The baseline visit was completed on the day of enrollment, including: (1) Basic information: ① Demographic data, including age, gender, age, height, weight, ethnicity,

1
2
3
4 occupation (years of work), marital status, region, etc. ②General clinical data,
5 including past disease history, drug susceptibility history, vaccination history, family
6 history, current disease history, comorbidities and medication. (2) Evaluation of
7 respiratory symptoms and quality of life: ① the COPD Assessment Test (CAT) Scale,
8 the modified Medical Research Council (mMRC) dyspnea scale; ② St.George's
9 Respiratory Questionnaire(SGRQ) scale. (3) 6-minute walking distance; (4) Survey of
10 satisfaction with inhalers; (5) Measurement of pulmonary ventilation function; (6)
11 Types and dosages of COPD-related drugs.

12
13
14
15
16
17
18
19 1-month on-site visit includes: (1) Evaluation of respiratory symptoms and quality
20 of life: ① the COPD Assessment Test (CAT) Scale, the modified Medical Research
21 Council (mMRC) dyspnea scale; ② St.George's Respiratory Questionnaire(SGRQ)
22 scale. (2) Survey of satisfaction with inhalation devices; (3) the error rates of inhaler
23 use; (4) Measurement of pulmonary ventilation function; (5) Acute exacerbation
24 conditions of patients; (6) Types and dosages of COPD-related drugs.

25
26
27
28
29
30
31 3-month telephone visit includes: (1) Evaluation of respiratory symptoms: the
32 COPD Assessment Test (CAT) Scale the modified Medical Research Council (mMRC)
33 dyspnea scale; (2)the error rates of inhaler use; (3) Acute exacerbation conditions of
34 patients; (4) Types and dosages of COPD-related drugs.

35
36
37
38
39 The inspections required during the visit are all based on the clinical needs of regular
40 diagnosis and treatment. There is no need to take additional specimens, which will not
41 increase your burden and risk outside of routine medical treatment.

42
43
44 (3) How long will this study last?

45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 It took 3 months from enrollment to the end of observation. You can opt out of the
study at any time without losing any benefits you would have received. However, if
you decide to withdraw from the study during the study, we encourage you to discuss
it with your doctor first. If you have a serious adverse event, or if your research doctor
feels that continuing to participate in the study is not in your best interest, he / she will
decide to withdraw you from the study. The sponsor or regulator may also terminate the
study during the study period. Your withdrawal will not affect your normal medical
treatment and rights.

1
2
3
4 If you withdraw from the study for any reason, you may be asked about your
5 participation condition in the study. If your doctor thinks it is necessary, you may also
6 be asked to perform laboratory tests and physical examinations.
7

8
9 (4) Information and biological specimens collected during study
10

11 This study will collect your basic clinical information, relevant questionnaire
12 information, and information about your condition changes. No extra invasive
13 biological specimen collection will be performed.
14

15
16 The clinical information and samples will be coded by subject numbers and stored in
17 the Department of Respiratory Medicine, Zhongshan Hospital, Fudan University. They
18 will be destroyed after the publish of study and data analysis.
19
20
21
22

23
24
25 **4.Risks and benefits**
26

27 (1) What are the risks of participating in this study?
28

29 The risks that you may take from participating in this study are as follows. You can
30 discuss these risks with your research doctor if you prefer.
31

32 During the study, you may have some, all, or none of these adverse events (adverse
33 medical events after the patient or clinical trial subject receives a test product such as a
34 drug / medical device), risks, discomfort, inconvenience, such as:
35
36
37

38 ① There is no additional operation and medication, which will not affect the normal
39 diagnosis and treatment, and will not increase the medical risks other than the normal
40 diagnosis and treatment.
41
42

43 ② Participation in this research may involve risks in information security. We will do
44 our best to protect your information from leakage. Some of the questions we ask you in
45 this study may make you feel uncomfortable. You can refuse to answer such questions,
46 and you can rest at any time during the study process. You can also withdraw from the
47 study at any time during the study.
48
49
50
51
52
53

54 If you experience any discomfort or a new change in your condition or any
55 unexpected condition during the study, whether or not it is related to the study, you
56 should promptly notify your doctor, who will make a judgment and give appropriate
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

medical treatment.

During the study, you need to be followed up to the hospital on time and do some examinations. It will take some of your time and may cause some trouble or inconvenience.

(2) What are the benefits of participating in the study?

Immediate Benefit: If you agree to participate in this study, you will receive follow-up and free medical counseling for your disease during the study.

Potential benefits: This study may contribute to the improvement of the treatment methods of COPD, and your contribution to the medical cause is very meaningful. We hope that the information you get from this study will benefit you or another patient same as your condition in the future.

5. Alternative treatment options

No alternative treatment options.

6. Use of study results and confidentiality of personal information

All your information during the study is strictly confidential. Only relevant personnel can view your medical records so that they can check the accuracy of the information collected and ensure that the study proceeds normally. Any electronically transmitted information will be renamed to ensure the confidentiality of the information. Information on all computers will be protected with a password. Results of the study may be reported at medical conferences and published in scientific journals. However, no personally identifiable information will be used.

With your and other subjects' understanding and assistance, the results of the research through this project may be published in medical journals, but we will keep your research records confidential as required by law. The personal information of the study subjects will be kept strictly confidential, and your personal information will not be disclosed unless required by relevant laws. When necessary, government administrations, hospital ethics committees, and other relevant researchers can review your data as required.

Version identifier:1.0

Date: 2019/5/16

6 / 9

7. Study costs and related compensation

(1) Drugs / devices used in study and related inspection fees

There is no additional intervention in this study and it will not increase your costs. Inpatient and outpatient routine consultations will not be free. Routine treatments and examinations for other diseases you have combined at the same time will not be free.

(2) Compensation for participating in research

Throughout the study, you only need to visit the site in accordance with the follow-up consultation requirements. There is no additional cost for participating in the study, so no compensation will be made.

(3) Compensation / compensation after damage

The study will not cause additional damage.

8. Subject rights and related considerations

(1) Your rights

You are totally voluntary the study. If you decide not to participate in this study, other treatments you should get will not be affected. If you decide to participate, you will be asked to sign the informed consent form. You have the right to withdraw from the study at any stage of the trial without discrimination or unfair treatment, and your corresponding medical treatment and rights will not be affected.

(2) Related considerations

As a subject, you need to provide true information about your own medical history and current physical condition, tell the research doctor about any discomfort you feel during the study period, do not take restricted drugs and food that the doctor has informed, and tell the research doctor whether you has participated in other study recently or is currently participating in other research.

9. Contact details for information

Your doctor will notify you if there is any important new information during the research that may affect your willingness to continue participating in the study. If you

1
2
3
4 are interested in your research data or the findings of study, you can ask any questions
5 about the study at any time and get the corresponding answers. Please contact Dr. Jing
6 Zhang at 17898846216.
7
8

9 The ethics committee has reviewed the study, and if you have any questions related
10 to your rights / entitlements, or if you want to reflect the difficulties, dissatisfaction,
11 and anxieties encountered in participating in this study, or if you want to provide
12 comments and suggestions related to this study, please contact the Ethics Committee of
13 Zhongshan Hospital, Fudan University, Tel: 021-64041990 ext. 3257, Email: [ec@zs-](mailto:ec@zs-hospital.sh.cn)
14 [hospital.sh.cn](mailto:ec@zs-hospital.sh.cn).
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

Participant Signature Page

Informed Consent Statement:

33
34
35
36
37 I have been informed of the purpose, background, process, risks and benefits of this
38 research. I have enough time and opportunity to ask questions, and I am satisfied with
39 the answers.
40
41
42

43 I have also been told who to contact when I have questions, want to reflect difficulties,
44 concerns, suggestions for research, or want further information or help with the study.
45
46

47 I have read this informed consent and agree to participate in this study.
48

49 I understand that I can choose not to participate in the study and to withdraw from
50 the study at any time during the study process without any reason.
51
52

53 I already know that if my condition gets worse, or if I have serious adverse events,
54 or if my research doctor feels that continuing to participate in the study is not in my
55 best interest, he / she will decide to quit me from the study. Without my consent, the
56 funder or regulator may terminate the study during the study period. If it happens, the
57
58
59
60

1
2
3
4 doctor will notify me in time, and the research doctor will discuss my other options
5
6 with me.

7 I will get a copy of this informed consent, which contains the signatures of me and
8
9 the investigator.
10

11
12
13
14
15 Subject Signature:

Date:

16
17 (Note: If the subject is incapacitated / restricted, the legal representative's signature and signature
18
19 date are required.)
20
21
22
23
24

25 Legal representative Signature:

Date:

26
27 (Note: If the subject cannot read the informed consent, an independent witness is required to
28
29 prove that the researcher has informed the subject of the informed consent. The independent
30
31 witness's signature and signature date are required.)
32
33
34
35
36

37 Independent Witness Signature:

Date:

38
39
40
41
42 Investigator Signature:

Date:



STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Reported on page No
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	2
	2b	All items from the World Health Organization Trial Registration Data Set	N/A
Protocol version	3	Date and version identifier	1
Funding	4	Sources and types of financial, material, and other support	N/A
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1
	5b	Name and contact information for the trial sponsor	N/A
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	N/A
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	N/A
Introduction			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	3-5
	6b	Explanation for choice of comparators	3-5

1			
2	Objectives	7	Specific objectives or hypotheses
3			4-5
4	Trial	8	Description of trial design including type of trial (eg, parallel
5	design		group, crossover, factorial, single group), allocation ratio, and
6			framework (eg, superiority, equivalence, noninferiority,
7			exploratory)
8			
9			
10	Methods: Participants, interventions, and outcomes		
11			
12	Study	9	Description of study settings (eg, community clinic, academic
13	setting		hospital) and list of countries where data will be collected.
14			Reference to where list of study sites can be obtained
15			
16	Eligibility	10	Inclusion and exclusion criteria for participants. If applicable,
17	criteria		eligibility criteria for study centres and individuals who will
18			perform the interventions (eg, surgeons, psychotherapists)
19			
20	Interventio	11	Interventions for each group with sufficient detail to allow
21	ns	a	replication, including how and when they will be administered
22			
23			
24		11	Criteria for discontinuing or modifying allocated interventions for
25		b	a given trial participant (eg, drug dose change in response to
26			harms, participant request, or improving/worsening disease)
27			
28		11	Strategies to improve adherence to intervention protocols, and
29		c	any procedures for monitoring adherence (eg, drug tablet
30			return, laboratory tests)
31			
32			
33		11	Relevant concomitant care and interventions that are permitted
34		d	or prohibited during the trial
35			
36	Outcomes	12	Primary, secondary, and other outcomes, including the specific
37			measurement variable (eg, systolic blood pressure), analysis
38			metric (eg, change from baseline, final value, time to event),
39			method of aggregation (eg, median, proportion), and time point
40			for each outcome. Explanation of the clinical relevance of
41			chosen efficacy and harm outcomes is strongly recommended
42			
43			
44	Participant	13	Time schedule of enrolment, interventions (including any run-
45	timeline		ins and washouts), assessments, and visits for participants. A
46			schematic diagram is highly recommended (see Figure)
47			
48			
49	Sample	14	Estimated number of participants needed to achieve study
50	size		objectives and how it was determined, including clinical and
51			statistical assumptions supporting any sample size calculations
52			
53	Recruitmen	15	Strategies for achieving adequate participant enrolment to
54	t		reach target sample size
55			
56			
57			
58			
59			
60			

Methods: Assignment of interventions (for controlled trials)

Allocation:

1				
2	Sequen	16	Method of generating the allocation sequence (eg, computer-	12
3	ce	a	generated random numbers), and list of any factors for	
4	generati		stratification. To reduce predictability of a random sequence,	
5	on		details of any planned restriction (eg, blocking) should be	
6			provided in a separate document that is unavailable to those	
7			who enrol participants or assign interventions	
8				
9				
10	Allocatio	16	Mechanism of implementing the allocation sequence (eg,	12
11	n	b	central telephone; sequentially numbered, opaque, sealed	
12	conceal		envelopes), describing any steps to conceal the sequence until	
13	ment		interventions are assigned	
14	mechani			
15	sm			
16				
17				
18	Impleme	16	Who will generate the allocation sequence, who will enrol	13
19	ntation	c	participants, and who will assign participants to interventions	
20				
21	Blinding	17	Who will be blinded after assignment to interventions (eg, trial	13
22	(masking)	a	participants, care providers, outcome assessors, data	
23			analysts), and how	
24				
25				
26		17	If blinded, circumstances under which unblinding is permissible,	13
27		b	and procedure for revealing a participant's allocated	
28			intervention during the trial	
29				
30				
31	Methods: Data collection, management, and analysis			
32	Data	18	Plans for assessment and collection of outcome, baseline, and	9-10
33	collection	a	other trial data, including any related processes to promote	
34	methods		data quality (eg, duplicate measurements, training of	
35			assessors) and a description of study instruments (eg,	
36			questionnaires, laboratory tests) along with their reliability and	
37			validity, if known. Reference to where data collection forms can	
38			be found, if not in the protocol	
39				
40				
41				
42		18	Plans to promote participant retention and complete follow-up,	9-10
43		b	including list of any outcome data to be collected for	
44			participants who discontinue or deviate from intervention	
45			protocols	
46				
47	Data	19	Plans for data entry, coding, security, and storage, including	N/A
48	manageme		any related processes to promote data quality (eg, double data	
49	nt		entry; range checks for data values). Reference to where	
50			details of data management procedures can be found, if not in	
51			the protocol	
52				
53				
54	Statistical	20	Statistical methods for analysing primary and secondary	13
55	methods	a	outcomes. Reference to where other details of the statistical	
56			analysis plan can be found, if not in the protocol	
57				
58				
59				
60				

1			
2	20	Methods for any additional analyses (eg, subgroup and	13
3	b	adjusted analyses)	
4			
5	20	Definition of analysis population relating to protocol non-	13
6	c	adherence (eg, as randomised analysis), and any statistical	
7		methods to handle missing data (eg, multiple imputation)	
8			

Methods: Monitoring

11	Data	21	Composition of data monitoring committee (DMC); summary of	N/A
12	monitoring	a	its role and reporting structure; statement of whether it is	
13			independent from the sponsor and competing interests; and	
14			reference to where further details about its charter can be	
15			found, if not in the protocol. Alternatively, an explanation of why	
16			a DMC is not needed	
17				
18				
19		21	Description of any interim analyses and stopping guidelines,	N/A
20		b	including who will have access to these interim results and	
21			make the final decision to terminate the trial	
22				
23				
24	Harms	22	Plans for collecting, assessing, reporting, and managing	N/A
25			solicited and spontaneously reported adverse events and other	
26			unintended effects of trial interventions or trial conduct	
27				
28				
29	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and	N/A
30			whether the process will be independent from investigators and	
31			the sponsor	
32				

Ethics and dissemination

35	Research	24	Plans for seeking research ethics committee/institutional review	14
36	ethics		board (REC/IRB) approval	
37	approval			
38				
39				
40	Protocol	25	Plans for communicating important protocol modifications (eg,	14
41	amendmen		changes to eligibility criteria, outcomes, analyses) to relevant	
42	ts		parties (eg, investigators, REC/IRBs, trial participants, trial	
43			registries, journals, regulators)	
44				
45	Consent or	26	Who will obtain informed consent or assent from potential trial	14
46	assent	a	participants or authorised surrogates, and how (see Item 32)	
47				
48		26	Additional consent provisions for collection and use of	N/A
49		b	participant data and biological specimens in ancillary studies, if	
50			applicable	
51				
52				
53	Confidentia	27	How personal information about potential and enrolled	14
54	lity		participants will be collected, shared, and maintained in order to	
55			protect confidentiality before, during, and after the trial	
56				
57				
58	Declaration	28	Financial and other competing interests for principal	N/A
59	of interests		investigators for the overall trial and each study site	
60				

1				
2	Access to	29	Statement of who will have access to the final trial dataset, and	14
3	data		disclosure of contractual agreements that limit such access for	
4			investigators	
5				
6	Ancillary	30	Provisions, if any, for ancillary and post-trial care, and for	N/A
7	and post-		compensation to those who suffer harm from trial participation	
8	trial care			
9				
10	Disseminati	31	Plans for investigators and sponsor to communicate trial results	14
11	on policy	a	to participants, healthcare professionals, the public, and other	
12			relevant groups (eg, via publication, reporting in results	
13			databases, or other data sharing arrangements), including any	
14			publication restrictions	
15				
16				
17		31	Authorship eligibility guidelines and any intended use of	N/A
18		b	professional writers	
19				
20		31	Plans, if any, for granting public access to the full protocol,	N/A
21		c	participant-level dataset, and statistical code	
22				
23				
24	Appendice			
25	s			
26				
27	Informed	32	Model consent form and other related documentation given to	N/A
28	consent		participants and authorised surrogates	
29	materials			
30				
31				
32	Biological	33	Plans for collection, laboratory evaluation, and storage of	N/A
33	specimens		biological specimens for genetic or molecular analysis in the	
34			current trial and for future use in ancillary studies, if applicable	
35				

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.

BMJ Open

The effect of PIFR-based Optimized Inhalation Therapy in Patients Recovering From Acute exacerbation of Chronic Obstructive Pulmonary Disease: protocol of a prospective, multi-center, superiority, randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-034804.R4
Article Type:	Protocol
Date Submitted by the Author:	02-Apr-2020
Complete List of Authors:	Hua, Jianlan; Zhongshan Hospital Fudan University, Department of Pulmonary and Critical Care Medicine Zhang, wei; Fudan University, Department of Biostatistics Cao, Hui-fang; Shanghai Jing'an District Central Hospital Du, Chun-ling; Shanghai Qingpu District Central Hospital Ma, Jia-yun; North Branch of Shanghai Ninth People's Hospital Zuo, Yi-hui; Zhongshan Hospital Fudan University, Department of Pulmonary and Critical Care Medicine Zhang, Jing; Zhongshan Hospital Fudan University, Department of Pulmonary and Critical Care Medicine
Primary Subject Heading:	Respiratory medicine
Secondary Subject Heading:	Medical education and training, Pharmacology and therapeutics, Research methods
Keywords:	RESPIRATORY MEDICINE (see Thoracic Medicine), Chronic airways disease < THORACIC MEDICINE, MEDICAL EDUCATION & TRAINING

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **The effect of PIFR-based Optimized Inhalation Therapy in**
5
6 **Patients Recovering From Acute exacerbation of Chronic**
7
8 **Obstructive Pulmonary Disease: protocol of a prospective,**
9
10 **multi-center, superiority, randomized controlled trial**
11
12

13
14 Jian-lan Hua¹, Wei Zhang², Hui-fang Cao³, Chun-ling Du ⁴, Jia-yun Ma ⁵ , Yi-hui Zuo¹, Jing
15
16 Zhang^{1*}
17

18
19 ¹Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Shanghai Medical
20
21 College, Fudan University, Shanghai, China
22

23
24 ²Department of Biostatistics, School of Public Health, Fudan University, Shanghai, China
25

26
27 ³ Department of Pulmonary, Shanghai Jing 'an District Central Hospital, Shanghai, China
28

29
30 ⁴ Department of Pulmonary, Shanghai Qingpu District Central Hospital, Shanghai, China
31

32
33 ⁵ Department of Pulmonary, North Branch of Shanghai Ninth People's Hospital, Shanghai
34
35 JiaoTong University school of medicine, Shanghai, China
36

37
38 * Correspondence: Jing Zhang
39

40
41 Department of Pulmonary and Critical Care Medicine, Zhongshan hospital, Shanghai Medical
42
43 College, Fudan University, 180 Feng lin road, shanghai 200032, People's Republic of China
44

45
46 Email: jingatlas@hotmail.com
47

48
49
50 Date: 2019/3/31

51
52 version identifier: 2.1
53
54
55
56
57
58
59
60

Abstract:

Introduction: Acute exacerbation (AE) is a major cause of disease progression and death for patients with Chronic Obstructive Pulmonary Disease (COPD), accounting for a majority of medical expenditures. Correct inhalation therapy is effective in preventing AE attacks. However, inappropriate usages of dry powder inhaler (DPI), partially due to the unrecovered peak inhalation flow rate (PIFR) after AECOPD, result in increased risks of early treatment failure. Therefore, we design a multicenter randomized clinical trial, to determine whether PIFR-based optimized inhalation therapy and training of inhaler usage at discharge could effectively reduce the early treatment failure events.

Methods and analysis: A total of 416 hospitalized patients just recovering from AECOPD will be recruited and be equally randomized into the PIFR group and the control group at a 1:1 ratio. The PIFR group will receive additive support before discharge, including PIFR-guided inhaler choice and education of inhaler usage. PIFR is measure by InCheck DIAL®. In comparison, the control group will only receive inhalers depending on judgments of respiratory physicians. The primary outcome of the study is 30-day treatment failure rate. Other endpoints include PIFR, the error rate of inhalation device use, satisfaction with inhalation devices, 30-day mortality, 90-day mortality, symptoms and life quality of patients and COPD-related treatment costs.

Ethics and dissemination: This trial has been approved by the Ethics Committee of Zhongshan Hospital of Fudan University (B2019-142). Participants will be screened and enrolled from hospitalized patients with AECOPD by clinicians, with no public advertisement for recruitment. After this trial completed, the results will be reported to the public through conference presentations and peer-reviewed journals.

Trial registration: This trial has been registered in ClinicalTrials.gov (NCT04000958).

Strengths and limitations of this study:

1. To our knowledge, this is the first multicenter, randomized trial designed to study the efficacy of PIFR-based inhaler prescription in preventing short-term re-execration in patients recovering from severe acute exacerbation of COPD.

1
2
3
4 2. InCheck DIAL® is used to measure PIFR and objectively evaluate the capacity of using dry
5 powder inhalers.

6
7 3. The inhaler technique will be trained as well to achieve optimal inhalation therapy.

8
9 4. Inhalers studied in this trial include Turbuhaler®, Handihaler®, Respimat® and pMDI.

10
11 5. The limitation of the study is the single-blind study design, which would yield bias, although
12 blind evaluation is adopted to minimize the bias.
13
14

15
16
17 **Keywords:** chronic obstructive pulmonary disease, acute exacerbation of chronic obstructive
18 pulmonary disease, peak inhalation flow rate, InCheck DIAL®, dry powder inhalers
19
20
21

22 23 **Introduction**

24
25 Chronic Obstructive Pulmonary Disease (COPD) is a chronic inflammatory disease
26 with the characteristic of irreversible airflow limitation, ranking the 3rd leading cause
27 of death and causing heavy socioeconomic burden worldwide.¹ In China, COPD is
28 also a serious challenge, with the prevalence of 8.6% among adults and high
29 mortality.² Direct medical cost of COPD ranged from 72 to 3,565 USD per capita per
30 year, accounting for 33-118% of average annual income of Chinese people.³ As an
31 important event throughout the course of COPD, acute exacerbation (AE) could
32 accelerate the decline of spirometry and directly cause death, which brings about huge
33 health expenditure⁴.
34
35
36
37
38
39
40
41
42

43 Inhalation drugs is the core pharmaceutical therapy in the management of stable
44 COPD, such as inhaled corticosteroid (ICS), long-acting beta 2 agonists (LABA) and
45 long-acting muscarinic antagonists (LAMA).⁵ However, inappropriate usage of
46 inhalers is common in patients with chronic airway diseases, like insufficient
47 inspiratory force and no breath holding (or holding breath for less than 3s)^{6,7}. Previous
48 studies showed that errors of inhaler usage were significantly associated with poor
49 outcomes (like frequent exacerbations) and increased medical expenditure.⁸
50
51 Commonly-used inhalers are classified into four types with different characteristics,
52 including pressure metered dose inhaler (pMDI), dry powder inhalers (DPIs), soft
53
54
55
56
57
58
59
60

1
2
3
4 mist inhalers (SMIs), and nebulizers⁹. The usage of pMDIs is relatively complex,
5
6 requiring patients to slowly breath in and coordinate many operations to achieve a
7
8 clinically-effective dose. In comparison, the usage of DPIs is simple, but requires the
9
10 increase of inspiratory force to overcome internal resistance of the device¹⁰. Several
11
12 *in vitro* studies have demonstrated the efficacy of DPI is dependent on the inspiratory
13
14 flow rate.

15
16 When the patient's PIFR is less than a certain threshold required by the DPI device
17
18 (60 L/min measured at no resistance)¹¹, the DPI device releases a reduced dose of the
19
20 drug and generates aerodynamically large drug particles, which is inappropriate to
21
22 meet the therapeutic needs. Moreover, several studies demonstrated insufficient PIFR
23
24 in the stable COPD period was associated with poor prognosis, when patients
25
26 improperly used DPI^{12 13}. It should be noted that expiratory flow parameters are not
27
28 linearly correlated with inspiratory flow rate, suggesting post-bronchodilator forced
29
30 expiratory volume in one second (FEV₁) is not a suitable predictor of PIFR. Other risk
31
32 factors for early AECOPD recurrence include age grades, GOLD grades, AE
33
34 frequency in the previous year, pleural effusion, use of accessory respiratory muscles,
35
36 noninvasive mechanical ventilation, controlled oxygen therapy and length of hospital
37
38 stay, while inhaled long-acting β -2-agonists (LABA) and inhaled corticosteroids
39
40 (ICS) are protection factors¹⁴.

41
42 Short-term re-exacerbation is a prominent problem for patients hospitalized for
43
44 AECOPD with the 30-day re-admission rate of 16-20%.^{15 16} Whereas, many patients
45
46 with COPD do not have enough PIFR to reach the threshold that DPI devices required
47
48 both in the stable period (nearly 20%)¹⁷ and AE period (based on some small sample
49
50 studies)^{13 18}, which influences the effects of inhaled drug on preventing re-AE.
51
52 Moreover, the assessment of patients' PIFR and ability to use inhaler devices are not
53
54 integrated into the clinical pathway of discharge for patients hospitalized for
55
56 AECOPD. Clinicians are still inclined to choose the type of inhalers for patients that
57
58 they used before admission.

59
60 We speculate that the PIFR of patients in the AE recovery period does not return
to their baseline levels before AE, and untrained patients are more likely to use the

1
2
3
4 inhalers incorrectly. Neglect of evaluation of inhalers might result in treatment failure
5 and early re-exacerbation due to ineffective use of inhaled drugs. However, lack of
6 studies demonstrated whether the choice of inhalers based on the PIFR count could
7 reduce the risk of short-term re-exacerbation for patients with AECOPD.
8 Furthermore, although some researches showed that inappropriate use of inhalers was
9 associated with poor prognosis^{7,8}, it remains unclear whether training patients to
10 correctly use inhalers could reverse poor outcomes.

11
12 Therefore, we plan to perform this clinical trial to prospectively determine whether
13 the optimized inhaled drug administration based on PIFR and training patients with
14 InCheck DIAL® could reduce the rate of treatment failure and improve their
15 prognosis for patients hospitalized for AECOPD. Our hypothesis is that AECOPD
16 treatment failure rate is related to improper inhaler selection and missing inhaler use
17 education for patients.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33 **Methods and analysis**

34 **Overview**

35
36 This is a multi-center, single-blind, superiority, randomized clinical trial, in
37 which patients hospitalized for AECOPD are randomly assigned into two groups at a
38 1:1 ratio: the PIFR group and the control group. Compared with the control group,
39 the PIFR group will receive additive support before discharge, including PIFR-guided
40 inhaler choice and education of inhaler use. The primary outcome is 30-day treatment
41 failure rate. Other endpoints include symptoms and life quality of patients the error
42 rate of inhalation device use, satisfaction with inhalation devices, PIFR, 30-day
43 mortality, 90-day mortality, and COPD-related treatment costs.
44
45
46
47
48
49
50
51
52

53 The process of patient enrollment, intervention and follow-up of this study are
54 performed at Zhongshan Hospital of Fudan University, Shanghai Jing 'an District
55 Central Hospital, Shanghai Qingpu District Central Hospital and North Branch of
56 Shanghai Ninth People's Hospital in China. The study is expected to last for 2 years.
57
58
59
60

1
2
3
4 Recruitment of participants has started since November 2019.

5 This trial has been approved by the Ethics Committee of Zhongshan Hospital of
6 Fudan University (B2019-142) and registered in ClinicalTrials.gov (NCT04000958).
7
8
9

10 11 12 Inclusion criteria

13 All the patients with the diagnosis of COPD and hospitalization for AE will be
14 screened. Definitions of COPD and AE are according to the criteria of *Expert*
15 *Consensus on Acute Exacerbation of Chronic Obstructive Pulmonary Disease in the*
16 *People's republic of China – 2014 Edition*⁴. Briefly, AECOPD is defined as sudden
17 worsening of respiratory symptoms that require additional treatment (typical
18 manifestations include dyspnea, aggravated cough, increased sputum volume, and/or
19 sputum purulence), which is not explained by normal day-to-day variations and
20 requires additional treatments^{4 19}.
21
22
23
24
25
26
27
28

29 The subjects will be included if all of the following criteria are met: (1) being 40–
30 80 years old; (2) deteriorated respiratory symptoms being controlled and meeting
31 discharge criteria after 5-7 day standard treatment for AECOPD; (3) having a
32 recorded spirometry measured in the stable period, with post-bronchodilator forced
33 expiratory volume in one second (FEV1)/forced vital capacity (FVC) <70% and
34 FEV1% predicted value <80%; (4) having signed an informed consent form.
35
36
37
38
39
40

41 Standard treatment during the hospitalization include atomized or inhaled
42 bronchodilators, broad-spectrum antibiotics and corticosteroids (oral or intravenous
43 glucocorticoid daily equivalent to the 40-50 mg dose of prednisone, or Pulmicort™ 2
44 mg atomization twice daily).
45
46
47
48

49 Discharge criteria are as follows: (1) physician are confident that the patient can
50 manage successfully at home; (2) either LABA and/or LAMA can be used for
51 maintenance with or without ICS, and the frequency of short-acting inhaled β2
52 receptor agonists is less than every 4 hours; (3) the patient, if previously ambulatory,
53 is able to walk across the room; (4) the patient is able to eat and sleep without
54 frequent awakening due to dyspnea; (5) the patient achieves the clinically-stable
55
56
57
58
59
60

1
2
3 status lasting for 12–24 hours; (6) values of arterial blood gases have been stable for
4
5 12–24 hours⁴.
6
7

8 9 10 Exclusion criteria

11
12 Exclusion criteria include:(1) already using home nebulization therapy because
13
14 of the severe condition; (2) concomitant with asthma, interstitial lung disease,
15
16 bronchiectasis, pulmonary embolism and other lung diseases; (3) having
17
18 comorbidities including hypertension, heart diseases, chronic liver and kidney
19
20 diseases, diabetes, chronic gastrointestinal diseases, malignant tumors and critically ill;
21
22 (4) suffering from cognitive impairment or not cooperating with the study due to poor
23
24 mental state; (5) with PIFR less than 20 L/min.
25
26
27

28 29 30 Sample size

31
32 We plan to recruit 416 hospitalized patients with AECOPD whose deteriorated
33
34 symptoms are relieved after 5-7 days of standard therapy. The sample size was
35
36 calculated using PASS 15.0 Power Analysis and Sample Size Software (2017) (NCSS,
37
38 LLC. Kaysville, Utah, USA) to ensure the statistical power. Several studies have
39
40 found that 30-47% patients hospitalized for AECOPD had a PIFR < 60 liters/minute
41
42 prior to discharge^{5 10}. For the control group, 30-day treatment failure rate after
43
44 hospitalization for AECOPD is approximately 20% according to the literature and our
45
46 retrospective cohort study ^{15,16}. However, our preliminary research suggests 30-day
47
48 treatment failure rate is 10% in the PIFR group. Thus, the expected effect size of
49
50 superiority is around 10% between two groups. The ratio of number of people in the
51
52 two groups is 1: 1. A significant two-side *P* value is set as 0.05, and the power is set
53
54 as 80%. Considering potential dropout risks (5%), 208 patients per group will be
55
56 recruited, totaling 416 participants.
57
58

59 60 Study outline

1
2
3
4 The flow chart of the study design is shown in Figure 1.

5
6 The study will recruit 416 patients with AECOPD. After enrollment, the
7 participants are divided into PIFR group and control group at a 1:1 ratio. All the
8 participants in two groups will receive standard treatments for AECOPD described as
9 above during the hospitalized period, and be given the predesigned medications at
10 discharge. At discharge, all the patients will be prescribed with commercial
11 ICS/LABA combination, including either Symbicort turbuhaler®
12 (budesonide/formoterol, 160/4.5 µg *bid*, AstraZeneca AB) or Foster® pressure pMDI
13 (beclomethasone/formoterol, 100/6 µg 2 puff *bid*, Chiesi Farmaceutici S.p.A.). For
14 patients with more respiratory symptoms in the stable period ($mMRC \geq 2$ and $CAT \geq$
15 10), Spiriva handihaler® (18µg *qd*) or Spiriva respimat® (2.5µg *qd*, Boehringer
16 IngelheimPharma GmbH & Co.KG) will be given in combination with ICS/LABA.

17
18 As for inhalers, participants in the control group will be given DPI or pMDI with a
19 spacer according to the judgment of attending physicians, while participants in the
20 PIFR group will receive education of inhaler use and additive support of evaluation of
21 PIFR at the timepoint of discharge. Attending physicians will show the proper
22 operation of inhalers and correct some common mistakes to patients in the PIFR
23 group.

24
25 For PIFR group, PIFR is measured by InCheck DIAL® (Clement Clarke
26 International Ltd, Harlow, UK and Alliance Tech Medical), which is designed to
27 measure inspiratory flow and simulate the “internal resistance” of common inhalers.
28 The numerical values of PIFR provide reference for the attending physicians to guide
29 patients to improve their inspiratory techniques, like increasing or decreasing
30 inspiration forces, which is helpful to achieve a flow rate in consistent with clinical
31 efficacy. The colored ‘flow’ icons show the clinically effective flow ranges for each
32 different inhaler device. The InCheck DIAL® is accurate to $\pm 10\%$ or 10 L/min,
33 and is a low-range inspiratory flow meter (15 to 120 L/min) that has a selectable
34 resistance from high to low, shown by the colored ‘flow’ icons calibrated to enable
35 the measurement of airflow as if the patient was using certain different inhalers. When
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 measuring PIFR in this study, we will set the resistance of the InCheck DIAL® to
5 “Zero” and to “Med High” in line with pMDI and turbuhaler®, respectively. Before
6
7
8 measuring , patients are trained to use the InCheck DIAL® correctly. After the PIFR
9
10 of patients steadily reached the maximum value, the PIFR will be measured for 3
11
12 times to make the average as a final result. If PIFR is less than 60 L/min (measured
13
14 without a resistance), the patients will be given the pMDI with spacer. Otherwise,
15
16 they will be prescribed with the DPI. Patients using either pMDI or DPI will be taught
17
18 how to use the device on the spot, and can access to the education video via a WeChat
19
20 public account at any time.

21
22 Moreover, the InCheck DIAL® is also a training device of inhalation muscles,
23
24 which helps to improve patients' ability to use inhalers. When used for the training of
25
26 inspiratory muscles, the resistance threshold of InCheckDIAL® is set according to the
27
28 types of inhalers used by the patient.

33 Study step

34
35
36 Researchers collect baseline information from participants on the day of enrollment
37
38 and give interventions to COPD patients recovering from AE at the timepoint of
39
40 discharge. After discharge, all the participants will be followed up for 3 months and
41
42 asked for 2 separate visits at 1 and 3 month.

43
44 Table 1 shows the requirements of data collection for each visit. Baseline
45
46 information in the stable period is listed as follows: demographics, clinical
47
48 characteristics, evaluation of respiratory symptoms and quality of life in the stable
49
50 phase, PIFR, chest imaging (X-ray or computed tomography) and echocardiography
51
52 or electrocardiogram in the stable phase. Demographics includes age, gender, age,
53
54 height, weight, ethnicity, occupation(number of years of work), marital status, family
55
56 address, etc. Clinical characteristics includes past disease history, history of drug
57
58 sensitivity, history of vaccination, family disease history, current medical history,
59
60 comorbidities, medications, etc. Respiratory symptoms are assessed by the modified

1
2
3
4 Medical Research Council (mMRC) dyspnea scale and the COPD Assessment Test
5 (CAT) score for the patients and quality of life is evaluated by St.George's
6 Respiratory Questionnaire(SGRQ) scale. In addition, PIFR and routine laboratory
7 tests for AE patients (e.g. blood routine, C-reactive protein, liver and kidney function,
8 blood electrolytes, B-type natriuretic peptide, D-dimer) were also recorded.
9
10
11
12

13 At the 1-month and 3-month, patients are required to have an outpatient department
14 visit to assess the effects of intervention and collect some data, including CAT score,
15 mMRC score, SGRQ score, PIFR, spirometry, the error rate of inhalation device use,
16 satisfaction with inhalation devices, and COPD-related medications. To reinforce the
17 adherence, patients and their relatives will be contacted by telephone to confirm the
18 dates of evaluation in advance. If the patient is inconvenient to come to the hospital,
19 researchers will collect the above information from the patient as much as possible via
20 phone.
21
22
23
24
25
26
27
28
29
30
31
32
33

34 Outcomes

35
36 The primary endpoint is 30-day treatment failure rate of AECOPD. Treatment
37 failure means AECOPD recurrence resulting in an emergency visit, admission, or
38 need for intensified medication.
39
40

41 Secondary outcomes include PIFR, the error rate of inhalation device use,
42 satisfaction with inhalation devices, 30-day mortality, 90-day mortality, symptoms
43 and life quality of patients and COPD-related treatment costs.
44
45
46
47

48 Patient's satisfaction with inhalation devices will be assessed by the Feeling of
49 Satisfaction with Inhaler (FSI-10) questionnaire. The FSI-10 questionnaire is
50 supposed to be completed by patients themselves, which has been widely applied to
51 assess patients' opinions about inhalers in terms of ease of use, portability, and
52 usability²⁰.The symptoms of patients are evaluated by the CAT scale and mMRC
53 scale. The patients' quality of life are evaluated by SGRQ scale.
54
55
56
57
58

59 PIFR is measured by InCheck DIAL® (Clement Clarke International Ltd, Harlow,
60

1
2
3 UK and Alliance Tech Medical) under the guidance of respiratory physicians. Some
4 common errors in the usage of different inhalation devices are described in Table 2⁶⁷.
5
6
7
8
9

10 Randomization and blinding

11
12 The participants will be assigned into two groups at a 1:1 ratio using random
13 number table generated by IBM SPSS statistics 23 (SPSS Inc, Chicago, IL). The
14 randomization process was performed by an independent researcher who will not
15 participate in other research procedures. To maximize the objectivity and reliability of
16 our study, single-blind and allocation concealment are adopted. Sealed envelopes
17 containing an allocation number are distributed to attending physicians in advance to
18 achieve allocation concealment, and they will not know the allocation group until
19 giving intervention. Other researchers responsible for data collection and follow-up
20 are not informed of which group the patient has been assigned to. Patients and their
21 relatives are blinded to allocation during the whole process, and are only informed
22 that they participate in a study of COPD discharge plan. In addition, statistical
23 analysis will be performed by an independent statistician, who will also be blinded to
24 the group labels.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 Statistical analysis

42 1. Statistical analysis datasets

- 43 • Modified intent-to-treat set (MITTS)

44
45 Subjects that have undergone randomization and interventions, and carry out
46 primary endpoint evaluation.
47
48

- 49 • Safety set (SS)

50
51 Subjects that are randomized, undergo the intervention, and with safety
52 evaluation data.
53
54

55 2. Statistical analysis methods

56
57 Statistical analyses will be performed using IBM SPSS statistics 22 (SPSS Inc,
58 Chicago, IL). Continuous variables are described as mean (standard deviation) or
59
60

1
2
3
4 median (interquartile range), while categorical variables are described as frequency
5 and percentage. A two-tailed P value < 0.05 is considered as statistical significance.
6
7 Student's t-tests or Mann-Whitney test, depending on normality and homogeneity of
8
9 variance, was used to compare continuous variables between two groups, including
10
11 PIFR, CAT score, mMRC score, SGRQ score and COPD-related treatment costs. For
12
13 discrete variables, such as 30-day treatment failure rate, the error rate of inhalation
14
15 device use, satisfaction with inhalation devices, 30-day mortality and 90-day
16
17 mortality, Chi-Squared (χ^2) Test, Fisher's exact test or CMH χ^2 test will be applied for
18
19 comparison. To rule out the influence of confounding factors and identify optimal
20
21 subpopulation, subgroup analysis will be performed based on previous exacerbation
22
23 history and GOLD grades.
24
25
26
27
28

29 Patient and public Involvement

30
31 Patients or the public were not involved in the design, or conduct, or reporting, or
32
33 dissemination of our research. The results will be available to the public if necessary.
34
35
36
37
38
39

40 Ethics and dissemination

41
42 This trial has been approved by the Ethics Committee of Zhongshan Hospital of
43
44 Fudan University (B2019-142). In this study, diagnosis and treatment will be
45
46 performed in accordance with the routine management of COPD. Neither Additional
47
48 drug intervention nor invasive examination and charges will be needed. Therefore, the
49
50 study is relatively safe with minimal additional risks. Participants will be screened
51
52 and recruited from hospitalized patients by physicians, with no public advertisement
53
54 for recruitment. All participants will be supposed to sign an informed consent. A
55
56 blank copy of the original consent form is provided and shown as a supplementary
57
58 document. All information of participants will be kept private and will not be
59
60 provided to any company or institution. The results will be disseminated through

1
2
3
4 peer-reviewed journals and conference presentations.
5
6
7
8

9 10 **Discussion**

11
12 DPI drug delivery depends on the inherent resistance of the inhaler and the PIFR
13 of the patient. PIFR value is determined by an individual's subjective effort as well as
14 his/her respiratory muscle force, which may be decreased in patients with COPD due
15 to airway stenosis, lung hyperinflation, hypoxemia, and muscle wasting. As a
16 breath-actuated inhaler, DPI requires patients to create enough turbulent forces to
17 disaggregate the powder into respirable particles which can reach the lower
18 respiratory tract. Patients with a relatively high PIFR (> 60 L/min) enable DPIs to
19 release a sufficient amount of powder and disaggregate the drug to achieve sufficient
20 drug deposition in the lung.
21
22
23
24
25
26
27
28

29
30 Sharma and colleagues reported that 31.7% of hospitalized patients for AECOPD
31 had PIFR less than 60 L/min at the timepoint of discharge¹⁰. Patients with a PIFR less
32 than 60 L/min have been considered not be able to effectively inhale medications
33 using a DPI into their lower respiratory tracts, while a PIFR less than 30 L/min was
34 insufficient^{21 22}. For lack of availability of long-acting bronchodilators with pMDI,
35 most Chinese clinicians routinely prescribe DPIs to the patients recovering from
36 AECOPD without measuring their values of PIFR. Inappropriate inhaler selection
37 may result in treatment failure of AECOPD. To our knowledge, it remains unclear
38 whether treatment failure rate is negatively related to improper inhaler description. A
39 suitable inspiratory flow rate helps to improve the treatment efficacy. In addition to
40 appropriate inhaler selection, participants in PIFR group also receive inhaler training
41 to help them master the correct inhalation method.
42
43
44
45
46
47
48
49
50
51
52

53
54 Our research has proposed to measure PIFR of patients recovering from AECOPD
55 by InCheck DIAL® to guide the choice of inhalers and the training of inhalation
56 techniques. The aim of this study is to determine whether treatment failure rate of
57 patients just recovering from AECOPD could be reduced by the optimized inhalation
58
59
60

1
2
3
4 therapy based on PIFR which is measured against the simulated airway resistance. We
5 anticipate that the positive results of this study will provide evidence for improving
6 discharge protocols of AECOPD by including PIFR evaluation.
7
8
9
10
11
12
13
14

15 References

- 16 1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for
17 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study
18 2010. *Lancet (London, England)* 2012;380(9859):2095-128. doi:
19 10.1016/s0140-6736(12)61728-0 [published Online First: 2012/12/19]
20
21
- 22 2. Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in
23 China (the China Pulmonary Health [CPH] study): a national cross-sectional study. *Lancet*
24 (London, England) 2018;391(10131):1706-17. doi: 10.1016/s0140-6736(18)30841-9
25 [published Online First: 2018/04/14]
26
27
- 28 3. Zhu B, Wang Y, Ming J, et al. Disease burden of COPD in China: a systematic review. *Int J Chron*
29 *Obstruct Pulmon Dis* 2018;13:1353-64. doi: 10.2147/copd.S161555 [published Online First:
30 2018/05/08]
31
- 32 4. Cai BQ, Cai SX, Chen RC, et al. Expert consensus on acute exacerbation of chronic obstructive
33 pulmonary disease in the People's Republic of China. *Int J Chron Obstruct Pulmon Dis*
34 2014;9:381-95. doi: 10.2147/copd.S58454 [published Online First: 2014/05/09]
35
- 36 5. Mahler DA. Peak Inspiratory Flow Rate as a Criterion for Dry Powder Inhaler Use in Chronic
37 Obstructive Pulmonary Disease. *Ann Am Thorac Soc* 2017;14(7):1103-07. doi:
38 10.1513/AnnalsATS.201702-156PS [published Online First: 2017/05/10]
39
40
- 41 6. Cho-Reyes S, Celli BR, Dembek C, et al. Inhalation Technique Errors with Metered-Dose Inhalers
42 Among Patients with Obstructive Lung Diseases: A Systematic Review and Meta-Analysis of
43 U.S. Studies. *Chronic Obstr Pulm Dis* 2019;6(3):267-80. doi: 10.15326/jcopdf.6.3.2018.0168
44 [published Online First: 2019/07/26]
45
- 46 7. Price DB, Roman-Rodriguez M, McQueen RB, et al. Inhaler Errors in the CRITIKAL Study: Type,
47 Frequency, and Association with Asthma Outcomes. *The journal of allergy and clinical*
48 *immunology In practice* 2017;5(4):1071-81.e9. doi: 10.1016/j.jaip.2017.01.004 [published
49 Online First: 2017/03/14]
50
- 51 8. Usmani OS, Lavorini F, Marshall J, et al. Critical inhaler errors in asthma and COPD: a systematic
52 review of impact on health outcomes. *Respir Res* 2018;19(1):10. doi:
53 10.1186/s12931-017-0710-y [published Online First: 2018/01/18]
54
- 55 9. Lopez-Campos JL, Soler-Cataluna JJ, Miravittles M. Global Strategy for the Diagnosis,
56 Management, and Prevention of Chronic Obstructive Lung Disease 2019 Report: Future
57 Challenges. *Archivos de bronconeumologia* 2019 doi: 10.1016/j.arbres.2019.06.001
58 [published Online First: 2019/07/20]
59
60

10. Sharma G, Mahler DA, Mayorga VM, et al. Prevalence of Low Peak Inspiratory Flow Rate at Discharge in Patients Hospitalized for COPD Exacerbation. *Chronic Obstr Pulm Dis* 2017;4(3):217-24. doi: 10.15326/jcopdf.4.3.2017.0183 [published Online First: 2017/08/30]
11. Ross DL, Schultz RK. Effect of inhalation flow rate on the dosing characteristics of dry powder inhaler (DPI) and metered dose inhaler (MDI) products. *Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine* 1996;9(2):215-26. doi: 10.1089/jam.1996.9.215 [published Online First: 1997/02/01]
12. Al-Showair RA, Tarsin WY, Assi KH, et al. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? *Respiratory medicine* 2007;101(11):2395-401. doi: 10.1016/j.rmed.2007.06.008 [published Online First: 2007/07/17]
13. Mahler DA, Waterman LA, Ward J, et al. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate. *Journal of aerosol medicine and pulmonary drug delivery* 2014;27(2):103-9. doi: 10.1089/jamp.2013.1038 [published Online First: 2013/06/12]
14. Liu D, Peng SH, Zhang J, et al. Prediction of short term re-exacerbation in patients with acute exacerbation of chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis* 2015;10:1265-73. doi: 10.2147/COPD.S83378 [published Online First: 2015/07/15]
15. Hu WP, Lhamo T, Liu D, et al. Development of a Nomogram to Predict the Risk of 30-Day Re-Exacerbation for Patients Hospitalized for Acute Exacerbation of Chronic Obstructive Pulmonary Disease. *Copd* 2019;16(2):160-67. doi: 10.1080/15412555.2019.1606187 [published Online First: 2019/05/17]
16. Loh CH, Peters SP, Lovings TM, et al. Suboptimal Inspiratory Flow Rates Are Associated with Chronic Obstructive Pulmonary Disease and All-Cause Readmissions. *Ann Am Thorac Soc* 2017;14(8):1305-11. doi: 10.1513/AnnalsATS.201611-903OC [published Online First: 2017/04/14]
17. Mahler DA, Waterman LA, Gifford AH. Prevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus(R) dry powder inhaler. *Journal of aerosol medicine and pulmonary drug delivery* 2013;26(3):174-9. doi: 10.1089/jamp.2012.0987 [published Online First: 2012/10/03]
18. Broeders ME, Molema J, Hop WC, et al. The course of inhalation profiles during an exacerbation of obstructive lung disease. *Respiratory medicine* 2004;98(12):1173-9. [published Online First: 2004/12/14]
19. Kim V, Aaron SD. What is a COPD exacerbation? Current definitions, pitfalls, challenges and opportunities for improvement. *Eur Respir J* 2018;52(5) doi: 10.1183/13993003.01261-2018 [published Online First: 2018/09/22]
20. Perpina Tordera M, Viejo JL, Sanchis J, et al. [Assessment of patient satisfaction and preferences with inhalers in asthma with the FSI-10 Questionnaire]. *Archivos de bronconeumologia* 2008;44(7):346-52. [published Online First: 2008/08/30]
21. Broeders ME, Molema J, Vermue NA, et al. In Check Dial: accuracy for Diskus and Turbuhaler. *International journal of pharmaceuticals* 2003;252(1-2):275-80. [published Online First: 2003/01/29]
22. Atkins PJ. Dry powder inhalers: an overview. *Respiratory care* 2005;50(10):1304-12; discussion 12. [published Online First: 2005/09/28]

1
2
3
4
5
6
7 **Figure legends** : Figure 1. The flow chart of the study. The process of patient's screening,
8 recruitment, intervention, visits and data processing are described in the figure. V0, V1, V2, and
9 V3 are time points to collect data. AECOPD: acute exacerbation of chronic obstructive disease;
10 PIFR: peak inspiratory flow rate.
11
12

13
14 **Contributors:** JLH and JZ planned the study. WZ planned the Statistical analysis methods. All
15 authors contributed to design and development of the trail (JLH, JZ, WZ, HFC, CLD, JYM and
16 YHZ). JLH drafted the manuscript. JZ , HFC, CLD, JYM and YHZ contributed to revised the
17 manuscript. All authors read and approved the final manuscript.
18
19

20
21 **Ethics and dissemination:** This trial has been approved by the Ethics Committee of Zhongshan
22 Hospital of Fudan University (B2019-142) and registered in ClinicalTrials.gov (NCT04000958).
23
24

25
26 **Funding statement:** This research received no specific grant from any funding agency in the
27 public, commercial or not-for-profit sectors.
28
29

30 **Competing interests statement:** None declared.
31

32 **Word Count: 3217**
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Data collected at each visit

	<i>V0</i>	<i>V1</i>	<i>V2</i>	<i>V3</i>
	Hospitalization±1 day	At the time of discharge (meet discharge standards)	1 month after discharge	3 month after discharge
Basic Information	√			
Information of COPD at stable phase	√			
Blood routine	√	√		
Liver and kidney function	√	√		
Electrolyte	√	√		
C-reactive protein	√	√		
procalcitonin	√	√		
brain natriuretic peptide	√	√		
D-dimer ,	√	√		
Fibrinogen				
cardiac troponin T	√	√		
CAT score	√	√	√	√
mMRC	√	√	√	√
SGRQ		√	√	√
Drug for COPD	Stable phase	AE phase	Stable phase	Stable phase
PIFR		PIFR√	PIFR√	PIFR√

Prognosis		√	√
Pulmonary function	√	√	√
Echocardiography at stable phase			
CT at stable phase			
CT at AE phase			
Error of inhaler use		√	√
Satisfaction with the inhaler		√	√
Daily cost of COPD related treatment		√	√

Abbreviations: CAT, the COPD Assessment Test; mMRC, the modified Medical Research Council dyspnea scale; SGRQ, St. George's Respiratory Questionnaire; PIFR, peak inhalation flow rate.

Table 2. Common errors in the usage of different inhalation devices

Turbuhaler®	Handihaler®/Accuhaler®	pMDI	Respimat®
Cover is not removed or not covered properly.	Cover is not removed or not covered properly.	Cover is not removed or not covered properly.	Cover is not removed or not covered properly.
Dose is reduced due to patients shaking or tilt the device during preparation.	-		The device is not installed correctly before use.
Device is not held upright.	-	Device is not held upright.	-
Patient does not twist grip at the base or twist around and then back until click is heard.	-	-	Patient dose not turn the device toward the arrow in the label until it clicks.
Inhalation force is insufficient.	Inhalation force is insufficient.	Patient dose not inhale deeply and slowly.	Patient dose not inhale deeply and slowly.
Patient does not tilt his/her head to make his/her chin	Patient does not hold his/her head in a vertical position.	Patient does not tilt his/her head to make his/her chin	Patient dose not point the inhaler toward the back

slightly upturned.		slightly upturned.	of throat.
Patient does not exhale to empty the lung before the next inhalation.	Patient does not exhale to empty the lung before the next inhalation.	Patient does not exhale to empty the lung before the next inhalation.	Patient does not exhale to empty the lung before the next inhalation.
-	Patient does not turn his/her head away from device's mouthpiece before exhalation.	Patient exhales into the device before the next inhalation.	Patient covers the air entries while inhaling.
Patient does not seal the mouthpiece with his/her lips.	The patient did not place the mouthpiece in his/her mouth nor closed his/her lips.	Patient does not seal the mouthpiece with his/her lips.	Patient does not seal the mouthpiece with his/her lips.
NA	NA	Patients does not inhale them in sync with the drug releasing.	Patients does not inhale them in sync with the drug releasing.
Patient does not hold breath (or hold breath less than 3s).	Patient does not hold breath (or hold breath less than 3s).	Patient does not hold breath (or hold breath less than 3s).	Patient does not hold breath (or hold breath less than 10s).
Patient does not cover the lid and wait for 30-60 seconds for the second dose.	Patient dose not dispose of the capsule and cover the lid on the device.	Patient does not exhale and wait for 30-60 seconds before the second puff.	Patient dose not inhale twice to achieve the total daily dosage.




Figure 1. The flow chart of the study. The process of patient's screening, recruitment, intervention, visits and data processing are described in the figure. V0, V1, V2, and V3 are time points to collect data. AECOPD: acute exacerbation of chronic obstructive disease; PIFR: peak inspiratory flow rate.

Informed consent

Participant Information Page

Project Title: Optimized Inhalation Therapy Based on Peak Inspiratory Flow Rates Measured Against the Simulated Resistance in Patients Recovering From Acute Exacerbation of Chronic Obstructive Pulmonary Disease: a Randomized Trial

Principal investigator: Jing Zhang

Sponsor: Zhongshan Hospital, Fudan University

Dear participant:

You are invited to participate in a clinical study of Optimized Inhalation Therapy Based on Peak Inspiratory Flow Rates Measured Against the Simulated Resistance in Patients Recovering From Acute Exacerbation of Chronic Obstructive Pulmonary Disease, supported by Zhongshan Hospital, Fudan University. Please read this informed consent carefully and make a careful decision on whether to participate in this study. Participation in this research is entirely your autonomous choice. As a subject, you need to give your written consent before joining the clinical study. When your research doctor or researcher discusses your informed consent with you, you can ask him / her to explain to you what you don't understand. We encourage you to discuss this thoroughly with your family and friends before making a decision to participate in this research. You have the right to refuse to participate in the study and to withdraw from the study at any time without penalty and without losing your rights. If you are participating in another study, please inform your research doctor or researcher. The background, purpose, research process and other important information of this research are as follows:

1. Background

Chronic obstructive pulmonary disease (COPD) is a common, multiple, highly disabling and highly lethal respiratory disease. Epidemiological surveys in different

1
2
3
4 periods in China have suggested that COPD has caused a heavy burden of disease. The
5 prevalence of people over 40 years of age is as high as 8.2-13.7%, and it is on the rise.
6
7 The number of disabled and deadly people caused by COPD exceeds 5 million and 1.28
8 million each year respectively. Expenditure for patients with advanced COPD accounts
9 for 40% of household income. Therefore, the prevention and treatment of COPD is an
10 important part of Chinese current health undertakings.
11
12
13
14

15 Inhalation therapy directly affects the lungs, which has the advantages of rapid onset,
16 excellent curative effect, and good safety. It has an irreplaceable clinical status and is
17 the first-line basic treatment method for COPD. There are three main types of inhalation
18 devices: aerosols, dry powder inhalers (DPI) and miniature nebulizers. Aerosols are
19 divided into pressure metered dose inhaler (pMDI), pMDI and spacers, new pMDI, soft
20 mist inhaler (SMI) and so on. Different inhalation devices have different requirements
21 on the hand and mouth coordination and inhalation ability of patients, and their use
22 methods also have their own characteristics. Research results at home and abroad show
23 that some patients with severe COPD are unable to effectively inhale DPI due to
24 suboptimal lung function. In addition, 28% -68% of patients are unable to benefit from
25 prescription drugs due to improper use of inhalers. Quite a few patients have poor
26 adherence to inhalation therapy, and they have stopped their medication or used
27 irregularly when their symptoms have improved slightly. Therefore, the key to
28 improving the standardization and efficacy of inhalation therapy is: (1) how to choose
29 the most suitable inhaler for patients; (2) how to improve the patients' capacity to use
30 inhalers; (3) how to improve patients' compliance.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 In response to these problems, we have designed an optimized inhalation treatment
47 plan, which mainly includes 3 innovative measures and process improvements: (1)
48 selecting the most suitable inhalers for patients based on peak inspiratory flow rates
49 (PIFR), (2) the prescription was made after training and evaluation of the inhalation
50 device, (3) The WeChat public account will regularly push the inhaler using videos and
51 remind patients to take medication regularly to improve the accuracy and
52 standardization of patients' medication.
53
54
55
56
57
58
59
60

2. Study purpose

The aim of this study is to determine whether the optimized inhalation therapy based PIFR can reduce the rate of treatment failure in patients recovering from AECOPD and improve patients' prognosis. Errors in inhaler use and quality of life are also to be evaluated.

3. Study outline

(1) How many patients will participate in this study?

This study is a multi-center and approximately 250 people will participate in the study at our hospital.

(2) Study steps

If you agree to participate in this study, please sign this informed consent form. Before you are enrolled in the study, the doctor will ask, record your medical history, and collect information about your previous relevant examinations. We hope that you can truthfully and fully report your medical history and condition to your doctor in order to accurately evaluate your condition and determine whether you are suitable to participate in this study.

After determining that you will participate in this study, the doctor will assign you into the control or optimized group using a random envelope method. The control group will be treated and followed up according to the prescription drugs and devices of Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2019 Report. The optimized group will be given the appropriate inhaler based on their PIFR, and will be evaluated and trained their ability to use the inhalers before prescription. After the prescription, the WeChat public account will also be used to remind the medication regularly and provide patient education.

You will be needed to complete a total of 3 visits, including 2 on-site visits (i.e. baseline visits and 1-month visit), and 1 telephone visits (3-month visit).

The baseline visit was completed on the day of enrollment, including: (1) Basic information: ① Demographic data, including age, gender, age, height, weight, ethnicity,

1
2
3
4 occupation (years of work), marital status, region, etc. ② General clinical data,
5 including past disease history, drug susceptibility history, vaccination history, family
6 history, current disease history, comorbidities and medication. (2) Evaluation of
7 respiratory symptoms and quality of life: ① the COPD Assessment Test (CAT) Scale,
8 the modified Medical Research Council (mMRC) dyspnea scale; ② St. George's
9 Respiratory Questionnaire (SGRQ) scale. (3) 6-minute walking distance; (4) Survey of
10 satisfaction with inhalers; (5) Measurement of pulmonary ventilation function; (6)
11 Types and dosages of COPD-related drugs.

12
13
14
15
16
17
18
19 1-month on-site visit includes: (1) Evaluation of respiratory symptoms and quality
20 of life: ① the COPD Assessment Test (CAT) Scale, the modified Medical Research
21 Council (mMRC) dyspnea scale; ② St. George's Respiratory Questionnaire (SGRQ)
22 scale. (2) Survey of satisfaction with inhalation devices; (3) the error rates of inhaler
23 use; (4) Measurement of pulmonary ventilation function; (5) Acute exacerbation
24 conditions of patients; (6) Types and dosages of COPD-related drugs.

25
26
27
28
29
30
31 3-month telephone visit includes: (1) Evaluation of respiratory symptoms: the
32 COPD Assessment Test (CAT) Scale the modified Medical Research Council (mMRC)
33 dyspnea scale; (2) the error rates of inhaler use; (3) Acute exacerbation conditions of
34 patients; (4) Types and dosages of COPD-related drugs.

35
36
37
38
39 The inspections required during the visit are all based on the clinical needs of regular
40 diagnosis and treatment. There is no need to take additional specimens, which will not
41 increase your burden and risk outside of routine medical treatment.

42
43
44 (3) How long will this study last?

45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 It took 3 months from enrollment to the end of observation. You can opt out of the
study at any time without losing any benefits you would have received. However, if
you decide to withdraw from the study during the study, we encourage you to discuss
it with your doctor first. If you have a serious adverse event, or if your research doctor
feels that continuing to participate in the study is not in your best interest, he / she will
decide to withdraw you from the study. The sponsor or regulator may also terminate the
study during the study period. Your withdrawal will not affect your normal medical
treatment and rights.

1
2
3
4 If you withdraw from the study for any reason, you may be asked about your
5 participation condition in the study. If your doctor thinks it is necessary, you may also
6 be asked to perform laboratory tests and physical examinations.
7
8

9
10 (4) Information and biological specimens collected during study

11 This study will collect your basic clinical information, relevant questionnaire
12 information, and information about your condition changes. No extra invasive
13 biological specimen collection will be performed.
14
15

16
17 The clinical information and samples will be coded by subject numbers and stored in
18 the Department of Respiratory Medicine, Zhongshan Hospital, Fudan University. They
19 will be destroyed after the publish of study and data analysis.
20
21
22

23
24
25 **4.Risks and benefits**

26
27 (1) What are the risks of participating in this study?

28
29 The risks that you may take from participating in this study are as follows. You can
30 discuss these risks with your research doctor if you prefer.
31

32
33 During the study, you may have some, all, or none of these adverse events (adverse
34 medical events after the patient or clinical trial subject receives a test product such as a
35 drug / medical device), risks, discomfort, inconvenience, such as:
36
37

38 ① There is no additional operation and medication, which will not affect the normal
39 diagnosis and treatment, and will not increase the medical risks other than the normal
40 diagnosis and treatment.
41
42

43 ② Participation in this research may involve risks in information security. We will do
44 our best to protect your information from leakage. Some of the questions we ask you in
45 this study may make you feel uncomfortable. You can refuse to answer such questions,
46 and you can rest at any time during the study process. You can also withdraw from the
47 study at any time during the study.
48
49
50
51

52
53 If you experience any discomfort or a new change in your condition or any
54 unexpected condition during the study, whether or not it is related to the study, you
55 should promptly notify your doctor, who will make a judgment and give appropriate
56
57
58
59
60

1
2
3
4 medical treatment.

5 During the study, you need to be followed up to the hospital on time and do some
6 examinations. It will take some of your time and may cause some trouble or
7 inconvenience.
8
9

10
11 (2) What are the benefits of participating in the study?
12

13 Immediate Benefit: If you agree to participate in this study, you will receive follow-
14 up and free medical counseling for your disease during the study.
15

16
17 Potential benefits: This study may contribute to the improvement of the treatment
18 methods of COPD, and your contribution to the medical cause is very meaningful. We
19 hope that the information you get from this study will benefit you or another patient
20 same as your condition in the future.
21
22
23
24
25

26 27 **5. Alternative treatment options**

28
29 No alternative treatment options.
30
31

32 33 **6. Use of study results and confidentiality of personal information**

34 All your information during the study is strictly confidential. Only relevant personnel
35 can view your medical records so that they can check the accuracy of the information
36 collected and ensure that the study proceeds normally. Any electronically transmitted
37 information will be renamed to ensure the confidentiality of the information.
38 Information on all computers will be protected with a password. Results of the study
39 may be reported at medical conferences and published in scientific journals. However,
40 no personally identifiable information will be used.
41
42
43
44
45
46
47

48 With your and other subjects' understanding and assistance, the results of the research
49 through this project may be published in medical journals, but we will keep your
50 research records confidential as required by law. The personal information of the study
51 subjects will be kept strictly confidential, and your personal information will not be
52 disclosed unless required by relevant laws. When necessary, government
53 administrations, hospital ethics committees, and other relevant researchers can review
54 your data as required.
55
56
57
58
59
60

7. Study costs and related compensation

(1) Drugs / devices used in study and related inspection fees

There is no additional intervention in this study and it will not increase your costs. Inpatient and outpatient routine consultations will not be free. Routine treatments and examinations for other diseases you have combined at the same time will not be free.

(2) Compensation for participating in research

Throughout the study, you only need to visit the site in accordance with the follow-up consultation requirements. There is no additional cost for participating in the study, so no compensation will be made.

(3) Compensation / compensation after damage

The study will not cause additional damage.

8. Subject rights and related considerations

(1) Your rights

You are totally voluntary the study. If you decide not to participate in this study, other treatments you should get will not be affected. If you decide to participate, you will be asked to sign the informed consent form. You have the right to withdraw from the study at any stage of the trial without discrimination or unfair treatment, and your corresponding medical treatment and rights will not be affected.

(2) Related considerations

As a subject, you need to provide true information about your own medical history and current physical condition, tell the research doctor about any discomfort you feel during the study period, do not take restricted drugs and food that the doctor has informed, and tell the research doctor whether you has participated in other study recently or is currently participating in other research.

9. Contact details for information

Your doctor will notify you if there is any important new information during the research that may affect your willingness to continue participating in the study. If you

1
2
3
4 are interested in your research data or the findings of study, you can ask any questions
5 about the study at any time and get the corresponding answers. Please contact Dr. Jing
6 Zhang at 17898846216.
7
8

9 The ethics committee has reviewed the study, and if you have any questions related
10 to your rights / entitlements, or if you want to reflect the difficulties, dissatisfaction,
11 and anxieties encountered in participating in this study, or if you want to provide
12 comments and suggestions related to this study, please contact the Ethics Committee of
13 Zhongshan Hospital, Fudan University, Tel: 021-64041990 ext. 3257, Email: ec@zs-
14 hospital.sh.cn.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

Participant Signature Page

Informed Consent Statement:

33
34
35
36
37 I have been informed of the purpose, background, process, risks and benefits of this
38 research. I have enough time and opportunity to ask questions, and I am satisfied with
39 the answers.
40
41
42

43 I have also been told who to contact when I have questions, want to reflect difficulties,
44 concerns, suggestions for research, or want further information or help with the study.
45
46

47 I have read this informed consent and agree to participate in this study.
48

49 I understand that I can choose not to participate in the study and to withdraw from
50 the study at any time during the study process without any reason.
51
52

53 I already know that if my condition gets worse, or if I have serious adverse events,
54 or if my research doctor feels that continuing to participate in the study is not in my
55 best interest, he / she will decide to quit me from the study. Without my consent, the
56 funder or regulator may terminate the study during the study period. If it happens, the
57
58
59
60

1
2
3
4 doctor will notify me in time, and the research doctor will discuss my other options
5
6 with me.

7 I will get a copy of this informed consent, which contains the signatures of me and
8
9 the investigator.
10

11
12
13
14
15 Subject Signature:

Date:

16
17 (Note: If the subject is incapacitated / restricted, the legal representative's signature and signature
18
19 date are required.)
20
21
22
23
24

25 Legal representative Signature:

Date:

26
27 (Note: If the subject cannot read the informed consent, an independent witness is required to
28
29 prove that the researcher has informed the subject of the informed consent. The independent
30
31 witness's signature and signature date are required.)
32
33
34
35
36

37 Independent Witness Signature:

Date:

38
39
40
41
42 Investigator Signature:

Date:



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Reported on page No
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	2
	2b	All items from the World Health Organization Trial Registration Data Set	N/A
Protocol version	3	Date and version identifier	1
Funding	4	Sources and types of financial, material, and other support	N/A
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1
	5b	Name and contact information for the trial sponsor	N/A
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	N/A
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	N/A
Introduction			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	3-5
	6b	Explanation for choice of comparators	3-5

1			
2	Objectives	7	Specific objectives or hypotheses
3			4-5
4	Trial	8	Description of trial design including type of trial (eg, parallel
5	design		group, crossover, factorial, single group), allocation ratio, and
6			framework (eg, superiority, equivalence, noninferiority,
7			exploratory)
8			
9			
10	Methods: Participants, interventions, and outcomes		
11			
12	Study	9	Description of study settings (eg, community clinic, academic
13	setting		hospital) and list of countries where data will be collected.
14			Reference to where list of study sites can be obtained
15			
16	Eligibility	10	Inclusion and exclusion criteria for participants. If applicable,
17	criteria		eligibility criteria for study centres and individuals who will
18			perform the interventions (eg, surgeons, psychotherapists)
19			
20	Interventio	11	Interventions for each group with sufficient detail to allow
21	ns	a	replication, including how and when they will be administered
22			
23			
24		11	Criteria for discontinuing or modifying allocated interventions for
25		b	a given trial participant (eg, drug dose change in response to
26			harms, participant request, or improving/worsening disease)
27			
28		11	Strategies to improve adherence to intervention protocols, and
29		c	any procedures for monitoring adherence (eg, drug tablet
30			return, laboratory tests)
31			
32			
33		11	Relevant concomitant care and interventions that are permitted
34		d	or prohibited during the trial
35			
36	Outcomes	12	Primary, secondary, and other outcomes, including the specific
37			measurement variable (eg, systolic blood pressure), analysis
38			metric (eg, change from baseline, final value, time to event),
39			method of aggregation (eg, median, proportion), and time point
40			for each outcome. Explanation of the clinical relevance of
41			chosen efficacy and harm outcomes is strongly recommended
42			
43			
44	Participant	13	Time schedule of enrolment, interventions (including any run-
45	timeline		ins and washouts), assessments, and visits for participants. A
46			schematic diagram is highly recommended (see Figure)
47			
48			
49	Sample	14	Estimated number of participants needed to achieve study
50	size		objectives and how it was determined, including clinical and
51			statistical assumptions supporting any sample size calculations
52			
53	Recruitmen	15	Strategies for achieving adequate participant enrolment to
54	t		reach target sample size
55			
56			
57			
58			
59			
60			

Methods: Assignment of interventions (for controlled trials)

Allocation:

1				
2	Sequen	16	Method of generating the allocation sequence (eg, computer-	12
3	ce	a	generated random numbers), and list of any factors for	
4	generati		stratification. To reduce predictability of a random sequence,	
5	on		details of any planned restriction (eg, blocking) should be	
6			provided in a separate document that is unavailable to those	
7			who enrol participants or assign interventions	
8				
9				
10	Allocatio	16	Mechanism of implementing the allocation sequence (eg,	12
11	n	b	central telephone; sequentially numbered, opaque, sealed	
12	conceal		envelopes), describing any steps to conceal the sequence until	
13	ment		interventions are assigned	
14	mechani			
15	sm			
16				
17				
18	Impleme	16	Who will generate the allocation sequence, who will enrol	13
19	ntation	c	participants, and who will assign participants to interventions	
20				
21	Blinding	17	Who will be blinded after assignment to interventions (eg, trial	13
22	(masking)	a	participants, care providers, outcome assessors, data	
23			analysts), and how	
24				
25				
26		17	If blinded, circumstances under which unblinding is permissible,	13
27		b	and procedure for revealing a participant's allocated	
28			intervention during the trial	
29				
30				
31	Methods: Data collection, management, and analysis			
32	Data	18	Plans for assessment and collection of outcome, baseline, and	9-10
33	collection	a	other trial data, including any related processes to promote	
34	methods		data quality (eg, duplicate measurements, training of	
35			assessors) and a description of study instruments (eg,	
36			questionnaires, laboratory tests) along with their reliability and	
37			validity, if known. Reference to where data collection forms can	
38			be found, if not in the protocol	
39				
40				
41				
42		18	Plans to promote participant retention and complete follow-up,	9-10
43		b	including list of any outcome data to be collected for	
44			participants who discontinue or deviate from intervention	
45			protocols	
46				
47	Data	19	Plans for data entry, coding, security, and storage, including	N/A
48	manageme		any related processes to promote data quality (eg, double data	
49	nt		entry; range checks for data values). Reference to where	
50			details of data management procedures can be found, if not in	
51			the protocol	
52				
53				
54	Statistical	20	Statistical methods for analysing primary and secondary	13
55	methods	a	outcomes. Reference to where other details of the statistical	
56			analysis plan can be found, if not in the protocol	
57				
58				
59				
60				

	20	Methods for any additional analyses (eg, subgroup and adjusted analyses)	13
	20	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	13

Methods: Monitoring

Data monitoring	21	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	N/A
	21	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	N/A
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	N/A
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	N/A

Ethics and dissemination

Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	14
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	14
Consent or assent	26	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	14
	26	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N/A
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	14
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	N/A

1				
2	Access to	29	Statement of who will have access to the final trial dataset, and	14
3	data		disclosure of contractual agreements that limit such access for	
4			investigators	
5				
6	Ancillary	30	Provisions, if any, for ancillary and post-trial care, and for	N/A
7	and post-		compensation to those who suffer harm from trial participation	
8	trial care			
9				
10	Disseminati	31	Plans for investigators and sponsor to communicate trial results	14
11	on policy	a	to participants, healthcare professionals, the public, and other	
12			relevant groups (eg, via publication, reporting in results	
13			databases, or other data sharing arrangements), including any	
14			publication restrictions	
15				
16				
17		31	Authorship eligibility guidelines and any intended use of	N/A
18		b	professional writers	
19				
20		31	Plans, if any, for granting public access to the full protocol,	N/A
21		c	participant-level dataset, and statistical code	
22				
23				
24	Appendice			
25	s			
26				
27	Informed	32	Model consent form and other related documentation given to	N/A
28	consent		participants and authorised surrogates	
29	materials			
30				
31				
32	Biological	33	Plans for collection, laboratory evaluation, and storage of	N/A
33	specimens		biological specimens for genetic or molecular analysis in the	
34			current trial and for future use in ancillary studies, if applicable	
35				

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.